¬ÛÃö¤½¥q¡GF-¨È·à±d |
¼ÐÃD¡GAD/ý³Ý ³Ì¨ÎÀøªk¼ç¤O |
µoªí·s¸ÜÃD
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/1/6 ¤W¤È 11:37:38 |
¤@.¤¤-««×AD¥«³õ : 2029¦~¥þ²y¦ô240»õ¬ü¤¸(¬ü°ê72%/¼Ú¬w25%/¤é¥»3%)
Dupilumab ¾P°â°ªÂI;±N¹F145»õ¬ü¤¸.(2021¦~¤w¾P30¸U¤H,¦~¾P62»õ¬ü¤¸)
¬ü°ê«D¨ü±±±wªÌ AD 226.5¸U¤H///56% ý³Ý 97.5¸U¤H/// 24% ¨ä¥L¾AÀ³¯g 84¸U¤H///20% ¤pp 408¸U¤H
¤G.2021/09/27 1b ¸Ñª¼
1. ¤½§G1b·§©À©ÊÁ{§É¦¨¥\.½T»{MOA. ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
³oºØ¼Æ¾Ú¦b¤H¼Æ©ñ¤j¨ì¤T´ÁÁ{§É 400¤H(200:200) , P¡Õ0.000001 ,¤T´ÁÁ{§É¹êÅç²Õ°ª¹ï·Ó²Õ66%¡Ap<0.05´N¹LÃö¡C
---¬Ý§¹MOA¼v¤ù,¤@³q¥|Ãĺɳq! ªø§ë°ò¥»¥\.
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
Dupilumab MOA -¼v¤ù www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
2b Á{§É³]p¥XÄl:
Á{§É¤À¤²Õ¦@¦¬295¤H*16¶gªvÀø,2023,H1§¹¦¨. 2022/04/05 ¦b¬ü/¿D/¯Ã¤w¶}19Ó¦¬®×¤¤¤ß.
(1).300mg/Q2W(¨C¤G¶g¤@°w/²Ä0,1,2¶g¦U300mg),9¦¸, ¦Xp2700mg (2).400mg/Q2W(¨C¤G¶g¤@°w/²Ä0,1,2¶g¦U400mg),9¦¸, ¦Xp3600mg (3).400mg/Q4W(¨C¥|¶g¤@°w/²Ä0,1,2,¶g¦U400mg),6¦¸, ¦Xp2400mg (4).600mg/Q4W(¨C¥|¶g¤@°w/²Ä0,1,2¶g¦U600mg),6¦¸ ¦Xp3600mg (5).¹ï·Ó²Õ
2¡B¥i±æ¦P¯Å³Ì¨ÎÀø®Ä¤Î³Ì¨Î¦w¥þ©Ê
Dupilumab»PASLAN004 ¯à¦P®ÉªýÂ_IL-4©MIL-13ªº°T¸¹¶Ç¾É ----------------------------------------------------------- ¨ä¥LÃĪ«¨Ò¦plebrikizumab©Mtralokinumabµ¥¥u¯àªýÂ_IL-13¤Î³¡¥÷IL4°T¸¹¶Ç¾É
³Ì¨Î: Àø®ÄIGA 0/1/EASI 75/EASI50 ,¥ÎÃÄÀW²v¥i±æ4¶g¤@°w,°Æ§@¥Î¸û§C(Dupilumab ªñ40%µ²½¤ª¢¹ê»Ú³ø§i)
Àø®Ä¹w¦ô
(1b ,n=16-RITT/REEPP,¤¤Â_²v6.3%, IGA4=48%,ITT¼ÒÀÀ)
ASLAN004 ¦ô2b/P3 VS Dupilumab ¤T´Á
EASI50 94% VS 65% EASI75 75% VS 50% EASI90 62% VS 36% IGA 0,1 64% VS 38%
¤T¡BÁ`Ävª§¤O:
¦³¼ç¤O°ª¤@Ó¶q¯ÅªºÀø®Ä, ¥Dn¡«á«ü¼Ð,¬Û¹ï©óDupilumab EASI75, 150%(75%/50%) IGA0,1 , 168%(64%/38%) ,
¥B°Æ§@¥Î§C.¥|¶g¤@°wªº¼ç¤O
¥|¡B¹w¦ô·m¤U Dupilumab ¤@¥b,p72»õ¬ü¤¸II«¬ª¢¯g¥«³õ
ÁÉ¿Õµá 2022/03/26 Dupilumab 130»õ¼Ú¤¸(145»õ¬ü¤¸) ³Ì°ª¾P°â
¤¡B°ê»Ú¼Ð¹vªvÀø ¤¤-««×²§¦ì©Ê¥Öª¢AD¤§±ÂÅv¤Î¨ÖÁÊ:
1.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë) ²Ä¤@ÓÂê©wIL13 °tÅé¤À§OªýÂ_»PIL13¨üÅé¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤ÎªýÂ_¨üÅé£\2¦¸³æ¦ì (¥çºÙ¬°IL-13R£\2) µ²¦X¡A ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.1 , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
3.2019/05/31 , CSL»P¨È·à2014¦~°_¦@¦P¶}µo,§Q¼í¦U¥b. 1a °µ§¹ CSL ¨È·à¦@¦P±ÂÅvASLAN004 ¥þ²yµo®i/¥Í²£/°Ó·~¤Æµ¹ ¨È·à±d, (±ÂÅvª÷=(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)*2=7.8*2»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)*2 ¦U±o¤@¥b.
¨È·à¶RÂ_»ù =±ÂÅvª÷(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)=7.8»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)
4.2020/¤¸¤ë ,§¨Ó¨ÖÁÊDermira ¤½¥q/Lebrikizumab
§é²{»ùÈ 29»õ¬ü¤¸.
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 29»õ¬ü¤¸,
----------------
¤».资°T¤£¹ïºÙ»ùÈ
¬üªÑ¥«©|¥¼¤ÏÀ³ 1.¨È狮»PCSL¦@¦P¶}µoASLAN004¨ì1aÁ{§É§¹¦¨ªº§Q¯q¡C 2019/05/31¤w¸g°ê»Ú±ÂÅv¡A¨È·à©Ò±o§Q¯q¦ô§é现È10»õ¬ü¤¸¡C¥tCSL¥ç±o10»õ¬ü¤¸ªº¼ç¦b§Q¯q¡A¦@20»õ¬ü¤¸¡C ñ约°ò¦¡A°Ñ¦Ò°ê»Ú¦P级¦X¬ù¡A¦ô³Ì°ª销°â30»õ¬ü¤¸¡C (·í®ÉDupilumab ¥«³õ»{¦P¥¼¨Ó³Ì°ª¥i销50»õ¬ü¤¸)
2.2020¦~¤¸¤ë ¦PMOAªºLebrikizumab¨ÖÁʧé²{»ùÈ 29»õ¬ü¤¸. 2020/01 §¨Ó¨ÖÁÊDermira ¤½¥q
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 11»õ¬ü¤¸+18»õ¬ü¤¸=29»õ¬ü¤¸,
3.2022/3/26
a.¦]Dupilumab ¥«³õ»{¦P°ª¾P°âÃB´£¤É¨ì145»õ¬ü¤¸¡C ASLAN004ÀH¥«³õÂX¤j¡A¥¼¨Ó·s°ê»Ú±ÂÅvÈ¨Ì¾Ú ³Ì°ª¾P°â¦ô¥i¹F72.5»õ¬ü¤¸
b¡D2020¦~¤¸¤ë§¨Ó¨ÖDermiraªº§é现»ù¡A¤w¹F29»õ¬ü¤¸¡C
LebriKiulmabªº¤T´Áý³Ý¡A2017¦~¸Ñª¼¥¢±Ñ¡CªÍ³¡C0PD¥ç¥¢±Ñ¡C
C¡D¨È·à«O¦³¦Pdupilumab ¸ô®|, ý³Ý/ªÍ³¡COPD/EOE.... ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X -------------------------------------------------- ¤C.¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù:
11/50*145*2=64»õ¬ü¤¸(¨È·à¿W±o)
Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*2022/03/26 Dupilumab 145»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2023¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù. |
|
|
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/13 ¤W¤È 09:41:26
²Ä 215 ½g¦^À³
|
EASI75/EASI90 VS IGA0,1 Àø®Ä®t²§
¤@¡BDupilumab ¤T´ÁÁ{§É, EASI75 °ª¥XIGA0,1 8%~15%ªº¹F¦¨²v. EASI90 §C©óIGA0,1 2%~6%ªº¹F¦¨²v.
1.SOLO1*Q2w*16¶g EASI75 51% IGA0,1 38%(EASI75 °ª¥XIGA0,1 13%) EASI90 36%
2.SOLO1*Qw*16¶g EASI75 52% IGA0,1 37%(EASI75 °ª¥XIGA0,1 15%) EASI90 33%
3.SOLO2*Q2w*16¶g EASI75 44% IGA0,1 36%(EASI75 °ª¥XIGA0,1 8%) EASI90 30%
4.SOLO1*Qw*16¶g EASI75 48% IGA0,1 36%(EASI75 °ª¥XIGA0,1 12%) EASI90 31%
www.nejm.org/doi/full/10.1056/nejmoa1610020
¤G¡BLebrikizumab ¤T´ÁÁ{§É, EASI75 °ª¥XIGA0,1 16%~18%ªº¹F¦¨²v. EASI90 §C©óIGA0,1 3%~5%ªº¹F¦¨²v.
1.ADV1*Q2w*16¶g EASI75 59% IGA0,1 43%(EASI75 °ª¥XIGA0,1 16%) EASI90 38%
2.ADV2*Qw*16¶g EASI75 51% IGA0,1 33%(EASI75 °ª¥XIGA0,1 18%) EASI90 30%
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
¤T.¡BLebrikizumab 2bÁ{§É EASI75 °ª¥XIGA0,1 16%ªº¹F¦¨²v. EASI90 §C©óIGA0,1 1%ªº¹F¦¨²v.
Q2w*16¶g
EASI75 61% IGA0,1 45%(EASI75 °ª¥XIGA0,1 16%) EASI90 44%
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
------------------------ ¥|.ASLAN004 2b 16¶g¹w¦ô
(1)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gASLAN004, EASI75 69% VS 15%(¹ï·Ó²Õ),®t²§54%------ ²Ä16¶gASLAN004, EASI75 69%~81% VS 24%(¹ï·Ó²Õ),®t²§45%~57%------(¦ôp)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., EASI75 45% VS 18%(¹ï·Ó²Õ),®t²§27%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,EASI75 60.6% VS 24.3%(¹ï·Ó²Õ),®t²§36.3%------
(2)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gIGA0,1 44% VS 15%(¹ï·Ó²Õ),®t²§29%------ ²Ä16¶gIGA0,1 53%~65% VS 15%(¹ï·Ó²Õ),®t²§38%~50%-----(¨Ì¾Úlebrikizumab ©Ò±À¦ô²Ä16¶g,EASI75-IGA0,1¤§¶¡ ®t²§16%)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., IGA0,1 30% VS 5%(¹ï·Ó²Õ),®t²§25%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,IGA0,1 44.6% VS 15.3%(¹ï·Ó²Õ),®t²§29.3%------ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/9 ¤W¤È 09:38:37
²Ä 214 ½g¦^À³
|
2b EASI75´Á±æȦôp¡G ¨ÌASLAN004 1b mITT EASI75=11/16=69%
¨ä¤¤ì¥»«D¶Ç²ÎAD6¦ì¡A°ò缐EASI19ªº»´¯g¡A8¶gªvÀø«á0¦ì¦ì¹FEASI75¡C¡]mITT¤w±Æ°£¡^
Y¨Ì¶Ç²ÎADªvÀø¡]Y1b¿z¿ïÄY®æ±Æ°£«D¶Ç²ÎAD¡^
¦Ü¤Ö5/6¡ã6/6·|¹FEASI75
«hEASI75±N¦^Âk (11¤Q5)/(16+6)=73% (11+6)/(16+6)=77%
¥t¥~¤¤Â_²v3/16=19%
¨Ì¾Ú¤T´Á¤¤Â_²v¶È7%¡ã8% EASI75¡]11+6¡^/¡]16+6-1¡^=81%
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/8 ¤U¤È 04:30:47²Ä 5868 ½g¦^À³ ¥²n±ø¥ó :ASLAN004 2B ¸Ñª¼±ø¥ó¹F¦p¤U: EASI75 69% VS 24%(¹ï·Ó²Õ),®t²§45% IGA0,1 53% VS 15%(¹ï·Ó²Õ),®t²§38%
ASLAN004 2b ¸Ñª¼´Á±æÈ ----------------------------------- Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study aslanpharma.com/wp-content/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf
Lenrikizumab phs3 : www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
Lenrikizumab 2b : jamanetwork.com/journals/jamadermatology/fullarticle/2761466
(1)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gASLAN004, EASI75 69% VS 15%(¹ï·Ó²Õ),®t²§54%------ 2b²Ä16¶gASLAN004, EASI75 69%~81% VS 24%(¹ï·Ó²Õ),®t²§45%~57%------(¦ôp)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., EASI75 45% VS 18%(¹ï·Ó²Õ),®t²§27%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,EASI75 60.6% VS 24.3%(¹ï·Ó²Õ),®t²§36.3%------
(2)ASLAN004 1b mITT*8 ¶gªvÀø ²Ä8¶gIGA0,1 44% VS 15%(¹ï·Ó²Õ),®t²§29%------ 2b²Ä16¶gIGA0,1 53%~65% VS 15%(¹ï·Ó²Õ),®t²§38%~50%-----(¨Ì¾Úlebrikizumab ©Ò±À¦ô²Ä16¶g,EASI75-IGA0,1¤§¶¡ ®t²§16%)
VS Lenrikizumab phs2 *8/16 ¶gªvÀø ²Ä8¶gLenr., IGA0,1 30% VS 5%(¹ï·Ó²Õ),®t²§25%------(¥Øµø§P¹Ï) ²Ä16¶gLenr.,IGA0,1 44.6% VS 15.3%(¹ï·Ó²Õ),®t²§29.3%------ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/8 ¤U¤È 01:19:05
²Ä 213 ½g¦^À³
|
ASLN³Q¨ÖÁÊ»ùȦôºâ :×¥¿¤@
¨Ì¾Ú Lebrikizumabªº¤½¥qDERM. AD 2bÁ{§É°µ§¹, 11»õ¬ü¤¸,2019¦~©³³QLily¨ÖÁÊ.(ý³Ý/COPD¤T´Á¥¢±Ñ),¥Ø«e»ùÈ11*140/50=31»õ¬ü¤¸
2019¦~©³·í®Édupilmab ¥«³õ»{¦P³Ì°ª¾P°â50»õ¬ü¤¸. 2019¦~dupilumab ¾P°â23»õ¬ü¤¸. 2022¦~«e¤T©u¤w¾P 61»õ¬ü¤¸,¥þ¦~Á`¾P±Nªñ85»õ. REGN¤½¥q©Ò¦ôdupilumab ³Ì°ª¾P°â130»õ¼Ú¤¸(140»õ¬ü¤¸)¦b2024¦~¥i¹F¦¨.
31»õ¬ü¤¸ AD¦û55% «¬IIª¢¯g. 31/0.55=56»õ¬ü¤¸---«¬IIª¢¯g
31+25*0.6=46»õ¬ü¤¸-------¦ô²{ª÷¨ÖÁÊ»ù(¨ÖÁʪ̥²¶·¤ä¥I¤W´åCSL¶O¥Î)
°²¦p¥»¦¸2023/Q2¼W¸ê§¹¦¨ªÑ¥»¥Ñ7¸UªÑ¼W¥[¨ì15.14ªÑADR. ¶Ò¸ê4»õ¬ü¤¸¡]7¸U¤dªÑADRx5.6¬ü¤¸¡×4»õ¬ü¤¸¡^¥t¥[¼Ú°Ï±ÂÅv¡C
¦~©³¤½¥q²bÈ4»õ¬ü¤¸¤Q¤Wz46»õ¬ü¤¸¡×50»õ¬ü¤¸⋯³Q¨ÖÁÊ»ù
50»õ¬ü¤¸/15.14¸U¤dªÑADR=33 ¬ü¤¸/ªÑADR. -----
¥²n±ø¥ó :ASLAN004 2B ¸Ñª¼±ø¥ó¹F¦p¤U: EASI75 69% VS 24%(¹ï·Ó²Õ),®t²§45% IGA0,1 53% VS 15%(¹ï·Ó²Õ),®t²§38%
**Lebrikizumab 2b EASI75 61% VS 24%(¹ï·Ó²Õ),®t²§37% IGA0,1 45% VS 15%(¹ï·Ó²Õ),®t²§30%
***ASLAN004 2b¹w´Á VSLebrikizumab 2b(¦©°£¹ï·Ó²Õ)
EASI75 45% VS 37%=121% IGA0,1 38% VS 30%=126% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤U¤È 10:45:13
²Ä 212 ½g¦^À³
|
¤½¥q¸g¹L200mg/ml°ª¿@«×aslan004°w¾¯ªº¬ãµo(¤§«e100mg/ml),¥i¸`¬Ù50%¦¨¥». ¨C°w¥i¥´400mg/2ml.
°ê»Ú§ÜÅé°w¾¯ªº¥N¤u»ù¬O¨ÌÃĪº«¶qp»ù : ¬ü¤¸/¤½§J. ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2023/1/6 ¤U¤È 08:38:35²Ä 5854 ½g¦^À³ ¤µ¤Ñ¤~¬Ý³q¤½¥q²³øp.31/p.32, ¤Î Á{§É¹êÅç/clinicaltrials.gov ºô¤¤ªº¤å¦r
¦p¦¹¥i¥[±j«e¤G/¤T°wªº600Mmg ªºÀø®Ä½T«O:
ASLAN004 2b¤@½u Q2W«e0/1¶g¬Ò¥´600mg.¨ä¥LW2~W14,¨C¤G¶g¤À§O¥´300mg/400mg Q4W«e0/1/2¶g¬Ò¥´600mg.¨ä¥LW6/W10/W14,¨C¥|¶g¤À§O¥´400mg/600mg
------------------------------ ASLAN004 2b¤G½u QW«e0/1¶g¬Ò¥´600mg.¨ä¥L¨C¶g¥´400mg
clinicaltrials.gov/ct2/show/NCT05158023
Experimental: ASLAN004 300 mg q2w
ASLAN004 300 mg q2w - loading doses at Baseline and Week 1(²Ä0/1¶g¦U¥´600mg,), followed by regular doses of 300mg q2w from Week 2 to Week 14(²Ä2~14¶g¦U¥´300mg,).
ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2023/01/06 ¤½¥q²³øp.31/p.32
300mg Q2W W0/W1:600mg:Q2W (w2~w14):300mg ¦@9°w,¦Xp3300mg (²Ä0/1¶g¦U¥´600mg, ²Ä2~14¶g:¨C¤G¶g¥´¤@°w300mg)
400mg Q2W W0/W1:600mg/Q2W (w2~w14):400mg ¦@9°w,¦Xp4000mg (²Ä0/1¶g¦U¥´600mg, ²Ä2~14¶g:¨C¤G¶g¥´¤@°w400mg)
400mg Q4W W0/W1/W2:600mg/Q4W (w6~w14):400mg ¦@6°w,¦Xp3000mg (²Ä0/1/2¶g¦U¥´600mg, ²Ä6/10/14¶g:¨C¥|¶g¥´¤@°w400mg)
600mg Q4W W0/w1/W2:600mg/Q4W (w6~w14):600mg ¦@6°w,¦Xp3600mg (²Ä0/1/2¶g¦U¥´600mg, ²Ä6/10/14¶g:¨C¥|¶g¥´¤@°w600mg)
p.31 TREK-AD: Phase 2b in biologic naïve patients •Loading dose of 600mg for the Q2W dose groups at week 1(w0) and week 2(week 1) •Loading dose of 600mg for the Q4W dose groups at week 1(w0), week 2(w 1) and week 3(w 2)
400mg QW(¨C¶g¤@°w) W0/W1:600mg/w2~w15:400mg ¦@16°w,¦Xp6800mg (²Ä0/1¶g¦U¥´600mg, ²Ä2~15¶g:¨C¶g¥´¤@°w400mg) Loading dose of 600mg at week 1(w0) and week 2(w 1)
p.32 TREK-DX: Phase 2 study in dupilumab experienced patients Topline data expected 1Q 2024 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/6 ¤W¤È 08:47:06
²Ä 211 ½g¦^À³
|
ASLN³Q¨ÖÁÊ»ùȦôºâ :
¨Ì¾Ú Lebrikizumabªº¤½¥qDERM. AD 2bÁ{§É°µ§¹, 11»õ¬ü¤¸,2019¦~©³³QLily¨ÖÁÊ.(ý³Ý/COPD¤T´Á¥¢±Ñ),¥Ø«e»ùÈ11*140/50=31»õ¬ü¤¸
2019¦~©³·í®Édupilmab ¥«³õ»{¦P³Ì°ª¾P°â50»õ¬ü¤¸. 2019¦~dupilumab ¾P°â23»õ¬ü¤¸. 2022¦~«e¤T©u¤w¾P 61»õ¬ü¤¸,¥þ¦~Á`¾P±Nªñ85»õ. REGN¤½¥q©Ò¦ôdupilumab ³Ì°ª¾P°â130»õ¼Ú¤¸(140»õ¬ü¤¸)¦b2024¦~¥i¹F¦¨.
31»õ¬ü¤¸ AD¦û55% «¬IIª¢¯g. 31/0.55=56»õ¬ü¤¸---«¬IIª¢¯g
31+25*0.6=46»õ¬ü¤¸-------¦ô²{ª÷¨ÖÁÊ»ù(¨ÖÁʪ̥²¶·¤ä¥I¤W´åCSL¶O¥Î)
°²¦p¥»¦¸2023/Q2¼W¸ê§¹¦¨ªÑ¥»¥Ñ7¸UªÑ¼W¥[¨ì20¸UªÑADR.
46»õ¬ü¤¸/20¸UªÑADR=23 ¬ü¤¸/ªÑADR. -----¥²»ù±ø¥ó :ASLAN004 2B ¸Ñª¼±ø¥ó¹F¦p¤U: EASI75 69% VS 24%(¹ï·Ó²Õ),®t²§45% IGA0,1 53% VS 15%(¹ï·Ó²Õ),®t²§38%
**Lebrikizumab 2b EASI75 61% VS 24%(¹ï·Ó²Õ),®t²§37% IGA0,1 45% VS 15%(¹ï·Ó²Õ),®t²§30%
***ASLAN004 2b¹w´Á VSLebrikizumab 2b(¦©°£¹ï·Ó²Õ)
EASI75 45% VS 37%=121% IGA0,1 38% VS 30%=126% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/17 ¤W¤È 08:25:17
²Ä 210 ½g¦^À³
|
ASLAN004¤§Q4W(¥|¶g¤@°w)
Y¨ÌASLAN004 1a°·±d¤H¸ê®Æ±À¦ô 400¤@600mg¦ô¶È¥i§¹¥þ§í¨î¬ù12.5~13.5¤Ñ 0/1/2/6/10/14¶gx¦Xp6°w
¥H¤U004®£©ñ¶}«°ªù¡B¦³·ÀI¡D ²Ä28~42¤Ñ(²Ä¥|~¤»¶g) ²Ä55~72¤Ñ(²Ä¤K~¤Q¶g) ²Ä83~102¤Ñ(²Ä¤Q¤G~¤Q¥|¶g)
IGA0,1/IEASI90µ¥Àø®Ä¤ñ¸û§xÃø¹F¦¨¡D
¥Ø«eY¥¼¸Ñª¼ªºIGA0,1¥§¡¤£¬Æ²z·Q¡B³Ì¥i¯à¥X²{°ÝÃDªº´N¥i¯à¦b¨âÓQ4WÁ{§É¡D
Q2W·ÀI«D±`¤p¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/15 ¤U¤È 07:15:49
²Ä 209 ½g¦^À³
|
2b Á{§É 400mg xQ2W¡A¼ÒÀÀ
2b ®Ú¾ÚASLAN004 1b 400mg x8¶gx¤@°w¡þ¶g¡A¦@8°w¡AN=6 (2021/03/1¤½¥¬¸ê®Æ¡^
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
1.¥§¡EASI°´T⋯¡]lb=2b) ²Ä¤@¶g¡]²Ä8¤Ñ ¡^15% ²Ä¤G¶g¡]²Ä15¤Ñ¡^ 45% ²Ä¤T¶g¡]²Ä22¤Ñ¡^ 55%⋯¡]TRAC°´T¤w¹F¬Û¹ï§CÂI¬ù73%¡^
⋯⋯¤@¤@¤@ 2b Á{§É¡A²Ä23¤Ñ¡ã²Ä30¤Ñ¡A¼ÒÀÀ
300mg ¦b°·±d¤H1aÁ{§É²Ä8¤ÑIL13Ra1=0%¡A²Ä15¤Ñ=30%¡]¦ôp§¹¥þ§í¨î¤O逹²Ä13¤Ñ¡^ 600mg ¦b²Ä8¤ÑIL13Ra1=0%,²Ä15¤Ñ10%(¦ôp§¹¥þ§í¨î¤O逹²Ä14¡P4¤Ñ¡^ 400mg¦b1A ²Ä8¤ÑIL13Ra1=0%,²Ä14¤Ñ¦å²G¤¤¥i¯à¦³23%ªº¡A¡]¦ôp§¹¥þ§í¨î¤O逹13¡P5¤Ñ¡^
«h2bÁ{§É400mg§¹¥þ§í¨î¥i¥Ñ²Ä0¤Ñ¡ã²Ä27¡P5¤Ñ¡A¦å²G¤¤ªºIL13Ra1¥i«O«ù0%ª¬ºA¡C ¥§¡ªºEASI°´T¦ô62%¡AEASI50¦ô¤w¹F80%⋯⋯⋯⋯EASI75¦ôp>50% ¥Ñ©ó80%ªº±wªÌ¤w¸g¹FEASI50¡A,«h²Ä29¤ÑªºÀø®Ä³Ì¤j¥i¯à´N°±¯d¦b²Ä27¡P5¤Ñ¡A¦p²Ä8¶g¡ã11¶gªºTRAC´X¥Gºû«ù¦b§CÀÉ¡C ¦b²Ä29¤Ñªº²Ä¥|°w¬I¥´«á«Ü§Ö´N¦^´_§¹¥þ§í¨î¡C
µ²½×¡G2b ²Ä29¤ÑªºÀø®Ä¡AEASI¥§¡°´T¦ôp¥u´î3%¥ª¥k¡A¥i¹F°62%¡C ¨Ì¦¹Ãþ±À 2b ²Ä¤¶g¡]36¤Ñ¡^68% 2b ²Ä¤»¶g¡]43¤Ñ¡^71%(À³¸Ó¥i¸É¨¬¤§«e¬y¥¢ªº¤Ö¶qÀø®Ä¡A¦^¨ìIbªº¤ô·Ç¡C
⋯⋯⋯⋯ 1b ²Ä¥|¶g¡]²Ä29¤Ñ¡^65%⋯¡]¦ôEASI50 ¤w¹F83%¡^ ²Ä¤¶g¡]²Ä36¤Ñ¡^71%⋯¡]¬Û¹ï§CÂI¡AEASI75¦ô67%¡^ ¡K¡K¡K¡K 1b=2b
²Ä¤»¶g¡]²Ä43¤Ñ¡^73%⋯ ²Ä¤C¶g¡]²Ä50¤Ñ¡^75%⋯¡]³Ì§CÂI¡AEASI90¦ô¤w¹F67%¡^ ²Ä¤K¶g¡]²Ä57¤Ñ¡^74%
2.¨ä¥L«ü¼ÐÀø®Ä¡G EASI50=83% EASI75=67% EASI90=67%
TRAC°´T¡G aslanpharma.com/wp-content/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/12 ¤U¤È 07:52:46²Ä 5764 ½g¦^À³ Lebrikizumab 2b ¦PÀø®Äªº¹F¦¨³t«×§C©óDupilumab 2a ,¦ý²Ä16¶g¦³¬ÛªñªºÀø®Ä¡C ASLAN004 ¨C¶g¤@°w¡A«e8¶gEASI¤U°Àø®Ä³t«×©MDupilumab¬Ûªñ¡C
¤@¤@¤@¤@
Dupilumab 2a N=110 QWx12¶g Vs Lebrikizumab 2b Q2Wx16¶gN¡×75:52
1¡AEASI50 Dupilumab.//Lebrikizumab ²Ä¤T¶g 55%// ²Ä¥|¶g 65%//52% ²Ä¤¶g 85%¡]¨£°ªÂI¡^// ²Ä¤»¶g 85%// ²Ä¤K¶g 85%//70% ²Ä¤Q¤G¶g85%//81%¡]¨£°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//81%
Dupilumab ¥i¦P®Éªý¾×Âù¼Ð¹vIL4/IL13¡A©Ò¥H¦b²Ä¤¶gEASI50´N¹F°ªÂI85%¦ÓLebrikizumab¥u¯àªýÀÉIL13¤Î³¡¤ÀlL4©Ò¥Hª½¨ì²Ä¤Q¤G¶g¤~¹F81%°ªÂI¡C
¤G¡AEASI75 Dupilumab.//Lebrikizumab
²Ä¥|¶g 35%//30% ²Ä¤K¶g ¡X//42% ²Ä¤Q¤G¶g62%//62%¡]°ªÂI¡^ ²Ä¤Q¤»¶g¡X¡X//61%
¤T¡BIGA 0,1 Dupilumab.//Lebrikizumab
²Ä¥|¶g 18%//18% ²Ä¤K¶g ¤@¤@//30% ²Ä¤Q¤G¶g40%//41% ²Ä¤Q¤»¶g¡X¡X//43%¡]°ªÂI¡^ Lebrikizumab ªý¾×°T®§¯à¤O®Ä¯à¸û®t¡A¦ý®É¶¡©Ôªø¨ì16¶g¡A¤´¥i¸É¨¬IGA0,1ªºÀø®Ä¡C
www.nejm.org/doi/10.1056/NEJMoa1314768 ¹Ï¤@ Dupilumab
www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=7142380_jamadermatol-156-411-g002.jpg
¹Ï¤G¡þªí¤G Lebrikizumab |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/12/13 ¤U¤È 06:22:54
²Ä 208 ½g¦^À³
|
www.almirall.com/documents/portlet_file_entry/4257831/300322_ORI+Lebri+pres+ENG+%2B+pres+vf.pdf/5ad7034f-0dd9-492f-eb83-1515071417de
Lebrikizuma 2Ó¤T´ÁÁ{§É,¨C¨â¶gªºÁͶչÏ(2022/03/30)---Almirall ¤½¥q(¼Ú¬w°Ï¾P°â¤½¥q) °ª峄¾P°â:4.5»õ¼Ú¤¸
¥Dn«ü¼Ð:EASI75//IGA0,1 ¦¸n«ü¼Ð:EASI90 //Pruritus NRS ≥4-point improvementa from baseline //Sleep loss NRS ≥2-point improvementa from baseline //Quality of life: DLQI ≥4-point improvementa from baseline --------------------------------------------------------------------------- ¤ñ¹ïASLAN004 1b MITT ¹Ï«á,¹ïASLAN004 2B Á{§Éµ²ªG·|§ó¦³«H¤ß. §ÚÌ«e¤T¶g¬Ò¤j´T»â¥ý¦]¬°§¹¥þ«ÊªýIL4/IL13°T®§¶Ç»¼, ²Ä¥|¶g«áÁͶÕÀ³·|©MLebrikizumab ¨«¶Õ¬Ûªñ.¦]¬°ASLAN004¨C¤G¶g¥i¯à¶È§¹¥þ«ÊÂê7¤Ñªº³¡¥÷«Êªý, ¦ý¦]«eASLAN004´Á3~4¶g,¤w¤j´T´î±Óªñ50%,¥B¥Íª««ü¼ÐTRACC¤w°¦Ü©³ÂI(³Ì°ª°ªñ80%). ²Ä¥|¶g«áASLN004 2B À³¦p¯à¦pLebrikizumab ¦b(¥þµ{)³¡¥÷«ÊÂꪺª¬ªp¤U,¦U«ü¼Ð¯à³v¨B©Ô°ª,¹FÀ³¦³¤ô·Ç.
³Ì«á¦p¤½¥q©Ò¹w´úÀø®Ä(IGA 0,1)8% °ª©óDupilumab 2¶g¼Ð·ÇªvÀø¾÷·|°ª.
¥Ø¼Ð»ù¦pú³°Ó:4~7¬ü¤¸/ªÑ¾÷·|°ª
Aslan004 2b ²q´ú¤Î´Á±æ¡G¨Ì¾ÚDupilumab¤ÎLebrikizumab 2b,ASLAN004 1b 1.400mg/Q2W EASI75 69% IGA0,1 53%
2.400mg/Q4W EASI75=69%*93%=64% IGA0,1=53%*75%=40%
IGA0,1Àø®Ä²q´ú 400mg/Q2w//53%>300mg/Q2W//49%> 600mg/Q4W//47%>400mg/Q4W//40%> ¹ï·Ó组15%,¥¼¸Ñª¼¥H¤W¥§¡40%. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/4 ¤U¤È 01:58:33
²Ä 207 ½g¦^À³
|
¨ä¹ê¨C¶g¤@°w8¶g´N¥i¼ÒÀÀ¥X
IGA0,1 mITT 7/16=44% (7+6)/(16+6-1)=61% ì¦]¦P¤U¡D
EASI75=81%
¦A¥[9-16¶g¡B¨C¶g¤@°w¡B¥DnªvÀø°ò½uEASI>41 ªº±Ú¸s¡D
«D¶Ç统AD±wªÌ¥²¶·³Q±Æ°£¡D
............ 004-1b mITT*8¶g¼ÒÀÀ
EASI75 11/16=69%... mITT (11+6)/(16+6-1)=81% ¥t¥[6Ó°ò½u=EASI19»´¯gªÌ¡B¦ý°ªTRAc/°ªIgE
«h6/6Àø®Äªñ100%
¥t¥~3¤H¤¤Â_¡B°²³]´î¤Ö¬°2¤H¡B
¥Ø¼ÐEASI75=81% IGA0,1=65%(Lebrikizumab EASI75-16%=IGA0,1ªºÀø®Ä¡D)
......16 ¶gªvÀø
¯uªº¦³¾÷·|¡B¦p¤½¥q©Ò¨¥³ô¤ñ¤fªAÃÄ®Ä |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/3 ¤U¤È 09:17:05
²Ä 206 ½g¦^À³
|
¦UÃĦy®p¾P°â
1¡ALebrikizumab ¨âÓAD¤T´ÁÁ{§ÉÀø®Ä¥Dn«ü¼ÐIGA0,1 ¦©°£¹ï·Ó²Õ¡]16¶g¡^¡ã¦ô¦y®p¾P°â45»õ¬ü¤¸ AD¤@l 30%¡]43%-13%¡^//52¶g©Ô°ª¨ì¹êÅç²Õ46% AD¤@2 22% (33%-11%)//52¶g©Ô¨ì¹êÅç²Õ39%
2¡ADupilumab ¨âÓAD3´Á¡ã¦©°£¹ï·Ó²Õ¡A¦ôAD¦y®p¾P°â80»õ¬ü¤¸ Solo1 28%(38%-10%)//52¶g°¨ì¹êÅç²Õ¬ù36% Solo2 28%(36%-8%)//52¶g°¨ì¹êÅç²Õ¬ù34%
3¡AASLAN004 2b Á{§É16¶g¤G¶g¤@°w¤½¥q¦ô8%Àu©óDupilumab¡]¦©°£¹ï·Ó²Õ¡^ 28%x108%=30.3%
ASLAN004 2b 16¶gx¨C¶g¤@°w¡AÀø®Ä³ô¤ñ¤fªAÃĤG½u ´Á±æÈ64%¡ã15%=49%¡]¤é«á¤T´Á¹ï·Ó²Õ·|°¨ì8¡ã10%¡A¹êÅç²Õ¤@¹ï·Ó²Õ®t²§©Ô°ª¨ì52%¥ª¥k¡^
¦Xp¦ôASLAN004 ¦y®p¾P°â 26¤Q17¡×43»õ¬ü¤¸ ⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯ 4¡AUpadacitinib¤T´Á¡]¤fªAÃĪ«¡^¤@¤@¦ô¦y®p¾P°â35»õ¬ü¤¸¡]¦P½÷·çªº¤fªAÃĪ«¡^
IGA0,1
15mg 48.1% vs 8.4%¡]®t²§40%¡^ 30mg 62% vs 8.4%¡]®t²§54%¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/11/2 ¤W¤È 11:30:24
²Ä 205 ½g¦^À³
|
Ó¤H¦ô ¤@¡B _________________________ ASLAN004 2B 16¶g´Á±æÈ (¨C¤G¶g¤@°w) 295¤H °ò½u¦ô(EASI26~28)
EASI75 69% VS 24% IGA0.1 46% VS 15%
ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3%
µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤@½uÃÄÀø®Ä(¨C¤G¶g¤@°w) ¥i8% °ªDupilumab °w¾¯¾÷·|¤j.
¤G¡BASLAN004 2B 16¶g´Á±æÈ (¨C¶g¤@°w) 75¤H °ò½u¦ô(EASI26~28)
EASI75 73%~80% VS 24% IGA0.1 57%~64%% VS 15%
ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3%
µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤G½uÃÄÀø®Ä(¨C¶g¤@°w) ¥i¤ñ¤fªAUpadacitinib ¾÷·|¤j. .
¤T¡B¥«³õ¹w´Á
¤@½uÃĪ«47%¬Û¹ï©óDupilumab°¾¦n, ¥Ñ©ó¤G½uÃĪ«Àu²§ªí²{¡A¥¼¨Ó52¶gÀø®Ä¦³¼ç¤O¦A©Ô°ª¡B¥[¤W¨ä¥LÃĪ«¦Ò¶q¡B¥«¦û¦ô¬ùDupilumab1/3=80*1/3=26»õ¬ü¤¸¡KA
¤G½uÃĪ« 46% °¾¦n¬Û¹ï©ó¤fªAÃĪ«¡D ¨Ì¦~ªì½÷·ç¦Û¦ôAD ¤fªAÃÄ¥i¾P35»õ¬ü¤¸¡B ¦ô¬ù¦³ªñ½÷·ç1/2¥«¦û¬ù17»õ¬ü¤¸¥i´Á...B
A+B=26+17 =43»õ¬ü¤¸¤§³Ì°ª¾P°â 2023³Q¦~©³¨ÖÁÊ¥«È¦ô¬ù20-25»õ¬ü¤¸ ¨CªÑ20-25¬ü¤¸´Á±æÈ¡D
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/2 ¤W¤È 08:54:08²Ä 5732 ½g¦^À³ Upadacitinib AD ¤T´ÁÁ{§Éµ²ªG:
1. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1)
°ò½u EASI29(15mg)//EASI30(30mg)//EASI28(¹ï·Ó²Õ)
°ò½u IGA=4 46%(15mg)//47%(30mg)//45%(¹ï·Ó²Õ)
clinicaltrials.gov/ct2/show/results/NCT03569293?term=NCT03569293&draw=2&rank=1
2.16¶g Àø®Ä
(1).EASI75 ¹êÅç²Õvs¹ï·Ó²Õ
15mg 69.6% vs 16.3% 30mg 79.7% vs 16.3%
(2).IGA0,1
15mg 48.1% vs 8.4% 30mg 62% vs 8.4%
_________________________ Ó¤H¦ô ASLAN004 2B 16¶g´Á±æÈ (¨C¶g¤@°w) 75¤H °ò½u¦ô(EASI26~28)
EASI75 73%~80% VS 24% IGA0.1 57%~64%% VS 15%
ASLAN004 ¨ì¤T´Á°ò½u EASI·|©Ô°ª¨ìEASI31,¹ï·Ó²ÕÀø®Ä·|¤U°. EASI75=15%//IGA 8~10% ¦ý¹êÅç²ÕEASI·|©Ô°ª,Àø®Ä¤U°2~3%
µ²½× : ¦p¤½¥q9/15©Ò¼ÒÀÀ,¤G½uÃÄÀø®Ä(¨C¶g¤@°w) ¥i¤ñ¤fªAUpadacitinib ¾÷·|¤j.
----------------------- 3.AD-2/AD-3 没¤½¶}Á{§Éµ²ªG¸ê®Æ
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) clinicaltrials.gov/ct2/show/NCT03607422?term=NCT03607422&draw=2&rank=1
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) clinicaltrials.gov/ct2/show/NCT03568318?term=NCT03568318&draw=2&rank=1
--------------------------------------------------------------------------------------- ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/11/1 ¤U¤È 05:59:47²Ä 5731 ½g¦^À³ www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s004lbl.pdf RINVOQ® (upadacitinib) FDA ¼ÐÅÒÀÉ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/19 ¤W¤È 07:35:33
²Ä 204 ½g¦^À³
|
Pk
1.Lebrikizumab 2b clinicaltrials.gov/ct2/show/results/NCT03443024
Àø®ÄPK(°ò½uEASI25.5) ¹êÅç²Õ vs ¹ï·Ó组
EASI75 61% vs 24%(®t²§37%) IGA0,1 45% vs 15%(®t²§30%)
2.Lebrikizumab ph3
16¶g
Àø®ÄPK(°ò½uEASI???) ¹êÅç²Õ vs ¹ï·Ó组 (1)AD1 clinicaltrials.gov/ct2/show/results/NCT04146363
EASI75 59% vs 16%(®t²§43%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组¥§¡47% IGA0,1 43% vs 13%(®t²§30%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组47%~45%//¥§¡46%
(2)AD2 clinicaltrials.gov/ct2/show/results/NCT04178967
EASI75 51% vs 18%(®t²§33%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç组¥§¡41% IGA0,1 33% vs 10%(®t²§22%)¡K¡K¡K¡K°l¥[¨ì52¶g¹êÅç²Õ 41%~33%//¥§¡37%
(3)Lebrikizumab¤QTCS Lebrikizumab ¤QTCS¡Ñ16¶g ¤T´Á¡A¦©°£¹ï·Ó组 @% IGA. 41-22=19 EASI75 70-42=28
3.ASLAN004 2b ´Á±æÈ °ò½u°²³]EASI25.5(¦PLeb. 2b) Àø®ÄPK ¹êÅç组vs ¹ï·Ó²Õ EASI75 73% vs 24%(®t²§49%) IGA0,1 57% vs 15%(®t²§42%)
4.Dupilumab ph3 www.nejm.org/doi/full/10.1
16¶g °ò½uEASI32.5 (1)SOLO1 EASI75 51%vs 15%(®t²§36%) IGA0,1 38%vs 10%(®t²§28%) (2)SOLO2 EASI75 44%vs 12%(®t²§32%) IGA0,1 36%vs 8%(®t²§28%)
(3)Dupilumab +TCS 16¶gvs 52¶g clinicaltrials.gov/ct2/show/results/NCT02260986
A.EASI75 QW//Q2W//¹ï·Ó²Õ--%
16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6
B.IGA0,1 QW//Q2W//¹ï·Ó²Õ--%
IGA0,1
QW//Q2W//¹ï·Ó²Õ--%
16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------(2017/10 ¤½§G)
5¡BLebrikizumab ¦y®p¾P°â预¦ô¥«³õ¤À§é®v45-150»õ¬ü¤¸¡C §¨Ó¤½¥q»{¬°¥i¬° ¤¤-««×AD²Ä¤@½uÃĪ«¡C (Ó¤H»{¬°Lebrikizumab 45»õ¬ü¤¸¦³¾÷·|//YµLASLSN004¤W¥«)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/10/6 ¤W¤È 05:49:17
²Ä 203 ½g¦^À³
|
1. www.nejm.org/doi/full/10.1056/nejmoa1610020
¹Ï¤G¡C Dupilumab 2Ó¤T´ÁÁ{§É EASI ¤U°¦U¶gÁͶժí¡C ...16¶g
2.ASLAN004 1b mITT ¦U¶gEASI¤U°ÁͶժí¡C ¡K¡K8¶g¡A ¦p¹Ï¤@¡C ASLN ´Á¥Zºô¯¸ aslanpharma.com/news/?cat=publications
EADV(2022) ²Ä¤GÓ´Á¥Z Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
3.PK ASLAN004 EASI ¤U°´T«×/³t«×¤ñDupilumab ¤T´ÁÀu¡C
¤U°EASI50 ASLAN004 ¦b²Ä¤T¶g¹F¨ì¡ADupilumab ¦b²Ä¥|¶g¤~¨ì¹F¡C ¤U°¦ÜEASI60 :ASLAN004¦b²Ä¥|¶g¡ADupilumab ¦b²Ä5¶g ¡K¡KDupilumab ¤T´Á¤¤断²v7¡P5%¡C(°ò½uEASI32.5) A.°ò½uEASI25.5/§CTRAC ¡A¥§¡°´TEASI 77% B.°ò½uEASI31/¤¤TRAC ¡A¥§¡°´TEASI 67% C.°ò½uEASI42/°ªTRAC,¥§¡°´TEASI66% Á`¥§¡°ò½u32.5¡A¥§¡°´TEASI 70% ....¥H¤W¦U组¤H¼Æ¬Ûªñ¡C ¡K¡KASLAN004 1b mITT (°ò½uEASI 31.2) ¤¤断²v3/16=18.8%¡K¡K600mg |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/28 ¤W¤È 11:07:13
²Ä 202 ½g¦^À³
|
¤@.ASLAN004 2b 16¶g´Á±æÈ ASLAN004 VS¹ï·Ó²Õ//®t²§(¦©°£¹ï·Ó²Õ)
IGA 0,1= 57% VS 15%//®t²§42%(57%-15%=42%) EASI75= 73% VS 24%//®t²§49%(73%-24%=49%)
¤G.Tralokinumab °w¾¯,¥h¦~12¤ë ÀòFDA ,¤¤-«AD¬ü°êÃĵý(DUPILUMAB «áªº¥@¬É²Ä¤G¤ä,DUPILUMAB). MOA:§@¥Î¦bIL13 °tÅéA,DÁ³±Û¤W,¨Ï±oIL13 °T¸¹µLªk³Q¶Ç»¼.¦ýIL4 °T¸¹¥i¥¿±`¶Ç»¼.
(¤@).ECZTRA 1 1.IGA0,1
Q2W//Q4W VS ¹ï·Ó²Õ //¦©°£¹ï·Ó²Õ«á 16¶g 15.8%//-- VS 7.1% // 8.7% 52¶g 8.1%//6.2%
2.EASI75
16¶g 25%//-- VS 12.7%//12.3% 52¶g 15%//12.3%
(¤G).ECZTRA 2
1.IGA 0,1 Q2W//Q4W VS ¹ï·Ó²Õ //¦©°£¹ï·Ó²Õ«á 16¶g 22.2%//--VS 10.9% //11.3% 52¶g 13.1%//10.0%
2.EASI75 16¶g 32.2%//--VS 11.4%//20.8% 52¶g 18.0%//16.4%
pubmed.ncbi.nlm.nih.gov/33000465/
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
1.At week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0 or 1: 15¡P8% vs. 7¡P1% in ECZTRA 1 [difference 8¡P6%, 95% confidence interval (CI) 4¡P1-13¡P1; P = 0¡P002] and 22¡P2% vs. 10¡P9% in ECZTRA 2 (11¡P1%, 95% CI 5¡P8-16¡P4; P < 0¡P001)
and EASI 75: 25¡P0% vs. 12¡P7% (12¡P1%, 95% CI 6¡P5-17¡P7; P < 0¡P001) and 33¡P2% vs. 11¡P4% (21¡P6%, 95% CI 15¡P8-27¡P3; P < 0¡P001).
www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/
(¤T)Tralokinumab 52¶gºû«ù²v ¨Ì16¶g,¹FEASI75 OR IGA0,1¬°¤ÏÀ³ªÌ,¥t¶i¦æ18~52¶g Q2W/Q4W/Q2W¦w¼¢¾¯
(1)ECZTRA 1 Q2W//Q4W/Q2W¦w¼¢¾¯ A.IGA0,1 51%//39%//47% B.EASI75 60%//49%//33%
(2)ECZTRA 2 Q2W//Q4W/Q2W¦w¼¢¾¯ A.IGA0,1 59%//45%//25% B.EASI75 56%//51%//21%
¦b¨â¶µ¬°´Á 52 ¶g¡BÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº III ´Á¸ÕÅç ECZTRA 1 ©M ECZTRA 2 ¤¤¡A¤¤«×¦Ü««× AD ªº¦¨¤H³QÀH¾÷ (3:1) ±µ¨ü¨C 2 ¶g 300 mg ªº tralokinumab ¥Ö¤Uª`®g¡C Q2W¡^©Î¦w¼¢¾¯¡C ¥Dn²×ÂI¬O²Ä 16 ¶g®É¬ã¨sªÌªº¾ãÅéµû¦ô (IGA) µû¤À¬° 0 ©Î 1¡A²Ä 16 ¶g®ÉÀã¯l±¿n©MÄY«©Ê«ü¼Æ (EASI 75) §ïµ½≥ 75%¡C
IGA µû¤À¬° 0 ©Î 1 ©M/©Î EASI 75 ªº±wªÌ ¦b²Ä 16 ¶g¨Ï¥Î tralokinumab ªº±wªÌ³Q«·sÀH¾÷¤À°t¦Ü tralokinumab Q2W ©Î¨C 4 ¶g¤@¦¸©Î¦w¼¢¾¯¡A«ùÄò 36 ¶g¡C
³o¨Ç¸ÕÅç¤w¦b ClinicalTrials.gov µù¥U¡GNCT03131648 ©M NCT03160885¡C
In two 52‐week, randomized, double‐blind, placebo‐controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate‐to‐severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Primary endpoints were Investigator¡¦s Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. Patients achieving an IGA score of 0 or 1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. The trials were registered with ClinicalTrials.gov: NCT03131648 and NCT03160885.
¤T.ASLAN004 2b ´Á±æÈ VS Tralokiumab 3´Á(16¶g) ¦©°£¹ï·Ó²Õ
1.ASLAN004 2b ´Á±æÈ IGA 0,1= 57% VS 15%//®t²§42%----A EASI75= 73% VS 24%//®t²§49%----B
vs
2.Tralokiumab 3´Á(16¶g)---¦©°£¹ï·Ó²Õ
IGA 0,1= ®t²§8.7%~11.3%,¥§¡10%---C
EASI75= ®t²§12.3%~20.8%,¥§¡16.6%---D
3.16¶gPK IGA 0,1 A/C=42%/10%=420% EASI75 B/D=49%/16.6%=295%
¥|:µ²½×ASLAN004 ´Á±æÈ,¤T´Á¥Dn«ü¼Ð IGA0,1 //EASI75 ¤ñ¤w¦b¬ü/¼Ú¤W¥«ªºTralokiumab(¥@¬É²Ä¤G¤W¥«°w¾¯) Àø®Ä°ª¥X320%//195%.
ASLAN004 ADÃĵý §ä¤£¨ì²z¥Ñ®³¤£¨ì. ¦ý»ùȦ³¦h°ªnPKªº¤´¬O
Dupilumab ¤T´Á Q2W IGA 0,1= 38% VS 10%//®t²§28%----SOLO1 =36% VS 8% //®t²§28%----SOLO2 EASI75= 51% VS 15%//®t²§36%----SOLO1 = 44% VS 12%//®t²§32%----SOLO2 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/26 ¤W¤È 09:25:35
²Ä 201 ½g¦^À³
|
Leb. PK Dupilumab¡A(©Ò¦³¤T´Á¡A©Î¥[TCS¡A©Î16/52¶g)¡A¦©°£¹ï·Ó组¼vÅT
Leb. 40% Àu©óDup. ©Î Leb. 39% ¦H©óDup.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/26 ¤W¤È 08:15:11²Ä 5648 ½g¦^À³ Lebrikizumab ¤QTCS¡Ñ16¶g ¤T´Á¡A¦©°£¹ï·Ó组 @% IGA. 41-22=19 EASI75 70-42=28
¤G¡BDupilumab +TCS 16¶g¡A¦©°£¹ï·Ó组 @% IGA. 38.7-14.2=24.5 EASI75 68.9-23.2=45.7
¤T¡APK
Leb./Dup. @% IGA. 19/24.5=78 EASI75 28/45.7=61
结½× ¥[TCS«á¡ALeb. ¦H©ó Dup.
¦bIGA.¦H22%, ¦bEASI75 ¦H39%.
Leb.¤QTCS ©MLeb.AD2 ¤T´Á/16¶gêq®Ä°ò¦¸û¬Ûªñ¡C
Leb. AD2 16¶g¡C IGA. 33-11=22 EAS75 51-18=33 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/26 ¤W¤È 07:33:32
²Ä 200 ½g¦^À³
|
¤@¡ADupilumab+TCS vs Dupilumab (SOLO1/2 Q2W),
EASI75(%) pk¡A¡K¡K¤T´ÁÁ{§É
1.Dup.+TCS QW//Q2W//¹ï·Ó²Õ--%
16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6
52¶g/16¶g=95%, ¥§¡°h5%
2.Dup. SOLO 1/2 Q2W--%
16¶g 51/44,¥§¡47.5
3.pk
68.9/47.5=145...16¶g
Dupilumab¤Q TCS¡A¦b²Ä16¶g¬Û¹ï©ó¥¼¥[TCS, EASI75,¼W¥[45%ªºÀø®Ä¡C
¥B52¶g¥u°5%.
¤G¡BLebrikizumab ¤QTCS ¤T´ÁÁ{§Éx16¶gªvÀø¡A 2022/4/22 µ²ªG¡C¤½§G
1.Leb.+TCS vs ¹ï·Ó组
1.IGA0,1 41 vs 22 2.EASI75 70 vs 42
3.Leb.+TCS pK Lebrikizumab EASI75 16 ¶g AD1/AD2 59/51,¥§¡55
70/55=127%,¼W¥[27% TCS ¼W¥[EASI75 27%Àø®Ä ........................... News Release Lilly¡¦s Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis April 11, 2022
Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in pivotal combination trial that met all primary and key secondary endpoints
INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS.
Today¡¦s ADhere data, together with results from the ADvocate monotherapy studies, demonstrate the potential for lebrikizumab to reduce disease burden and provide relief for people with uncontrolled atopic dermatitis when used either alone or combined with topicals, said Eric Simpson, M.D., M.C.R., Professor of Dermatology and Director of Clinical Research at Oregon Health & Science University in Portland, and principal investigator of ADhere. Lebrikizumab specifically targets the IL-13 pathway, which plays the central role in this chronic inflammatory disease. These results strengthen our understanding of lebrikizumab in atopic dermatitis and help establish it as a possible new treatment option.
Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin 13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R£\1/IL-4R£\ (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.1-5 IL-13 plays the central role in Type 2 inflammation in AD.6,7 In AD, IL-13 underlies the signs and symptoms including skin barrier dysfunction, itch, infection and hard, thickened areas of skin.8
Among patients taking lebrikizumab plus TCS, 41 percent achieved clear or almost clear skin (IGA) at 16 weeks compared to 22 percent of patients taking placebo plus TCS. At 16 weeks, 70 percent of patients taking lebrikizumab plus TCS achieved an EASI-75 response compared to 42 percent taking placebo plus TCS. Differences between patients receiving lebrikizumab in combination with TCS and placebo with TCS were observed as early as four weeks for EASI-75.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/25 ¤U¤È 04:02:29
²Ä 199 ½g¦^À³
|
¤j§ó¥¿Ãö©óLebrikizumab ¤T´Á52¶gªº¼Æ¾Ú°ò¦ÅTÀ³ªÌ©w¸q ¬O16¶g®É¹F EASI75 ,«DEASI50(¤@¯ëAD ªvÀø«á Responders¤§©w¸q¬°EASI50)
* Responders were defined as those achieving a 75% reduction in the Eczema Area and Severity Index from baseline (EASI-75) or an IGA 0 or 1 (clear or almost clear) with a 2-point improvement and without rescue medication use at Week 16.
* ÅTÀ³ªÌ©w¸q¬°Àã¯l±¿n©MÄY«µ{«×«ü¼Æ±q°ò½u (EASI-75) ´î¤Ö 75% ©Î IGA 0 ©Î 1¡]¡§²M°£¡¨©Î¡§´X¥G²M°£¡¨¡^¡A§ïµ½ 2 ¤À¥B¥¼¶i¦æ±Ï´©ªº¤H ²Ä 16 ¶gªºÃĪ«¨Ï¥Î±¡ªp¡C
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly¡¦s Phase 3 Monotherapy Atopic Dermatitis Trials September 8, 2022
finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html
¤@.Lebrikizumab 52¶gªºªvÀø®ÄªG---¨Ì°ò½u²Ä¤@¶g¦ôp°ò¦--------¤j×¥¿¦p¤U:
1¡AAD1. 52¶gQ4W//Q2W
IGA ¡G59%(EASI75)x74%//76% =47%//45%
Vs 16¶gÀø®Ä 43%¡A 52¶g/16¶g=107%
EASI75: 59%(EASI75)x79%//79% =47%
52¶g/16¶g=47%/59%=80%
2.AD2
IGA ¡G51%(EASI75)x81%//65% =41%//33%
Vs 16¶gÀø®Ä 33%
52¶g/16¶g=112%
EASI75: 51%¡]EASI75)x85%//77% =43%//39%
Vs 16¶gÀø®Ä 51%
52¶g/16¶g=80%
µ²½×¡G±q16¶g©µªø¨ì52¶g§MÀø¹ïIGA ®ÄªG ¥§¡´£¤É9%¡A ¦ý¹ïEASI75 ¥§¡¤U°20%¡C
¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@
Lebrikizumab Week 52 Results
1¡PADvocate 1(¦b²Ä16¶g¦³59%¹FEASI75¡^
Lebrikizumab 250 mg Q4W//Q2W
IGA (0,1) 74 %//76 % EASI¤@75 79%//79% Pruritis (Itch) NRS 80 %//81 %
2¡PADvocate2¡]¦b²Ä16¶g51%¹FEASI75¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 %
Pruritis (Itch) NRS 88 %//90 %
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁÁ{§Éµ²ªG
clinicaltrials.gov/ct2/show/results/NCT04146363
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)
clinicaltrials.gov/ct2/show/results/NCT04178967?term=ADvocate2+lebrikizumab&draw=2&rank=1
¤@.Lebrikizumab(16¶g)¡A¤T´Á ¹êÅç²Õvs¹ï·Ó²Õ In ADvocate 1,
(IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B
In ADvocate 2,
(IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D
--------------------------------------------
¤G..Lebrikizumab PK DUupilumab+TCS 52¶gÀø®ÄPK ---¨Ì°ò½u²Ä¤@¶g¦ôp°ò¦--------¤j×¥¿¦p¤U:
¤T´Á¥Dn«ü¼ÐIGA0,1 ¤jPk
1¡B16¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ
38.7%-14.2%=24.5%¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^//¥t¥~2Ó¥¼¥[TCSªºSolo1/2 ¦©°£¹ï·Ó²Õ«á¬°28%¡^ vs 43%-13%=30%¡K.Leb. AD1¡KB 33%-11%=22%¡KLeb. .AD2...C ¡]¥h¦~©³¸ê°T¡^
B/A=30%/24.5%=122%(Leb.22%ÀuDupilumab)¡K..D C/A=22%/24.5%=90%¡]Leb. 10%¦H©óDupilumab)¡K.E
ASLN004©M Lebrikizumab ¦P¨Ì¾aIL13-Ra1 ¡]ª½±µ¡þ¶¡±µ¡^¦Y¶º¡C ¦bASLN004Á{§É ITT¤ÀªR¥¼¶W¶VLebrikizumab(²¼gLeb.¡^«e¡A¤ÀªR®v¨ÌLeb.³Q¨ÖÁÊ»ùÈ11»õ¬ü¤¸¦ôºâASLAN004»ùÈ¡A¹êÄÝ¥¿±`¡C 9¤ë15¤é ASLN R&D ³ø§i¡A150¤H¥«½Õ³ø§i¡A¨Ì¾Ú8%Àu©óDupilumab°µ¥«½Õ°ò¦¡C«Ü¤j¥i¯à¨Ó¦ÛLeb.¤T´Á¡]SOLO1/2)¼Æ¾Ú¬°°ò¦¡C
³o¼ËDupilumab ¥é¥ÍÃĨÌ80%»ù®æ¾P°â¡AASLAN004ªº¥«³õ±N¦³«Ü¦hÄvª§ªÌ¡C ²H°¨¿ü¯à·Q¨ìªº´N¬O¦p¦¹¤F¡C¬GµL«ù¦¹¼W¥[«ùªÑ¤]¦X²z¡C
2.52¶g IGA0,1 PK
Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F
46%-13%=33%¡K.Leb. AD1¡KG ¡]2022/9/8 ¸ê°T¦ôp¡^ 37%-11%=26%⋯Leb. AD2¡KH ¡]2022/9/8¤½¥¬¸ê°T¦ôp¡^
G/F=33%/23.5%=140%¡KJ¡]Leb. 40%Àu©óDupilumab) H/F=26%/23.5%=111%¡K..K (Leb 11% Àu©óDupilumab)
¤T.16¶g VS 52 ¶g
1. Lebrikizumab ¤T´ÁÁ{§É
A.IGA0,1
AD1//AD2/(¹ï·Ó²Õ)---% 16¶g43//33//(13~11) 52¶g46//37//(°²³]¦P16¶g 13~11).------(2022/09/08 ¤½§G)
52¶g/16¶g=109%,¥§¡´£¤É9%
B.EASI75
AD1//AD2/(¹ï·Ó²Õ)---% 16¶g59//51//(16~18) 52¶g47//41//(°²³]¦P16¶g 16-18 ).------(2022/09/08 ¤½§G)
52¶g/16¶g=80%, ¥§¡°h20%.
2..Dupilumab+TCS ¤T´ÁÁ{§É
A.IGA0,1
QW//Q2W//¹ï·Ó²Õ--%
16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------(2017/10 ¤½§G)
52¶g/16¶g=97.5%,¥§¡°h2.5%
B.EASI75(%)
QW//Q2W//¹ï·Ó²Õ--%
16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6
52¶g/16¶g=95%, ¥§¡°h5% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/25 ¤U¤È 01:28:49
²Ä 198 ½g¦^À³
|
¤T.¸É¥R Lebrikizumab 52¶g PK Dupilumab 16¶g ,¤T´Á¥Dn«ü¼ÐIGA0,1
SOLO1/SOLO2 Dupilumab 16¶g ¦©°£¹ï·Ó²Õ0,1=28%----L (
G/L=42.5%/28%=152%¡KM¡]Leb. 52%Àu©óDupilumab) H/L=36%/28%=129%¡K..N (Leb 29% Àu©óDupilumab)
¤G.52¶gPK
Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F
55.5%-13%=42.5%¡K.Leb. AD1¡KG ¡]2022/9/18 ¸ê°T¦ôp¡^ ¡]51%+43%¡^/2-11%=36%⋯Leb. AD2¡KH ¡]2022/9/18¤½¥¬¸ê°T¦ôp¡^
G/F=42,5%/23.5%=180%¡KJ¡]Leb. 80%Àu©óDupilumab) H/F=36%/23.5%=156%¡K..K (Leb 56% Àu©óDupilumab) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/24 ¤U¤È 03:30:35
²Ä 197 ½g¦^À³
|
×¥¿2
38.7%-14.2%=24.5%¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^ //¥t¥~2Ó¥¼¥[TCSªºSolo1/2 ¦©°£¹ï·Ó²Õ«á¬Ò¬°28%(solo1 38%-10%=28%//solo2 36%-8%=28%¡^
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/24 ¤U¤È 03:16:15
²Ä 196 ½g¦^À³
|
¬Ü¨¤¦b¦¹¡K×¥¿l
¤T´Á¥Dn«ü¼ÐIGA0,1 ¤jPk
¤@¡B16¶gPK Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ
38.7%-14.2%=24.5%¡K.Dupilumab ¡K¡K..A¡]2017/10¸ê°T¡^//¥t¥~2Ó¥¼¥[TCSªºSolo1/2 ¦©°£¹ï·Ó²Õ«á¬°30%¡^ vs 43%-13%=30%¡K.Leb. AD1¡KB 33%-11%=22%¡KLeb. .AD2...C ¡]¥h¦~©³¸ê°T¡^
B/A=30%/24.5%=122%(Leb.22%ÀuDupilumab)¡K..D C/A=22%/24.5%=90%¡]Leb. 10%¦H©óDupilumab)¡K.E
ASLN004©M Lebrikizumab ¦P¨Ì¾aIL13-Ra1 ¡]ª½±µ¡þ¶¡±µ¡^¦Y¶º¡C ¦bASLN004Á{§É ITT¤ÀªR¥¼¶W¶VLebrikizumab(²¼gLeb.¡^«e¡A¤ÀªR®v¨ÌLeb.³Q¨ÖÁÊ»ùÈ11»õ¬ü¤¸¦ôºâASLAN004»ùÈ¡A¹êÄÝ¥¿±`¡C 9¤ë15¤é ASLN R&D ³ø§i¡A150¤H¥«½Õ³ø§i¡A¨Ì¾Ú8%Àu©óDupilumab°µ¥«½Õ°ò¦¡C«Ü¤j¥i¯à¨Ó¦ÛLeb.¤T´Á¡]SOLO1/2)¼Æ¾Ú¬°°ò¦¡C
³o¼ËDupilumab ¥é¥ÍÃĨÌ80%»ù®æ¾P°â¡AASLAN004ªº¥«³õ±N¦³«Ü¦hÄvª§ªÌ¡C ²H°¨¿ü¯à·Q¨ìªº´N¬O¦p¦¹¤F¡C¬GµL«ù¦¹¼W¥[«ùªÑ¤]¦X²z¡C
¤G.52¶gPK
Dupilumab ¤QTCS 3´Á PK Lebrikizumab¡K.¦©°£¹ï·Ó²Õ 36%-12.5%=23.5%⋯Dupilumab¡K(2017.10¸ê°T¡^¡K.F
55.5%-13%=42.5%¡K.Leb. AD1¡KG ¡]2022/9/18 ¸ê°T¦ôp¡^ ¡]51%+43%¡^/2-11%=36%⋯Leb. AD2¡KH ¡]2022/9/18¤½¥¬¸ê°T¦ôp¡^
G/F=42,5%/23.5%=180%¡KJ¡]Leb. 80%Àu©óDupilumab) H/F=36%/23.5%=156%¡K..K (Leb 56% Àu©óDupilumab)
Leb.52¶g±N¨ú¦¨¬°AD ·s¥D¤O¡C¡K..¦ôp2023¦~©³¨úFDAÃĵý¡C »ùȳs«°¡A¦ôAD¤W¥«5¦~¶W¶VDupilumab. ¦³40¡ã80»õ¬ü¤¸ªº¾P°â¹ê¤O¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K..
½Ö¯à·Q¨ìLebrikizumab AD¤T´ÁÁ{§É2ÓÁ{§É52¶g¤jÃzµo¡C 16¶gIGA.0,1=43%~33%, 52¶gIGA,0.1=56%/55%~51%/44%.------Àø®Ä¤j´T´£¤É.(2022/09/08 ¤½§G) (Lebrikizumabý³Ý/COPD ¤T´ÁµL¦¨¥\) -------------------------------------- ¦ÓDupilumab+TCS ¤T´ÁÁ{§É
QW//Q2W//¹ï·Ó²Õ
16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------©M16©PÀø®Ä¬Û·í.(2017/10 ¤½§G)
Lebrikizumab 52 ¶g IGA,0.1Àø®Ä¡A
16¶g ¥Ñ44%´£¤É¦Ü52¶g55%/56% 33%´£¤É¦Ü51%/43%
16¤Ñ«e¤~µo§G¡C
±N¥´±ÑDupilumab 52¶g36%¥é¥ÍÃÄ¡C (¤é«á¥´8§é¾P°â) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/23 ¤U¤È 07:44:47
²Ä 195 ½g¦^À³
|
¥xÁÞ¤j´¿»¡§ë¸ê·sÃÄn¾aÂI¹B®ð, §¨Ó¤½¥q¥H11»õ¬ü¤¸¨ÖÁÊDERM ¤½¥q/Lebrikizumab ¤é«áÅK©w¤jÁÈ¿ú.
½Ö¯à·Q¨ìLebrikizumab AD¤T´ÁÁ{§É2ÓÁ{§É 16¶gIGA.0,1=43%~33%, 52¶gIGA,0.1=56%/55%~51%/44%.------Àø®Ä¤j´T´£¤É.(2022/09/08 ¤½§G) (Lebrikizumabý³Ý/COPD ¤T´ÁµL¦¨¥\) -------------------------------------- ¦ÓDupilumab+TCS ¤T´ÁÁ{§É
QW//Q2W//¹ï·Ó²Õ
16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5-----------©M16©PÀø®Ä¬Û·í.(2017/10 ¤½§G)
MOA
Lebrikizumab µ²¦X¦bIL-13°tÅé B,C Á³±Û,¦ý¥i©MIL13-R£\1 µ²¦X µ²¦X¦bIL-13°tÅé B,C Á³±Û¦Ó¨ÏIL13-R£\1 µLªkµ²¦X²Õ¦¨«¬II½Æ¦X¨üÅ餧Àø®Ä ¯ÊÂI:IL4µ²¦XIL4-R£\¦A§ä¦³ªÅªºIL-13R£\1¬O¦³¾÷·|ªº. ¬G³y¦¨ý³Ý¤T´ÁÁ{§É¤@Ó¹F¼Ð/¤@Ó¥¼¹F¼Ð//AD¤T´Á2ÓÁ{§É16¶g IGA,0.1 Àø®Ä43%/33%.---®t30%
ASLAN004 µ²¦X¦bIL-13R£\1 ¨ÏIL13µLªkµ²¦X IL-13R£\1 µ²¦X¦bIL-13R£\1 ¨ÏIL-13R£\1µLªkµ²¦X¦Ó²Õ¦¨«¬II½Æ¦X¨üÅ餧Àø®Ä
Dupilumab µ²¦X¦bIL4-R£\1 ¨ÏIL4µLªkµ²¦XIL4-R£\//YC-R µ²¦X¦bIL4-R£\1 ¨ÏIL4-R£\ µLªkµ²¦X¦Ó²Õ¦¨«¬II½Æ¦X¨üÅ餧Àø®Ä |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/23 ¤W¤È 08:45:47
²Ä 194 ½g¦^À³
|
Lebrikizumsb 52¶g vs dupilumsb +TCS 1.IGA ¥§¡54% vs 36%(¨â¶g¤@°w)¡A
Lebrikizumab ¦b52¶g¤jĹ Dupilumab 50% ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
Dupilumab+TCS ¤T´Á¡A°µ¨ì52¶g¤§740¤HÁ{§É
结ªG: 1.IGA 16¶g vs 52¶g¡AÀø®Ä¬Û·í¡C 2.EASI75 l6¶g vs 52¶g¡AÀø®Ä¬Û·í¡C
Lebrikizumsb 52¶g vs dupilumsb +TCS 1.IGA ¥§¡54% vs 36%(¨â¶g¤@°w)¡A
Lebrikizumab ¦b52¶g¤jĹ Dupilumab 50% 2.EASI75 58% vs 65%
Lebrikizumab ¥¼¥[TCS Dupilumab ¥¼¥[TCS EASI75 16¶g44~51%
¬G¦b¥¼TCS¤§ª¬ªp¤U¡C Lebrikizumsb ¤´¤j赢Dupilumab 约15%
ASLAN004 ¦PLebrikizumab ª½±µ¨ÏIL13¨üÅ餣©MIL4±µ¦X¡C ªýÀÉIL13ªº°T¸¹¶Ç»¼±j©ódupilumab
®¥³ßLebrikizumab 52¶gªºÀu²§ªí²{¡C
¦ÓASLAN004 ¥i±æ¦b16¶g´N¤j´T领¥ýLebrikizimab EASI 75= ASLAN 73% vs Leb 61%(2bªºpk)
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (CHRONOS)
clinicaltrials.gov/ct2/show/results/NCT02260986
¦¹¤T´ÁÁ{§É2014/10-2017/10
¤T´ÁÁ{§É 16 ¶gvs 52¶g Dupilumab+TCS qw//q2w vs ¹ï·Ó组 +TCS
N=315/106 vs 319 °ò½u32.1//33.6 vs 32.6
Àø®Ä Qw//Q2W//¹ï·Ó组(TCS) 1.IGA0,1 (%) 16¶g39.2//38.7//14.2 52¶g40.0//36.0//12.5
2.EASI75(%)
16¶g63.9//68.9//23.2 52¶g64.1//65.2//21.6 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/20 ¤U¤È 07:27:03
²Ä 193 ½g¦^À³
|
¦bÁú°ê©Ò°µ99¦ì52¶gDupilumab ªvÀø ¤¤-««×ªXAD °O¿ý.
A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
N=99
www.ncbi.nlm.nih.gov/pmc/articles/PMC8651808/
²Ä¤@¤ÑDupilumab 600mg--¨C2¶g¤@°w*300MG +TCS (¥~¥ÎÃþ©T¾J³n»I)
°ò½uEASI=30.02
EASI¥§¡°´T 16¶g=75% 32¶g=84% 52¶g=88%
EASI75 16¶g=56% 32¶g=87% 52¶g=90%
EASI90 16¶g=10% 32¶g=35% 52¶g=54%
DUPILUMAB TCS (¥~¥ÎÃþ©T¾J³n»I) ¹ïEASI°´T¦b16¶g®É¬ù¼W16%.¦ý¹ïIGA 0,1 ¼W¥[À°§U¤£¤j. ¥»³ø§iµLIGA 0,1 ¤§Àø®Ä. ¤@¯ëIGA 0,1 ¤ñEASI90¤ñ²v°ª¬ù1~2%. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/20 ¤U¤È 04:08:41
²Ä 192 ½g¦^À³
|
Lebrikizumab 52¶gªºªvÀø®ÄªG
1¡AAD1. 52¶gQ4W//Q2W
IGA ¡G74%(EASI50)x74%//76% =55%//56%
Vs 16¶gÀø®Ä 43%¡A¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉIGA 12%//13%
EASI75: 74%(EASI50)x79%//79%% =58%
Vs 16¶gÀø®Ä 59%¡A¸g18¡ã52¶gªvÀø«á¦ôpEASI75,Ë°h1%¡C
2.AD2
IGA ¡G66%(EASI50)x81%//65% =53%//43%
Vs 16¶gÀø®Ä 33%¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉIGA 23%//10%
EASI75: 66%¡]EASI50)x85%//77% =56%//51%
Vs 16¶gÀø®Ä 51%¸g18¡ã52¶gªvÀø«á¦ôp´£¤ÉEASI75 5%//0%
µ²½×¡G©µªø52¶g§MÀø¹ïIGA´£¤É®ÄªG顕µÛ¡A¦ý¹ïEASI75¤§´£¤É®ÄªG¤£¤j¡C
¤@¤@¤@¤@¤@¤@¤@¤@¤@¤@
Lebrikizumab Week 52 Results
1¡PADvocate 1(¦ôp¦b²Ä16¶g¦³74%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI750¼Æ¾Ú¡^
Lebrikizumab 250 mg Q4W//Q2W
IGA (0,1) 74 %//76 % EASI¤@75 79%//79% Pruritis (Itch) NRS 80 %//81 %
2¡PADvocate2¡]¦ôp¦³66%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI50ªº¼Æ¾Ú¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 %
Pruritis (Itch) NRS 88 %//90 %
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁÁ{§Éµ²ªG
clinicaltrials.gov/ct2/show/results/NCT04146363
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)
clinicaltrials.gov/ct2/show/results/NCT04178967?term=ADvocate2+lebrikizumab&draw=2&rank=1
¤@.Lebrikizumab(16¶g)¡A¤T´Á ¹êÅç²Õvs¹ï·Ó²Õ In ADvocate 1,
(IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B
In ADvocate 2,
(IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/20 ¤U¤È 03:02:52²Ä 5607 ½g¦^À³ §¨Ó¤½¥q¦b9¤ë¦bEADVªº¤fÀY³ø§i ¿ï¨ú16¶gLebrikizumabªvÀø¤¤-«AD«áÀø®Ä¹FªºEASI50¥H¤WªÌÄ~ÄòªvÀø18¡ã52¶gªº¤T´Áµ²ªG³ø§i
⋯⋯
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly¡¦s Phase 3 Monotherapy Atopic Dermatitis Trials
¦b§¨Ó¤½¥qªº 3 ´Á³æÃĪvÀø¯SÀ³©Ê¥Öª¢¸ÕÅ礤¡A¨C¥|©Pµ¹ÃĤ@¦¸ªº Lebrikizumab ¥i«O«ù«ù¤[ªº¥Ö½§²M°£
finance.yahoo.com/news/lebrikizumab-dosed-every-four-weeks-121500944.html
September 8, 2022¡P
These data were featured in a late-breaking, oral presentation at the 31st European Academy of Dermatology and Venerology (EADV) Congress.
New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity
Results suggest less frequent, every four week dosing of lebrikizumab provided similar improvements to every two week dosing
Regulatory submissions for U.S. and EU planned for this year
³Ì·sªº³Ì·s¼Æ¾ÚÅã¥Ü¡Alebrikizumab À³µªªÌ¡]16¶gEASI¶W¹L50%,¦ôp74%¡þAD1¡ã66%/AD2) ¦bªvÀø¤@¦~«á ³ø§i¤F¦b¥Ö½§²M°£¡Bæ±Äo©M¯e¯fµ{«×©MÄY«µ{«×§ïµ½¤è±ªºªø´Áµ²ªG
µ²ªGªí©ú¡Alebrikizumab ¨C 4 ¶gµ¹ÃÄÀW²v¸û§C¡A»P¨C 2 ¶gµ¹ÃĦ³¬Û¦üªº§ïµ½
p¹º©ó¤µ¦~¦V¬ü°ê©M¼Ú·ù´£¥æºÊºÞ¤å¥ó
Lebrikizumab Week 52 Results
1¡PADvocate 1(¦ôp¦b²Ä16¶g¦³74%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI750¼Æ¾Ú¡^
Lebrikizumab 250 mg Q4W//Q2W
IGA (0,1) 74 %//76 % EASI¤@75 79%//79% Pruritis (Itch) NRS 80 %//81 %
2¡PADvocate2¡]¦ôp¦³66%¹FEASI50¡A¦b¤T´Áµ²ªG¤¤§ä¤£¨ìEASI50ªº¼Æ¾Ú¡^ Q4W//Q2W IGA (0,1) 81 %//65 % EASI-75 85 %//77 %
Pruritis (Itch) NRS 88 %//90 %
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) ¤T´ÁÁ{§Éµ²ªG
clinicaltrials.gov/ct2/show/results/NCT04146363
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)
clinicaltrials.gov/ct2/show/results/NCT04178967?term=ADvocate2+lebrikizumab&draw=2&rank=1
¤@.Lebrikizumab(16¶g)¡A¤T´Á ¹êÅç²Õvs¹ï·Ó²Õ In ADvocate 1,
(IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B
In ADvocate 2,
(IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/19 ¤U¤È 07:26:49
²Ä 191 ½g¦^À³
|
§ó¥¿-1
ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 ---9/15 R&D ¤é¸ê®ÆÀÉ
¤@.P.39 ¥»¶ªº60»õ¬ü¤¸¬O2021¦~Dupilumab¦b¦U°Ïªº¾P°â¹êÁZ. ¨Ã«DASLN ¤½¥q¦Û¦ô¥¼¨Ó¾P°â¼ç¤O¹w´ú.
P.39 Commercialization of eblasakimab has potential in different regional markets
Eblasakimab(ASLAN004) ¦b¤£¦P»â°ì¨ã¦³¼ç¤O °Ï°ì¥«³õªº°Ó·~¤Æ.
2021¦~Dupilumab ¾P°â¹êÁZ//2019¦~,AD±wªÌ¤H¼Æ US $4,849M //41.4M(226¸U¤H)(¥¼¨ü±±¤¤-««×¥Íª«»s¾¯¤H¤f¬ù¦û5.5%----REGN¸ê®Æ) EU $793M//30.7M JAPAN $322M//5.0M CHINA $35M//535M
¦Xp $5,999M
¤G. P.38 Eblasakimab could be the favoured biologic, despite dermatologists¡¦ long experience with dupilumab
Eblasakimab ¥i¯à¬O³Ì¨üÅwªïªº¥Íª«»s¾¯¡A¾¨ºÞ ¥Ö½§¬ìÂå¥Íªø´Á¨Ï¥Î dupilumab ªº¸gÅç
150¤H¥«½Õ ASLAN004 VS DUPILUMAB ³ß¦nµ{«×
¤è®×A Àø®ÄÀu©óDUPILUMAB 8%+4¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×B Àø®ÄÀu©óDUPILUMAB 8%+2¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×C Àø®Äµ¥©óDUPILUMAB +¨C¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g
¤è®×A//¤è®×B//¤è®×C ¤@½u 51%//44%//20% ¤G½u 55%//54%//47%
¤T.¥H¤UÓ¤H¦ôºâASLAN004¾P°â¼ç¤O----
Dupilumab 80»õ¬ü¤¸AD³Ì°ª¾P°â¥«³õ(REGN «Å¥¬Dupilumab 140»õ¬ü¤¸³Ì°ª¾P°â*56% AD/¥þ³¡«¬IIª¢¯g¥¼¨ü±±¬ü°ê¥«³õ)--
1.AD °²³]DUPILUMAB AD ¤@½u¾P°â¦û2/3,¤G½u¦û1/3 Dupilumab ¨Ï¥Î52¶g«á¦³¤ÏÀ³ªº约50%(9¤ë15¤é CMO³ø§i资®Æ)
80*2/3¡Ñ50%=26.6(¤@½u) + 80*1/3x50%=13.4(¤G½u) =40»õ¬ü¤¸¡C
(¥H¤WÓ¤H¨Ì¥«½Õµû¦ô³ß¦nµ{«×¤j¬ù¤ñ²v¦ôp,¥¼¨Ó¨Ì2b¸Ñª¼¼Æ¾Ú¥i¯à·|¦A×¥¿)
2.ASLN004 ¥þ³¡¾P°â¦ô¬ù70»õ¬ü¤¸
40/56%=¬ù70»õ¬ü¤¸ (¬ùDUPILUMAB 140»õ¬ü¤¸³Ì°ª¾P°âªº 50%) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/17 ¤U¤È 03:12:02
²Ä 190 ½g¦^À³
|
clinicaltrials.gov/ct2/show/results/NCT03443024 Lebrikizumab 2b AD Á{§É
2¶g¤@°wx16¶g¡AN=75:52¡A°ò½uEASI25¡P5 ¡G27¡P5 ©M¹ï·Ó²ÕÀø®Äpk 1.IGA0¡A1 45%¤@15%=30%
2EASI 75 61%¤@24%=37%
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¥¼¨Ó2b ASLAN004Àø®Ä¡A16%°ª©óLebrikizumab ¾÷²v«D±`°ª
EASI75 =73%¡K.ASLAN004 2b ´Á±æÈ ¡]°²³]¹ï·Ó²Õ¦PLebrikizumab ªºÀø®Ä24%) 73%/61%=116%
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/17 ¤U¤È 12:06:59²Ä 5599 ½g¦^À³ ¤@.Lebrikizumab(16¶g)¡A¤T´Á
In ADvocate 1,
(IGA) 43%-13%=30%...A EASI75 59%-16%=43%...B
In ADvocate 2,
(IGA) 33%-11%=22%...C EASI75 51%-18%=33%...D
¤G.Dupilumab ¤T´Á(16¶g) In SOLO 1,
(IGA) 38%-10%=28%...E EASI75 51%-15%=36%...F
In SOLO2 2,
(IGA) 36%-8%=28%...G EASI75 44%-12%=32%...H
¤T¡BLebrikizumab pk Dupilumab ¦©°£¹ï·Ó组
1.(IGA) PK A/E=30%/28%=107%¡K¡K J C/G=22%/28%=79%
Lebrikizumab pk Dupilumab 79%-107%
MOA¨Ï±oLebrikizumabÀø®Ä¤W¤U30%¥ª¥k¡C ASLAN004 MOA¥i±æ§ïµ½Lebrikizumab °ÝÃD¡A¦pDupilumab¬Û¹ïéwÀø®Ä¡C
2.EASI75
B/F=43%/36%=119%...K D/H=33%/32%=103%...L
Lebrikizumab ©úÅãÀuDupilumab 103%-119%¦bEASI75«ü¼Ð
¥|¡B¥Ñ©óASLAN004 §@¥Î¦bIL13¨üÅé¡A§ó±µªñ©óLebrikizumab §@¥Î¦bIL13°tÅé¡C
¦P®É¥h¼vÅTIL4/IL13°T¸¹¶Ç»¼¡C
¥»¦¸ASLN ¤½¥q¡A150¤Hªº¤¤-««×AD±wªÌªº¥«½Õ®×¡C
ASLAN004 Àø®Ä8%Àu©óDupilumab ¤§°²³]¨Ì¾Ú¡A Ó¤H²q´ú¨Ó¦Û¤WzLebrikizumab pk Dupilumab IGA ªº¤T´ÁÁ{§É¼Æ¾ÚPK结½×¡C
ASLAN004 2b ¸Ñª¼¡A ¼Æ¾ÚÀu¤~ÁÙ·|½Õ¤É预测¡C
´Nµ¥§a¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/16 ¤W¤È 06:10:27
²Ä 189 ½g¦^À³
|
ASLAN004 60»õ¬ü¤¸AD¼ç¦b¦ôºâ¥«³õ: ¥]§t¤@½u&¤G½u¥«³õ.
Dupilumab 80»õ¬ü¤¸AD³Ì°ª¾P°â¥«³õ
80¡Ñ50%(¤@½u)+80¡Ñ50%x50%(¤G½u)=60»õ¬ü¤¸¡C (¥H¤WÓ¤H¦ôp)
150¤H¥«½Õ ASLAN004 VS DUPILUMAB ³ß¦nµ{«×
¤è®×A Àø®ÄÀu©óDUPILUMAB 8%+4¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×B Àø®ÄÀu©óDUPILUMAB 8%+2¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g ¤è®×C Àø®Äµ¥©óDUPILUMAB +¨C¶g¤@°w+¦w¥þ©ÊÀu+¥iªv¦hºØ¨Öµo¯g
¤è®×A//¤è®×B//¤è®×C ¤@½u 51%//44%//20% ¤G½u 55%//54%//47%
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:29:06²Ä 5588 ½g¦^À³ ¬ü°ê¤w22¸U¤H¥Î¹LDupilumab,¦ôp35%¬O¹FIGA0,1=0 , ¦ô¥Ø«e22*65%=15¸U¤H ¬°¤G½u¥«³õ¼ç¦b«È¤á. ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:23:08²Ä 5587 ½g¦^À³ 150¤H -¤¤-««× AD±wªÌ ¥«½Õ
°²³] 8% Àø®ÄÀu©óDUPILUMAB+ §C结½¤ª¢°Æ§@¥Î + ¦U4/2/1 ¶g¤@°w
°Ý±wªÌ³ßÅw (1)ASLAN004(2) DUPILUMAB
±o¥X¤@¤ñ²v*¦U¥«³õ¼ç¤O.=ªñ60»õ¬ü¤¸. ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/15 ¤U¤È 11:03:17²Ä 5586 ½g¦^À³ 9¤ë15¤é R&D DAY ¸ê®Æ: ASLN ¤½¥q¦ôp (2019 BASE)
ASLAN004 ¦b¤¤-««×AD ¥þ²y¥«³õ ¦³ªñ60»õ¬ü¤¸¼ç¤O, ®Ú¾Ú150¤H ¤¤-««×AD±wªÌ¥«½Õ¤ÀªR¦Ó¨Ó. ¾P°â¼ç¤O//±wªÌ¤H¼Æ US $4,849M //41.4M EU $793M//30.7M JAPAN $322M//5.0M CHINA $35M//535M
¦Xp $5,999M
ir.aslanpharma.com/events/event-details/aslan-hybrid-rd-day
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/9/11 ¤U¤È 12:20:15
²Ä 188 ½g¦^À³
|
ASLAN004 1b ¤TÓÁ{§É³ø§i,µoªí©ó2022 EVDA(¼Ú¬w¥Ö½§¦~·|)--2022/09/07~10
1.Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
aslanpharma.com/app/uploads/2022/09/EADV-PRO-poster_FINAL.pdf
2.Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
aslanpharma.com/app/uploads/2022/09/EADV-Efficacy-Outcomes-poster_FINAL-1.1.pdf
3.Eblasakimab, a Monoclonal Antibody Targeting IL‑13R£\1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis
aslanpharma.com/app/uploads/2022/09/EADV-2022-Biomarker-Poster_P0243_upload.pdf
¥H¤W¤T½g³ø§i¤§¤ÀªR:¬Ò±ÄmITT¤ÀªR
1b ´Á¬ã¨s¤¤ªºÀø®Ä¤ÀªR¨Ï¥Î¤Fקï«áªº·N¦V ªvÀø¡]mITT¡^¤H¸s¡A ¨ä¤¤¨Ó¦Û¤@Ó¦aÂIªº 9 ¦W¬ã¨s±wªÌ ¦b´¦ª¼¤§«e³Q±Æ°£¦b ITT ¤ÀªR¤§¥~¡A ¦]¬°°Ñ»PªÌªº¯e¯f¯S¼x¤£²Å¦X¤¤«×¦Ü««× AD¡C
Efficacy analysis in the Phase 1b study used a modified Intent to Treat (mITT) population in which 9 study patients from one site were excluded from the ITT analysis prior to unblinding as the the participants did not have disease characteristics consistent with moderate to severe AD. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/17 ¤U¤È 01:44:58
²Ä 187 ½g¦^À³
|
EASI75 Àø®Ä PK---×1
¤@.Dupilumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) (Àø®Ä®t²§=¹êÅç²Õ-¹ï·Ó²Õ, ¹êÅç²Õ/¹ï·Ó²Õ)
Solo 1 51%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(51%-15%=36%, 51%/15%=3.4) Solo 2 44%(¹êÅç²Õ) VS 12%(¹ï·Ó²Õ)(44%-12%=32%, 44%/12%=3.7)
¤G.Lebrikizumab ¤T´Á EASI75 Àø®Ä(2¶g¤@°w) Advocate 1 59%(¹êÅç²Õ) VS 16%(¹ï·Ó²Õ)(59%-16%=43%, 59%/16%=3.7) Advocate 2 51%(¹êÅç²Õ) VS 18%%(¹ï·Ó²Õ)(51%-18%=33%, 51%/18%=2.8)---¦]MOA¬G,¤£Ã©w¤§Àø®Ä
¤T.ASLAN004 2b EASI75 Àø®Ä(2¶g¤@°w)---¹w¦ô
73%(¹êÅç²Õ) VS 15%(¹ï·Ó²Õ)(73%-15%=58%, 73%/15%=4.9)
------------------------
ASLAN004 2b EASI75Àø®Ä ³]p¦ô:
1B EASI75 Àø®Äì³]p¦ô:
= A²Õ(°ò½u/¤¤µý=EASI31):11¤H/16¤H=69% + B²Õ(°ò½u/»´¯gEASI=19): 5¤H/6¤H=83%--)
A²Õ+B²Õ=¦Xp16/22=73%
---¤£±M·~ªº¦¬¤J«D¶Ç²ÎAD , 6¦ì¹êÅç²Õ±wªÌ+3¦ì¹ï·Ó²Õ, ¨Ï±o¸Ó²Õ6¦ì¹êÅç²Õ±wªÌ EASI75 Àø®Ä=0%.
¨Ï±oITT¤ÀªR EASI75 =¹êÅç²Õ(11+0)/22=50% VS ¹ï·Ó²Õ13% ---------------------------------------
2022¦~6¤ë7¤é ASLN CEO «Å§i: 2bÁ{§É¿z¿ï®É±N¥ý±Æ°£«D¶Ç²ÎAD±wªÌn©M Dupilumab ¤T´ÁÁ{§É¤@¼Ëªº±wªÌ²Õ¦¨µ²ºc(¥i¯à¥ý±Æ°£«D¶Ç²ÎAD±wªÌ,§CEASI/§CIgE/§CTRAC²Õ¥u¦³0%~3%ªº¾÷²v).
¦]¦¹2023¦~ASLAN004 AD 2b ¸Ñª¼, Y°ò½u¥§¡EASI27~30¤§³]p©Û¶Ò(¦PASLAN004 1b/¦PLebrikizumab 2b)
EASI75 ªº¥Ø¼ÐÀø®Ä¬ù73% VS ¹ï·Ó²Õ15%.(¹êÅç²ÕÀø®ÄÀu¹ï·Ó²Õ 73%-15%=58%, 73%/15%=4.9¿)
------------------------------------------------ Lebrikizumab 2b, EASI75=60% VS 24%(¹ï·Ó²Õ), (¹êÅç²ÕÀø®ÄÀu¹ï·Ó²Õ 60%-24%=36%, 60%/24%=2.5¿) ------------------------ ------------------------- Dupilumab ¤T´Á¹êÅç²Õ §CTRAC²Õ(°ò½uEASI25), Àø®Ä¥§¡EASI°´T77%(©Û¶Ò¤H¼Æ¤ñ1/3) ¤¤TRAC²Õ(°ò½uEASI31), Àø®Ä¥§¡EASI°´T67%(©Û¶Ò¤H¼Æ¤ñ1/3) °ªTRAC²Õ(°ò½uEASI41), Àø®Ä¥§¡EASI°´T66%(©Û¶Ò¤H¼Æ¤ñ1/3) ------------------------------------------ ¥§¡ (°ò½uEASI31),Àø®Ä¥§¡EASI°´T70% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤U¤È 05:48:57
²Ä 186 ½g¦^À³
|
¥¼¨Óý³Ý¤ÎEOE¡K¡KAD¥H¥~ªºASLAN004¾AÀ³¯gªº±ÂÅv¡C
¥i¥H参¦Ò¥H¤ULebrikizumab*300%
2.2017/08/08 ±qAD¤G´ÁÁ{§É¶}©l°µ°_ (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB. ------------------------------------------------------ ¼Ú°Ï±ÂÅv¤Î¸êª÷ª¬ªp¸Õºâ:¡K¡K×1
¨Ì¾ÚLebrikizmab ¼Ú°Ï±ÂÅv Almirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C
®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C
(1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸.
¨Ì¥Ø«eAD±ÂÅv¦æ±¡ASLAN004¥i¯ànLebrikizmab*3¿. ----(2019/02 Dupilumab ³Ì°ª¾P°â¦ô50»õ¬ü¤¸, 2022¦~Dupilumab ³Ì°ª¾P°â¦ô140»õ¬ü¤¸,2022¦~¦ô¥i¹F80»õ¾P°â)
AD¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸*3=2.4»õ¬ü¤¸. ¦©°£¤ä¥ICSL 3000¸U¬ü¤¸,¤Î2023¦~¦ô6000¸U¬ü¤¸ªºÁ{§ÉºÞ¾P. 2023¦~ªºASLN µ|«eÀç¾l¦ô¥i¦³1.5»õ¬ü¤¸.¡K¡KC
================================= (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C
(3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C
(4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C
¥H¤W1.15»õ¬ü¤¸ *3=3.45»õ¬ü¤¸----ASLN 欧·ùº¦¸°Ó业¤Æ销°âASLAN004 ---¦©°£¤ä¥ICSL 9250¤d¸U ---2.5250»õ¬ü¤¸ ³Ñ¾l.-----A
--3´ÁADÁ{§É¶O¥Î¬ù4»õ¬ü¤¸+3¦~ºÞ¾P5000¸U+¨ä¥L¤G´ÁASLN004/ASLNA003¦ô1.5»õ¬ü¤¸.=¦Xp6»õ¬ü¤¸----B
B-A-C=2.0»õ¬ü¤¸¯Ê¤f,©ú¦~¸Ñª¼«á¤½¶}¥«³õ¶Ò¸ê©Î¨p¶Ò.
¥H¤W¬°Ó¤H¦ôºâ2024/2025/2026¦~ªºASLN¸êª÷¶i¥X.
±ÂÅvª÷ªº¤j¤p©M¶Ò资³W¼Ò¤j¤p¬ÛÃö¡C
¥H¤W¶È¹ïAD¡A¨ä¥L¾AÀ³¯g¦û¬ùAD¥«³õªº80%¡A¦ý±N¥u¶i¤J¤G´Á ý³Ý¡AEOE¡A³o¤G项¦ôp·|¥ý°µ¡A9¤ë15¤éR&D day ´Nª¾¹D¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/8/16 ¤U¤È 12:08:55
²Ä 185 ½g¦^À³
|
¼Ú°Ï±ÂÅv¤Î¸êª÷ª¬ªp¸Õºâ:
¨Ì¾ÚLebrikizmab ¼Ú°Ï±ÂÅv Almirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C
®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C
(1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸.
¨Ì¥Ø«eAD±ÂÅv¦æ±¡ASLAN004¥i¯ànLebrikizmab*3¿. ----(2019/02 Dupilumab ³Ì°ª¾P°â¦ô50»õ¬ü¤¸, 2022¦~Dupilumab ³Ì°ª¾P°â¦ô140»õ¬ü¤¸,2022¦~¦ô¥i¹F80»õ¾P°â)
AD¤T´Á«e¥i¨ú±o8¤d¸U¬ü¤¸*3=2.4»õ¬ü¤¸. ¦©°£¤ä¥ICSL 3000¸U¬ü¤¸,¤Î2023¦~¦ô6000¸U¬ü¤¸ªºÁ{§ÉºÞ¾P. 2023¦~ªºASLN µ|«eÀç¾l¦ô¥i¦³1.5»õ¬ü¤¸.
================================= (2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C
(3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C
(4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C
¥H¤W1.15»õ¬ü¤¸ *3=3.45»õ¬ü¤¸----ASLN 欧·ùº¦¸°Ó业¤Æ销°âASLAN004 ---¦©°£¤ä¥ICSL 9250¤d¸U ---2.5250»õ¬ü¤¸ ³Ñ¾l.-----A
--3´ÁADÁ{§É¶O¥Î¬ù4»õ¬ü¤¸+3¦~ºÞ¾P5000¸U+¨ä¥L¤G´ÁASLN004/ASLNA003¦ô1.5»õ¬ü¤¸.=¦Xp6»õ¬ü¤¸----B
B-A=3.5»õ¬ü¤¸¯Ê¤f,©ú¦~¸Ñª¼«á¤½¶}¥«³õ¶Ò¸ê©Î¨p¶Ò.
¥H¤W¬°Ó¤H¦ôºâ2024/2025/2026¦~ªºASLN¸êª÷¶i¥X. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/23 ¤W¤È 07:58:17
²Ä 184 ½g¦^À³
|
ASLAN004 2b Á{§É¤ñ1bÁ{§É ¼W¥[¤U¦C¨â¶µµ{§Ç¥H¿z¿ï¶Ç²ÎAD±wªÌ
1.ASLN ¤½¥q¨Ì±wªÌ°ò½uªº°ò¥»¸ê®Æ(IgE/TRAC/¶Ý»Ä²ÓM/¨Öµo¯g...)¼f¬dÄݶDzÎAD±wªÌ«á¦X®æ,¤~·|¶i¤J¤¹ã¶i¤JÁ{§ÉÀH¾÷¤À°t.
2.±wªÌ¥[¤J«e,¤½¥q³]p´XÓ°ÝÃD,¦p¤U : ¥H¶i¤@¨B¿z¿ï¶Ç²ÎAD±wªÌ www.withpower.com/trial/phase-2-eczema-11-2021-74a37
3.¦ôp¥h°£10%-15%ªº«D¶Ç统AD±wªÌ¡C ¥H±µªñdupilumab ¤T´Áªº¤À°t组¦X¡C
4.Àø®Ä¡B¦w¥þ¡B¦¨¥» ¤T¤j·sÃÄ¥«³õÄvª§ªk«h¡C
¥²¶·Àu©óDupilumab,§_«h·|½ü¬°¤G½uÃÄ¡C
¥H¤WCEO 6/8 °Ñ¥[Jefferies ú³°Ó²{³õ°Ýµª¬ù¦b18~21¤ÀÄÁ.
wsw.com/webcast/jeff240/register.aspx?conf=jeff240&page=asln&url=wsw.com/webcast/jeff240/asln/1843950
ir.aslanpharma.com/events/event-details/jefferies-healthcare-conference |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/9 ¤U¤È 05:03:58
²Ä 183 ½g¦^À³
|
ASLAN004 2B ,¨Ìç°£§CTRAC²Õ/§CIgE/§C¶Ý»Ä²ÓM/µL¨Öµo¯g «D¶Ç²Î¤¤-««×AD±wªÌ.
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä PK ¼ÒÀÀ
ASLAN004 54%(1b RITT) VS Dupilumab 28%~32% (¤T´Á2ÓÁ{§É,¤¤/°ªTRAC²Õ)
ASLAN004 AD ¤j´T»â¥ýDupilumab EASI75Àø®Äªñ70%~90%,¥§¡Àu80%ÁͶաI
³oºØÀø®Ä®t²§ASLN³Q¨ÖÁÊ»ù¤~·|°ª!
---------------------------------------------------- EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä PK
¤@.¨ÌITT¤ÀªR, EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 37% (P<0.05) VS Dupilumab32%~36% (P<0.05) VS FB825 ¦ô10%¥ª¥k(24.4%*1/3+2/3(«D¥Ø¼Ð±wªÌ)*0%=8.1%, ©M¹ï·Ó²ÕµL²Îp¤Wªº©úÅã®t²§,p>0.05, )
¤G.¨ÌRITT¤ÀªR<ç°£§CTRAC²Õ>
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä
ASLAN004¡A¤j´T»â¥ý¨ä¥L¨âÃÄÁͶաI
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 54% VS Dupilumab28%~32% VS FB825 24.4%
---------------------------------------------------------------- <ç°£§CTRAC²Õ¤ÀªR>°ò¥»¸ê®Æ ---ASLAN004 ©Òç°£¬°°ò½u§CTRAC <1115,§CIgE<1/10¥L²Õ¼Æ,§CEASI<20,¤T§C²Õ, ¹êÅç²Õ6¤H,6/22=27%
---Dupilumab °ò½u§CTRAC <1115 ¦û¬ù30% ¨ä¥§¡EASI=25,§CIgE ¦û¬ù15% ¨ä¥§¡EASI=25 ¦ôp°ò½u¦PASLAN004 §CEASI<21,¥B§CIgE²Õ¥X²{¤ñ¨Ò0%~3.75%, (15%/2/2=3.75%)
---FB825 ç°£¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò½uȧC©ó700 pg/ml (Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml (Dupixent¬°2,451-10,754 IU/ml)
--ASLAN004 1b ç°£6/22=27% ¡A --Dupilumab PH3*2Á{§É,ç°£300/900=30% ¡A --FB825 2Aç°£66/99=67% ¡A
----------------------------------------------- Lebrikizumab 2bÁ{§É,°ò½u¶}©l«eªº¤H¿ï¿z¿ï¥h°£²v51%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
424 ¤H°Ñ¥[¿z¿ï ,280¤H¶i¤J¤G´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v : (424-280)/280=51%
¯uªºÄY®æ¿z¿ï.
---------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/15 ¤U¤È 07:17:40²Ä 5310 ½g¦^À³ Dupilumab 2Ó¤T´ÁÁ{§É,°ò½u¶}©l«e35¤Ñ¶¡ªº¤H¿ï¿z¿ï¥h°£²v36.3%
1.SOLO1 ,Out of 917 participants, 671 were randomized (¿z¿ï¥h°£±¼917-671=246¤H, ¥h°£²v36.6%) 2.SOLO2, Out of 962 participants, 708 were randomized (¿z¿ï¥h°£±¼962-708=254¤H, ¥h°£²v35.8%) ¤pp 1879 ¤H°Ñ¥[¿z¿ï ,1379¤H¶i¤J¤T´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v: (1879-1379)/1379=36.3%
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2022/5/27 ¤W¤È 08:50:49²Ä 5350 ½g¦^À³ ¤½¥q°ª¼h¹ïADÁ{§É¦³Â×´I¸gÅç¡A¥i¥H¬d¤@¤U¥L̪ºI´º ¥[¤WIQVIA¾Þ½L¡A§ä¹ï¯f¤H¡AÁ{§É¼Æ¾Ú´N¤£·|°¾®t¤Ó¦h ð¦ÑÀn¡A§A¦Y¹¡¨S¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/5/27 ¤W¤È 08:08:08²Ä 5349 ½g¦^À³ ¦Ñ·àªºÃöÁ䦨±ÑªºÃöÁä¦b©ó¡A¦p¥ý«e¤Ñ©R¤j©Ò´£ªº¯f±wªº¿z¿ï¡AÁÙ¦³¥t¤@Ó·¥§C¾÷²vµ²½¤ª¢¬O§_¯à¹ê²{¡AY¯àº¡¨¬«ez±ø¥ó¡A¨äÁ{§É«ü¼Ð¤ñ§ù¥²ª¢¦nªº¾÷²v¬O«Ü°ªªº¡A§Æ±æ©_ÂÝ»PÃĪº¥»½è¯àµo¥Í¤Îµo´§¡Cªü·à¥[ªo!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/6/3 ¤W¤È 11:34:32
²Ä 182 ½g¦^À³
|
2030¦~ ¤¤-««×ADÃĪ«¾P°â¹w´ú:168»õ¬ü¤¸/2020¦~64»õ¬ü¤¸¡C
Dupilumab: 62»õ¬ü¤¸¡C Lebrikizumab & Tralo: 22»õ¬ü¤¸¡C JAK2¤fªAÃÄ:35»õ¬ü¤¸(¦³«°Æ§@¥Î)
The atopic dermatitis (AD) market is expected to grow from a value of $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets at a compound annual growth rate (CAGR) of 10.1%, according to GlobalData. www.thepharmaletter.com/article/growth-in-atopic-dermatitis-market-to-exceed-10-at-cagr
2022/04/05
Ramla Salad, healthcare analyst at GlobalData, said: ¡§Biologics are expected to retain a large market share during the forecast period for the treatment of moderate to severe AD. Dupixent (dupilumab) is anticipated to be market leader with estimated peak sales of $6.2 billion in 2030. Furthermore, it is already known as the gold standard for the treatment of moderate to severe AD across the 7MM.¡¨
GlobalData expects that upcoming interleukin (IL) inhibitors - LEO Pharma¡¦s Adtralza/Adbry (tralokinumab), Eli Lilly¡¦s (NYSE: LLY) lebrikizumab, and Galderma¡¦s nemolizumab - will take market share from Sanofi (Euronext: SAN) and Regeneron¡¦s (Nasdaq: REGN) Dupixent and other immunomodulators over the forecast period as they are all targeting the moderate to severe patient population, with combined 2030 sales of $2.2 billion.
Innovation on the way Oral JAK inhibitors are also expected to see strong growth during the forecast period with combined sales of $3.5 billion, and AbbVie¡¦s (NYSE: ABBV) Rinvoq (upadacitinib) leading the pack.
Amgen (Nasdaq: AMGN) and Kyowa Kirin¡¦s (TYO: 4151) anti-OX40 inhibitor, KHK4083, and Pfizer¡¦s (NYSE: PFE) sphingosine-1-phosphate receptor (S1PR) modulator, etrasimod, are two new therapies in the late-stage development and hold huge promise.
Ms Salad said: ¡§Based on insight from key opinion leaders (KOLs) interviewed by GlobalData, enthusiasm for these late-stage agents is due to their new mechanisms of action and the innovation they would bring to the market; if approved they would both be the first in their respective classes.¡¨
An increasing uptake of topical therapies for the treatment of mild to moderate AD is expected to greatly improve the overall control of flare-ups and consequently decrease the use of traditional therapies such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI).
Notable therapies include topical JAKs, Incyte¡¦s (Nasdaq: INCY) Opzelura (ruxolitinib) and LEO Pharma¡¦s Corectim (delgocitinib) and phosphodiesterase-4 (PDE-4) inhibitors, AstraZeneca¡¦s (LSE: AZN) roflumilast and Otsuka Pharmaceutical¡¦s (TYO: 4578) Moizerto (difamilast). Peak sales for topical JAK and PDE-4 inhibitors are expected to reach combined sales of $630.6 million.
¡¦Very dynamic space¡¦ Ms Salad added: ¡§The AD market is a very dynamic space as exemplified by the pipeline activity, but there are some barriers to growth which could limit the uptake of these therapies. Pipeline topical JAK inhibitors will be entering a considerably competitive landscape where more expensive options, such as Eucrisa (crisaborole), are struggling to increase patient uptake. While KOLs were excited at the prospect of new pipeline drugs, many of them have a high ACOT, which will prevent uptake. As a result, physicians are likely to continue prescribing TCs, TCIs, and systemic immunomodulators.
¡§Although these barriers will have some impact on growth, the market is expanding at an impressive rate and ample opportunities exist for developers to further improve the AD treatment landscape for all ages and severities.¡¨
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/19 ¤U¤È 08:34:17²Ä 5314 ½g¦^À³ Eblasakimab may be efficacious against a wide range of AD comorbidities, such as asthma and allergy
Eblasakimab¥i¯à¹ï¼sªxªºAD¦X¨Ö¯g¦³Àø®Ä¡C ¡A¦pý³Ý©M¹L±Ó¯g¡C
p.12 ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2
81% of moderate-to-severe AD patients have Type 2 inflammatory comorbidities:
¤¤«¯gAD±wªÌ,±w¦³«¬2ª¢¯gªº¨Öµo¯g81%
¨ä¤¤±w¹L±Ó©Ê»óª¢ªÌ¨Öµo¯g 50% ¨ä¤¤±w¹L±ÓªÌ¨Öµo¯g 38% ¨ä¤¤±wý³Ý¨Öµo¯g 35% ¨ä¤¤±w¹ª«¹L±Ó¨Öµo¯g 34%
Blockade of IL-4 and IL-13 signaling through the Type 2 receptor will be important to address both IL-4 and IL-13 driven comorbidities in AD patients.
Physicians would prefer treatment options that can address these other conditions.
ªýÂ_ IL-4 ©M IL-13 ³q¹L«¬ 2 µo«H¸¹¨üÅé ±N«Ü«n¥i¦P®É¸Ñ¨MAD±wªÌ¦] IL-4 ©M IL-13ÅX°Êªº¦X¨Ö¯g ¡C
Âå¥Í̧ó³ßÅw¥i¦P®ÉªvÀø¨ä¥L¦X¨Ö¯gªºÃÄ¡C
¸ê®Æ¨Ó·½: 237¦ì±wªÌªº¬ã¨s.µoªí©ó2022¦~AAD ¦~·|. Source: Calzavara-Pinton et al (2022) AAD Annual Meeting poster presentation, Baseline patient demographics and comorbidities in patients with atopic dermatitis from the GLOBOSTAD registry (237 patients) -------- |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/27 ¤W¤È 09:02:55
²Ä 181 ½g¦^À³
|
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä PK
¤@.¨ÌITT¤ÀªR, EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 37% (P<0.05) VS Dupilumab32%~36% (P<0.05) VS FB825 ¦ô10%¥ª¥k(24.4%*1/3+2/3(«D¥Ø¼Ð±wªÌ)*0%=8.1%, ©M¹ï·Ó²ÕµL²Îp¤Wªº©úÅã®t²§,p>0.05, )
¤G.¨ÌRITT¤ÀªR<ç°£§CTRAC²Õ>
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä
ASLAN004¡A¤j´T»â¥ý¨ä¥L¨âÃÄÁͶաI
EASI75(¦©°£¹ï·Ó²Õ)Àø®Ä ASLAN004 54% VS Dupilumab28%~32% VS FB825 24.4%
---------------------------------------------------------------- <ç°£§CTRAC²Õ¤ÀªR>°ò¥»¸ê®Æ ---ASLAN004 ©Òç°£¬°°ò½u§CTRAC <1115,§CIgE<1/10¥L²Õ¼Æ,§CEASI<20,¤T§C²Õ, ¹êÅç²Õ6¤H,6/22=27%
---Dupilumab °ò½u§CTRAC <1115 ¦û¬ù30% ¨ä¥§¡EASI=25,§CIgE ¦û¬ù15% ¨ä¥§¡EASI=25 ¦ôp°ò½u¦PASLAN004 §CEASI<21,¥B§CIgE²Õ¥X²{¤ñ¨Ò0%~3.75%, (15%/2/2=3.75%)
---FB825 ç°£¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò½uȧC©ó700 pg/ml (Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml (Dupixent¬°2,451-10,754 IU/ml)
--ASLAN004 1b ç°£6/22=27% ¡A --Dupilumab PH3*2Á{§É,ç°£300/900=30% ¡A --FB825 2Aç°£66/99=67% ¡A
----------------------------------------------- Lebrikizumab 2bÁ{§É,°ò½u¶}©l«eªº¤H¿ï¿z¿ï¥h°£²v51%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
424 ¤H°Ñ¥[¿z¿ï ,280¤H¶i¤J¤G´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v : (424-280)/280=51%
¯uªºÄY®æ¿z¿ï.
---------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/5/15 ¤U¤È 07:17:40²Ä 5310 ½g¦^À³ Dupilumab 2Ó¤T´ÁÁ{§É,°ò½u¶}©l«e35¤Ñ¶¡ªº¤H¿ï¿z¿ï¥h°£²v36.3%
1.SOLO1 ,Out of 917 participants, 671 were randomized (¿z¿ï¥h°£±¼917-671=246¤H, ¥h°£²v36.6%) 2.SOLO2, Out of 962 participants, 708 were randomized (¿z¿ï¥h°£±¼962-708=254¤H, ¥h°£²v35.8%) ¤pp 1879 ¤H°Ñ¥[¿z¿ï ,1379¤H¶i¤J¤T´ÁÅç§ÉªºÀH¾÷¤À°t, ¥h°£²v: (1879-1379)/1379=36.3%
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2022/5/27 ¤W¤È 08:50:49²Ä 5350 ½g¦^À³ ¤½¥q°ª¼h¹ïADÁ{§É¦³Â×´I¸gÅç¡A¥i¥H¬d¤@¤U¥L̪ºI´º ¥[¤WIQVIA¾Þ½L¡A§ä¹ï¯f¤H¡AÁ{§É¼Æ¾Ú´N¤£·|°¾®t¤Ó¦h ð¦ÑÀn¡A§A¦Y¹¡¨S¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2022/5/27 ¤W¤È 08:08:08²Ä 5349 ½g¦^À³ ¦Ñ·àªºÃöÁ䦨±ÑªºÃöÁä¦b©ó¡A¦p¥ý«e¤Ñ©R¤j©Ò´£ªº¯f±wªº¿z¿ï¡AÁÙ¦³¥t¤@Ó·¥§C¾÷²vµ²½¤ª¢¬O§_¯à¹ê²{¡AY¯àº¡¨¬«ez±ø¥ó¡A¨äÁ{§É«ü¼Ð¤ñ§ù¥²ª¢¦nªº¾÷²v¬O«Ü°ªªº¡A§Æ±æ©_ÂÝ»PÃĪº¥»½è¯àµo¥Í¤Îµo´§¡Cªü·à¥[ªo!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/23 ¤W¤È 09:24:40
²Ä 180 ½g¦^À³
|
¤@¡BLebrikizumab(16¶g),¤T´Áªº¨âÓÁ{§É
In ADvocate 1,
(IGA) 43%-13%=30% EASI75 59%-16%=43%
In ADvocate 2,
(IGA) 33%-11%=22% EASI75 51%-18%=33%
¤G¡BASLAN004 (8¶g)1b¡A¡K¡K¼ÒÀÀ2b¡A16¶g
EASI75 69%-15%(¹ï·Ó²Õ)=54% (IGA) 53%-12%(¹ï·Ó组)=41%
¤T¡BASLAN004 2b vs Lebrikizumab
1. ASLAN004 Vs ADvocat1 EASI75 54% VS 43%, (54%/43%=126%) (IGA) 41% VS 30%, (41%/30%=137%)
2.ASLAN004 VS ADvocat2 EASI75 54% VS 33%,(54%/33%=164%) (IGA) 41% VS 22%,(41%/22%=186%)
¥|¡Aµ²½×¡ALebrekizumab MOA³y¦¨¹ïIL4ªº资°T¶Ç»¼¡A®É¦³®ÉµL¡C³y¦¨2ÓAD¤T´ÁÀø®Ä®É¦n®É®tª¬ºA¡C
¦bý³Ý¤T´Áªº2ÓÁ{§É¤]§e²{¡A¥Dn«ü¼Ð¤@ÓPÈ<0.05¡A¥t¤@Ó>0.05ªºª¬ºA¡A¦Ó¤¤¤î¬ã¨s¡C
¤¡B¨Ì¾ÚLebrekizumab ³Q§ª«¨Ó¨ÖÁÊ»ù11»õ¬ü¤¸¡C
¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù: ¦ôp¤Î±ø¥ó
11/50*145*2=64»õ¬ü¤¸(¨È·à¿W±o)
Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*2022¦~dupilumab 145»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2023¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù.
¤»¡BASLAN004 2b vs Dupilumab ¤T´Á ¦©°£¹ï·Ó组«áªºPK EASI75 54% vs 36%(54%/36%=150%) (IGA) 41% vs 28% (41%/28%=146%)
ASLAN004 ±N¤j´TÀu©óDupilumabªºÁͶաC
¥H¤WÓ¤H¼ÒÀÀ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/19 ¤W¤È 09:32:11
²Ä 179 ½g¦^À³
|
¥@¬ö¯«ÃÄHumiraºÙÅQ¥þ²y20¦~ 2021¦~¡A¾P°â207»õ¬ü¤¸¡A2003¦~²Ä¤@Ó¾AÀ³¯g¤W¥«¡C¦@¦³11Ó¾AÀ³¯g¤W¥«¡C
2000¦~¡A¨È°ö¤½¥q¥H69»õ¬ü¤¸·m¤U¡C¡A2´Á§¹¦¨¶RÂ_¡C
21¦~¨Ó²Öp¾P°â1507»õ¬ü¤¸¡C(¨ì2017¬°¤î)¡A Yºâ¨ì2022¦~¡A¶W¹L2500»õ¬ü¤¸¡C
2023¦~¡A¥é¥ÍÃĥثe¦ô11Ó¡A¥i³°Äò¦b¬ü°ê¤W¥«¡C
®Ö¤ß±M§Q¡A2016¦~¡A¬ü°ê¨ì´Á¡A¦ý§Q¥Î100¦hÓ±M§Q¡A¥´©x¥qÅý¥é¥ÍÃĪ½¨ì2023¤~¯à¦b¬ü°ê¤W¥«¡C
¬G¨Æ¸Ô¨£¡A¦p¤U¡C
www.wealth.com.tw/articles/cfadd307-f325-494e-aad8-801766fe4c37
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/15 ¤W¤È 10:02:11
²Ä 178 ½g¦^À³
|
Dupilumab ¤T´ÁÁ{§É
1¡A¤¤Â_²v<7% 2¡A°ò½uTRAC<1115 ¬ù33%¡A¥§¡EASI约25 2.1°ò½uTRAC<1115,¥§¡EASI<25,¥u¦û16.5% ±À½×¥»组°ò½uEASI<21,¦û8.25%, ³o´N¬Oµý¾Ú¡ADupilumab ¤T´Á°ª«×±M·~¡C Á׶}¥i¯à«D¶Ç²ÎAD±wªÌ¡C
3¡A°ò½uIgE §C²Õ¬ù15% 3.1,°ò½uIgE§C组ªº¥§¡EASI¬°25 °ò½uIgE组¥B¥§¡EASI<25¡A¥u¦û7.5% ±À½×¥»组EASI<21,¥u¦û3.75% ³o´N¬OÃÒ¾Ú¡Adupilumab¤T´Á¡A«Ü±M·~¡A«Ü·|¿z¿ï¤H¡C 4¡A°ò缐EASI<21¬ù25%
4.1±À½× °ò½uEASI<21 ¡A25%¤¤ °ªIgE 组¦û21.25% °ªTRAC组¦û16.75% °ò½u§CIgE¡A§CTRAC(<1115),§CEASI(<21)¤T§CªÌ,³Ì°ª¦û3.75%
³o´N¬ODupilumab¤T´Á¡A§CTRAC¡A©Û¶Òªº«ÂI¡C
¬Ý³ø§i¤£²`¤J¡A·|³Q»~¾Éªº¡C Fb825 2a,ASLAN004 1b,CBO201 2b ADÁ{§É¡K¡K¬Ò¦³¤j¶q«D¶Ç²ÎAD¡C
§Æ±æASLN ¤½¥q¦b2b¯à¯uªº§ïµ½¡C ¦n¦nªº¦VDupilumab ¤T´Á¾Ç²ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/7 ¤U¤È 07:07:46
²Ä 177 ½g¦^À³
|
Humira®ªº¥Íª«¥é»sÃı¡ªp·§z ¬ü°êªº¥Íª«¥é»sÃÄ¥«³õ¦b2023¦~±N¬O«D±`¿E°Ê¤H¤ßªº¤@¦~¡A³o¥Dn¬O¥Ñ©ó¥i¯à·|¦³10¦hӥͪ«¥é»sÃÄÄvª§ªÌ°w¹ï¥@¬É¤W¦³¥v¥H¨Ó³ÌºZ¾PªºÃĪ«Humira®¡]ªü¹F¤ì³æ§Ü¡^1±À¥X¡C¦Û2003¦~º¦¸¦b¬ü°ê¤W¥«¥H¨Ó¡AHumira®§@¬°¤@ºØ²£«~¤w¸g¦b³\¦h¤è±µo¥Í¤FÅܤơA¥]¬A·sªº¿@«×¡BµLÂfÂc»ÄÆQª©¥»¡BµL¨Å½¦µ¹Ãĸ˸m©M§ó¤pªº°wÀY¤Ø¤o¡CŲ©ó¹L¥h18¦~¤¤¥X²{ªº²³¦h²£«~ÄÝ©Ê¡A¤F¸Ñ±q²£«~®t²§¤Æªº¨¤«×¹w´Á¤°»ò¬O¤@¶µ¨ã¦³¬D¾Ô©Êªº¥ô°È¡C
www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/humira-biosimilar-landscape-overview.html
FDA approved (FDA ¤w®Ö·Ç7ºØHurmira ¥Íª«¬Û¦üÃÄ)
Product Company Estimated launch Concentration Seeking interchangeability Citrate free Latex free Needle size Amjevita™ Amgen Jan 31, 2023 Low (50MG) No2 Yes No 29G Syr. / 27G Pen Hadlima™ Organon July 1, 2023 Low (50MG) No3 No Yes 29G Syr. / 29G Pen Cyltezo® Boehringer Ingelheim July 1, 2023 Low (50MG) Yes (Oct 18, 2021)4 Yes No 27G Syr. / 27G Pen Yusimry™ Coherus July 1, 2023 Low (50MG) No Yes Yes Unknown Hulio™ Viatris July 31, 2023 Low (50MG) No Yes Yes 29G Syr. / 29G Pen Hyrimoz™ Sandoz Sept 30, 2023 Low (50MG) No No No 27G Syr. / 27G Pen Abrilada™ Pfizer Nov 20, 2023 Low (50MG) Yes5 Yes Yes 29G Syr. / 29G Pen
Pending approval («Ý®Ö·Ç5ºØHurmira ¥Íª«¬Û¦üÃÄ) Product Company Estimated launch Concentration Seeking interchangeability Citrate free Latex free Needle size SB5-HC Organon July 1, 2023 High (100MG) Yes6 Yes Yes 29G Syr. / 29G Pen Idacio® Fresenius Kabi Sept 30, 2023 Low (50MG) No7 Yes Yes 29G Syr. / 29G Pen AVT-02 Teva July 1, 20238 High (100MG) Yes Yes Yes Unknown CT ¡V P17 Celltrion TBD High (100MG) No Yes Yes 29G Syr. / 29G Pen ABP ¡V 501 HC Amgen TBD High (100MG) Yes2 Yes No 29G Syr. / 27G Pen |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/7 ¤U¤È 06:55:17
²Ä 176 ½g¦^À³
|
Humira ªº²Ä¤@ӥͪ«¬Û¦üÃÄ ¦w¶i¤½¥qªº2016¦~AMJEVITA (adalimumab-atto)FDA®Ö·Ç ,2023¦~¤~¯à¦b¬ü°ê¤W¥«.
¦³7ºØ¾AÀ³¯g,¦U¤T´ÁÁ{§Éµ²ªG¸ê®Æ¦p¤U: ¼ÐÅÒÀÉ AMJEVITA (adalimumab-atto) injection for subcutaneous use. Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar* to HUMIRA (adalimumab).
www.accessdata.fda.gov/drugsatfda_docs/label/2016/761024lbl.pdf Ãþ·Àã©ÊÃö¸`ª¢¡]RA¡^¡]1.1¡^¡C´î¤ÖÅé¼x©M¯gª¬¡C »¤µo¥DnªºÁ{§É¤ÏÀ³¡A§í¨îµ²ºc©Ê·l®`ªºµo®i¡A§ïµ½¦¨¦~RA±wªÌªº¨Åé¥\¯à¡C ·l¶Ë¡A¨Ã§ïµ½¦¨¦~RA±wªÌªº¨Åé¥\¯à¡C ¤¤«×¦Ü««×¬¡°Ê©ÊRA±wªÌ¡C - «C¤Ö¦~¯Sµo©ÊÃö¸`ª¢¡]JIA¡^¡]1.2¡^¡C´î¤Ö¤¤«×¦Ü««×¬¡°Ê©ÊRAªº¯gª¬©MÅé¼x¡C 4·³¤Î¥H¤W±wªÌªº¤¤«×¦Ü««×¬¡°Ê©Ê¦hÃö¸`ª¢ªº¯gª¬¡C 4·³¤Î¥H¤W¡C - »È®h¯fÃö¸`ª¢¡]PsA¡^¡]1.3¡^¡C´î¤ÖÅé¼x©M¯gª¬¡C §í¨îµ²ºc©Ê·l®`ªºµo®i¡A¨Ã§ïµ½¬¡°Ê©Ê»È®h¯f±wªÌªº¨Åé¥\¯à¡C ¬¡°Ê©Ê»È®h¯f¦¨¦~±wªÌªº¥\¯à¡C - ±jª½©Ê¯á¬Wª¢¡]AS¡^¡]1.4¡^¡C´î¤Ö¬¡°Ê©Ê±jª½©Ê¯á¬Wª¢¦¨¦~±wªÌªºÅé¼x©M¯gª¬¡C ¬¡°Ê©Ê±jª½©Ê¯á¬Wª¢ªº¦¨¦~±wªÌªºÅé¼x©M¯gª¬¡C - ¦¨¤H§Jù®¦¯f¡]CD¡^¡]1.5¡^¡C´î¤ÖÅé¼x©M¯gª¬¨Ã»¤¾É©Mºû«ùÁ{§É½w¸Ñ »¤¾É¨Ãºû«ù¦¨¤H§Jù®¦¯f±wªÌªºÁ{§É½w¸Ñ¡C ¤¤«×¦Ü««×¬¡°Ê©Ê§Jù®¦¯f±wªÌ¡A¹ï±`³WªvÀø¤ÏÀ³¤£¥R¤À¡A´î¤Ö¯gª¬©M»¤¾É¨Ãºû«ùÁ{§É½w¸Ñ¡C ¹ï±`³WªvÀø¤ÏÀ³¤£¨¬ªº¤¤«×¦Ü««×¬¡°Ê©Ê§Jù®¦¯f¦¨¤H±wªÌ¡A´î¤Ö¯gª¬©M»¤¾É¨Ãºû«ùÁ{§É½w¸Ñ¡C´î¤ÖÅé¼x©M ´î¤Ö³o¨Ç±wªÌªºÅé¼x©M¯gª¬¡A¨Ã»¤¾É¨äÁ{§É½w¸Ñ¡A¦pªG¥L̹ï¶Ç²ÎÀøªk¥¢¥h¤ÏÀ³©Î¤£@¨üªº¸Ü¡C ¹ï^¤Ò§Q¦è³æ§Ü¥¢¥h¤ÏÀ³©Î¤£@¨ü¡C - ¼ìºÅ©Êµ²¸zª¢¡]UC¡^¡]1.6¡^¡C»¤¾É©Mºû«ùÁ{§É½w¸Ñ ¤¤«×¦Ü««×¬¡°Ê©Ê¼ìºÅ©Êµ²¸zª¢ªº¦¨¦~±wªÌ¡A¹ï§K¬ÌªvÀø¤ÏÀ³¤£¥R¤ÀªÌ¡C ¹ï§K¬Ì§í»s¾¯¦p¥Ö½èÃþ©T¾J¡B´áªãµ¥¤ÏÀ³¤£¥R¤Àªº¤¤««×¬¡°Ê©Ê¼ìºÅ©Êµ²¸zª¢ªº¦¨¤H±wªÌ¡A»¤¾É©Mºû«ùÁ{§É½w¸Ñ¡C ¥Ö½èÃþ©T¾J¡B²¸ÐüáIËï©Î6-ÝW°òáIËï¡]6-MP¡^µ¥§K¬Ì§í»s¾¯¤ÏÀ³¤£¥R¤Àªº¤¤««×¬¡°Ê©Ê¼ìºÅ©Êµ²¸zª¢¦¨¦~±wªÌ¡Cªü¹F¤ì³æ§Ü²£«~ªº¦³®Ä©Ê ªü¹F¤ì³æ§Ü²£«~ªº¦³®Ä©Ê©|¥¼¦b¥H¤U±wªÌ¤¤±o¨ìÃÒ¹ê ¹ïTNFªýÂ_¾¯¥¢¥h¤ÏÀ³©Î¤£@¨üªº±wªÌ¡Aªü¹F¤ì³æ§Ü²£«~ªº¦³®Ä©Ê©|¥¼½T©w¡C - ´³¶ôª¬»È®h¯f¡]Ps¡^¡]1.7¡^¡CªvÀø±w¦³¤¤«×¦Ü««×ºC©Ê´³¶ôª¬»È®h¯fªº¦¨¦~±wªÌ¡C ¤¤«×¦Ü««×ºC©Ê´³¶ôª¬»È®h¯f±wªÌªºªvÀø¡C ´³¶ôª¬»È®h¯f(Ps)(1.7)¡GªvÀø¤¤«×©M««×ºC©Ê´³¶ôª¬»È®h¯fªº¦¨¦~±wªÌ¡A³o¨Ç±wªÌ¾A¦X¨Ï¥Î¨t²ÎªvÀø©Î¥úÀø¡A¨Ã¥B¨ä¥L¨t²ÎªvÀø¤èªk¦bÂå¾Ç¤W¨Ã¤£¦X¾A¡C Âå¾Ç¤W¤£¦X¾A¡C
Rheumatoid Arthritis (RA) (1.1): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) (1.2): Reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 4 years of age and older. • Psoriatic Arthritis (PsA) (1.3): Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with activePsA. • Ankylosing Spondylitis (AS) (1.4): Reducing signs and symptoms in adult patients with active AS. • Adult Crohn¡¦s Disease (CD) (1.5): Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn¡¦s disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. • Ulcerative Colitis (UC) (1.6): Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) (1.7): The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemictherapy or phototherapy, and when other systemic therapies are medicallyless appropriate. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/7 ¤W¤È 10:32:37
²Ä 175 ½g¦^À³
|
Herceptin ¶PÀù¥ 1999¦~FDA ®Öã¤W¥«,
2019¦~¬ü°ê ²Ä¤@ÓHerceptin ¶PÀù¥¬Û¦üÃľP°â.
¬ü°ê«OÅ@´Á¦Xp20¦~.
----------------- --
Hurmira ¥Íª«¬Û¦üÃÄ
Hurmira FDA 2002¦~12¤ë31¤é®Öã¤W¥« ¬ü°ê¤W¥«±M§Q12¦~¡A2014¦~12¤ë31¤é¨ì´Á¡C ¬ü°ê销°â¦û80%,¦~¾P¦Ê»õ¬ü¤¸¡C
Hurmira §Q¥Î±M§Q¤Î¨ä¥L¾AÀ³¯g«OÅ@¡Aª½¨ì±M§Q¨ì´Áªº 2023¦~²Ä¤@ÓHurmira¬Û¦üÃĤ~¯à¦b¬ü°ê¾P°â¡C
¬ü°ê«OÅ@´Á¦Xp20¦~.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/7 ¤W¤È 10:08:29
²Ä 174 ½g¦^À³
|
ibmi.taiwan-healthcare.org/zh/news_detail.php?REFDOCTYPID=0o4dd9ctwhtyumw0&REFDOCID=0r17acjpb7mxy46z
www.genetinfo.com/investment/featured/item/7060.html
Hurmira ¥Íª«¬Û¦üÃÄ
Hurmira FDA 2002¦~12¤ë31¤é®Öã¤W¥« ¬ü°ê¤W¥«±M§Q12¦~¡A2014¦~12¤ë31¤é¨ìÃÄ¡C ¬ü°ê销°â¦û80%,¦~¾P¦Ê»õ¡C Hurmira §Q¥Î±M§Q¤Î¨ä¥L¾AÀ³¯g«OÅ@¡Aª½¨ì±M§Q¨ì´Áªº 2023¦~²Ä¤@ÓHurmira¬Û¦üÃĤ~¯à¦b¬ü°ê¾P°â¡C 2016¦~¨ÓFDA¤w®Öã6ÓHurmira ¤W¥«¡A¥u¬OµLªk¦b¬ü¤W¥«¡C
Dupilumab ¬ü°ê 12¦~销°â±M§Q´Á¡A2029/03¦~¨ì´Á¡C
¥i¯à§Q¥Î±M§Q¤Î¨ä¥L¾AÀ³¯g¡A¥i¯à©µªø¦b¬ü°ê¥«³õ¨ì2036¦~¥H¤W¤W¡Aªý¬Û¦üÃĦb¬ü°ê¤W¥«¡C
©Ò¥HASLAN004 ¤T´Á¥Dn«ü¼Ð¡A¡«áEASI75 /IGA0,1¡AÀø®Ä>dupilumab ¤T´Á 20%
则ASLAN004¥«¦û70»õ¬ü¤¸(dupilumab 1/2)¾P°â¤£¬O¹Ú¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Lebrekizumab 2Ó¤T´ÁªºEASI 75 (¦©°£¹ï·Ó组)¡A 33%~43%
Dupilumab 2Ó¤T´Á(¦©°£¹ï·Ó组)=32%~36%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/3 ¤W¤È 09:11:18
²Ä 173 ½g¦^À³
|
www.morressier.com/o/event/5d4178148fb7e44098e72af1/article/5d4980cb8fb7e44098e72cd2
Dupilumab ¤T´Á/2ÓÁ{§Ésolo1/solo2
IgE °ò½u¤ÀªR
(1) IgE < 150 kU/L
¹ï·Ó²Õ/¤G¶g¤@°wQ2w/¤@¶g¤@°wQ1w n = 66 n = 73 n = 81 EASI score, mean (SD) 26.2 (9.8)/ 25.0 (9.6) /28.3 (12.5) CCL17 levels, mean (SD), pg/mL 1,467.6 (2,787.3) /2,281.9 (5,052.9)/ 2,295.0 (6,306.8) Total IgE levels, mean (SD), kU/L 59.0 (40.3)/ 55.1 (41.9) /57.6 (44.7)
(2) IgE >= 150 kU/L
¹ï·Ó²Õ/¤G¶g¤@°wQ2w/¤@¶g¤@°wQ1w n = 393 n = 384 n = 381 EASI score, mean (SD) 35.4 (14.6)/ 33.8 (13.5) /33.4 (13.4) CCL17 levels, mean (SD) 6,668.9 (10,987.1)/ 7,531.0 (15,176.1)/ 6,886.3 (12,413.0) Total IgE levels, mean (SD) 8,131.7 (10,649.3)/ 8,063.9 (11,034.3) /6,609.7 (9,916.7)
------------------------- §CIgE VS °ªIgE(Q2W)
(1)¦¬®×¤H¼Æ¤ñ N 73 ¤HVS 384¤H, §CIgE ²Õ¥u¦û16%ªº¦¬®×¤H¼Æ, 73/(73+384)=16% , (FB825 ¬°66%/ASLAN004 6/22=27%)
(2)EASI(°ò½u) §CIgE ²Õ¥§¡EASI 25.9 (ASLAN004 1B ,EASI 19.8 /§CTRAC/§CIgE²Õ)---2B Á{§ÉÀ³¤j´T©Ô¤É°ò½uEASI¨ì25¥H¤W,¦b§CIgE/§CTRAC²Õ)
(3)CCL17/(TRAC) --°ò½u
§CIgE ²ÕTRAC¥§¡2281
§CIgE<150 ²Õ¦¬¤£§CªºTRAC=2281,-----------Ó¤H»{¬°³oÓ´N¬ODupilumab §CIgE²Õ¦¨¥\ÃöÁä. §CTRAC <1115 ²Õ ¦¬¤£§Cªº¥§¡EASI25-----Ó¤H»{¬°³oÓ¤]¬ODupilumab §CTRAC ²Õ¦¨¥\ÃöÁä ------------------------------- ASLAN004 2b Y¯à¦pdupilumab ¤T´Á, ¦¬®×¤À°t, «h¡«á«ü¼Ð¼Æ¾Ú¥i¹w´Á>DUPILUMAB¾÷ 25%~50% ¾÷·|°ª.
¦pRITT ¤ÀªR(¦©°£§CTRAC ²Õ)
-- EASI75(¦©°£¹ï·Ó²Õ)----
ASLAN004 54% VS Dupilumab 28%~32% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/5/2 ¤U¤È 10:02:06
²Ä 172 ½g¦^À³
|
FB825 2A a.¥Dnµû¦ô«ü¼Ð¤§²Îpµ²ªG¤Î²Îp¤W¤§·N¸q: (a)®Ú¾Ú°õ¦æ¥»¸ÕÅ礧°ê»ÚCRO¤½¥q´£¨Ñ¸ÕÅç¸Ñª¼§¹¾ã¼Æ¾Ú¡A¦b¥»¸ÕÅçµ²§ô«á©Ò °õ¦æ¤§©Ò¦³¨ü¸ÕªÌ¦å²G¥Í¤ÆȤÀªR¡AÅã¥Ü¦³2/3ªº¨ü¸ÕªÌ¤£²Å¦X¥Ø¼Ð±Ú¸s- ¤¤««×²§¦ì©Ê¥Ö½§ª¢(AD)¤§¥Í¤Æ«ü¼Ð¡A¦b¨â¶µÃöÁ䪺TARC(¯Ý¸¢¬¡¤Æ½Õ¸`ÁÍ ¤Æ¦]¤l)»PIgE(§K¬Ì²y³J¥ÕE)¥Í¤Æ«ü¼Ð¤W²§±`°¾§C¡A¥»¸ÕÅç2/3¨ü¸ÕªÌTARC°ò ½uȧC©ó700 pg/ml(Äv«~ÃĪ«Dupixent¦¬®×°ò½uȬ°1,953-6,147 pg/ml)¡B IgE°ò½u¥§¡È569 IU/ml(Dupixent¬°2,451-10,754 IU/ml)¡A¦]¦¹¡A§t¬A¤W z¤£²Å¦X¥Ø¼Ð±Ú¸s¨ü¸ÕªÌ«á¡A¥»¸ÕÅç¥Dnµû¦ô«ü¼ÐµLªk¹F¨ì²Îp·N¸q¡AµLªk ¶i¦æ³o¨Ç«D¥Ø¼Ð±Ú¸s¤§¨ü¸ÕªÌ¦³·N¸qµû¦ô¡C
¤@¤@¤@RITT ¤ÀªR
(b)¸g¶i¤@¨B¤ÀªR¡A©ó1/3¥Ø¼Ð±Ú¸s(TARC°ò½uȤj©ó700 pg/ml)ªºÃöÁäÀø®Ä«ü¼Ð EASI 75(²§¦ì©Ê¥Ö½§ª¢§ïµ½75%¡A¬°ÃÄ«~¤T´ÁÁ{§É¸ÕÅç¥DnÀø®Ä«ü¼Ð)¡A FB825¹F¨ì53.8%¡A¹ï·Ó²Õ¬°29.4%¡A»PÄv«~ÃĪ«Dupixentªº¨â¶µ¤T´Á¸ÕÅçµ² ªG44%¤Î51%¬Û·í¡C¤@¤@¤@¡]Dupilumab ¹ï·Ó²Õ 12%/15%) FB825©ó¥Ø¼Ð±Ú¸s¹F¨ì¹w´Á¤§¸ÕÅçªvÀø®ÄªG¡A¥i¤ä«ù¶i¦æ¡@ «áÄò¸ÕÅç¡C ¤@¤@¤@¤@¤@¤@ www.nejm.org/doi/full/10.1056/nejmoa1610020 ir.aslanpharma.com/static-files/662c1f39-bb78-4407-911d-19aa10cb1da6 ¤@¤@¤@¤@¤@ EASI75 Àø®ÄPK
Dupilumab¦©°£¹ï·Ó²Õ=32%¡ã36%¡]ITT) Dupilumab¦©°£¹ï·Ó²Õ¡×¬ù28%¡ã32%(RITT¡A¦©°£§CTRAC²Õ¡^
FB825¦©°£¹ï·Ó²Õ=24.4%(RITT)
ASLAN004 1b ¦©°£¹ï·Ó²Õ=54%(69%-15%=54%,N=16:13,RITT/¦©°£9¦ì«D¶Ç²ÎAD¤@§CTRAC¡^ ASLAN0041b ¦©°£¹ï·Ó²Õ=37%(50%-13%=37%¡]ITT N =22:16¡^ ¤@¤@¤@¤@¤@¤@¤@ µ²½×¡GY¨ÌRITT¤ÀªR ¡A¦©°£§CTRAC²ÕASLAN004 Àø®Ä¡A EASI75¡A¤j´T»â¥ý¨ä¥L¨âÃÄÁͶաI |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/4/12 ¤W¤È 07:08:59
²Ä 171 ½g¦^À³
|
¬°ÁקK¸¨¤J ASLAN0041b¤ÎCBP201 2b ¡A©Û¶Ò§CTRAC/§CEAS¤u(EASI<21) ¥xÆWªºªÑªF¥i¼gemail ¡A«ØijASLN¤½¥q¡A
ASLAN004 2b¿z¿ï¤Hû®É¡A¥h°£°ò½u§CEASI(EASI21¥H¤UªÌ)¡A
§â°ò½u§CTRAC<1115ªÌªº¥§¡EAS¤u¡A¦pDupilumab 3´Á©Ô°ª¨ì24.1-25.8¡A
¡K¡K¡K¡KASLAN004 1b °ò½uTRAC<1115¡A9¦ì¡A«D¶Ç²ÎAD¡A¥§¡EASI约18-19¡K¡K
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
Dupilumab 3´ÁÁ{§É¡AÁ׶}¤F«D¶Ç²ÎAD组¸s¡K¡K ¡K¡K§CTRAC/°ò½u ¡K¡K§CEASI/°ò½u
EASI<21¥BTRAC<1115/°ò½uªÌ´X¥G设¦¬¤J¤T´Á¡A
(¥Ñ¤GÓ¤T´ÁÁ{§É¥§¡EASI24.1-25.8)......×¥¿1
www.morressier.com/article/biomarkers-ccl17tarc-total-ige-not-predict-clinical-response-dupilumab-atopic-dermatitis-ad-post-hoc-analysis-pooled-phase-3-data-solo-1--2/5d4980cb8fb7e44098e72cd2?
Biomarkers CCL17/TARC and Total IgE Do Not Predict Clinical Response to Dupilumab in Atopic Dermatitis (AD): a Post hoc Analysis of Pooled Phase 3 Data (SOLO 1 & 2) Submitted Sep 2, 2019
Jennifer D. Hamilton
Zhen ¡K¡K
结½×1..CCL17/TRAC ªº¥Íª«¼Ð»xª«®Ä»ù§C¡A°ò½uEASI´N§C¡C
¤Ï¤§°ª«h°ª¡C
CCL17/TRAC// ¤H¼Æ// °ò½u¥§¡EASI//ªvÀø«áEASI¥§¡°´T(¤ñ²v)//¥§¡°ªº¤À¼Æ¡C
Dupilumab 组 solo1 ¤pp 457. //32.4//70//22.6 <1115 154//24.1// 77.9// 19.5 1115~4300//153//32.4//67.4%//21.9 >4300//149//41.1/63.1%//26.2
Solo2 ¤pp 462 //32.5//70.7%//23,1 <1115 160//25.8//75.4%/19.1 1115~4300//147//31.2//66.4%//21.9 >4300//152//40.9//67.5%/27.5 ¡K¡K¡K¡K ¡K¡K¡K¡K ¹ï·Ó组 ¤pp460 //34.1//34.3%//11.5
143 //25.3//43.7%//11.5 157//32.4//23.3%//8.7 156//43.9//27.1%//11.5
结½×2 Dupilumab ªvÀø«áªºEASI¥§¡°´TÀø®Ä»P°ò½uCCL17/TRAC¥Íª««ü¼Ð®Ä»ù°ª§CµL¥¿¬ÛÃö¡C
¤T组CCL17/TRAC¤£¦P®Ä»ù¡A ¦P¼Ë¦³Àø®Ä¡C
investors.connectbiopharm.com/events/event-details/global-phase-2b-trial-cbp-201-atopic-dermatitis-data-review-call
CBP201¤@ AD 2b ¸Ô²Ó¤ÀªRÀÉ(2022/01/05) ½Ð¦Û¦æ¤U¸ü¡C
CBP201 ©Ò¹J§x¹Ò©MASLAN 1b ¬Û¦ü¡C
1.¤¤断²v°ª约19% (Dupilumab 3´Á6%//2´Á¨ä¹ê¤]ªñ19%) ¨ä¥LLebtri/Tralo ¤]¬O¤G´Á¤¤断²v°ª约20%¡A¤T´Á¤¤断²v´N¤j°8%¥ª¥k¡C
2.CBP 201 TRAC §C²Õ (°ò½u)¡A16¶g¡«á EASI ¥§¡°´T53% TRAC ¤¤°ª组(°ò½u)¡A 63%¡K¡K2¶g¤@°wx300mg组 EASI §C组(°ò½u<18), 52%¡K¡K2¶g¤@°wx300mg组
Dupilumab TRAC §C组/EASI¥§¡25.1(°ò½u)¡A 16¶g¡«áEASI¥§¡°78%
__
«Øij¤½¥q¡A2b¡AÀ³®ÄªkDupilumab 3´Á TRAC§C组¡AEASI¥§¡¦¬¦b25
§C©óEASI20ªº¤£n¦¬¡C
¡¦¡K¡K¡K¡K¡K¡K¡K¡K¥i¯à¤j¦h«D¶Ç²ÎAD¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/4/5 ¤U¤È 06:09:29
²Ä 170 ½g¦^À³
|
¤C.¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù: ¦ôp¤Î±ø¥ó
11/50*145*2=64»õ¬ü¤¸(¨È·à¿W±o)
Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*2022¦~dupilumab 145»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2023¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù.
¥H¤W¥²n±ø¥ó¦p¤U:
ASLAN004 2b (16¶g¦©°£¹ï·Ó²Õ¤§½Õ¾ã)EASI 75 & IGA0,1 ,¨â«ü¼ÐªºÂ¡«áÀø®Ä >= Dupilumab 20%.
IGA,01 (¹êÅç²Õ-¹ï·Ó²Õ)38%-10%>=28% *1.2=33.6% EASI75 (¹êÅç²Õ-¹ï·Ó²Õ)>=36*1.2=43%
ASLAN004 1b (RITT) IGA,01 (¹êÅç²Õ44%-¹ï·Ó²Õ15%)=29%<33.6%-----(16¶g¤§ªvÀø¦³¾÷·|©Ô¤É¹F¼Ð) EASI75 (¹êÅç²Õ69%-¹ï·Ó²Õ15%)=54% >43%------OK
========================== .Dupilumab ¤T´Á(16¶g) In SOLO 1,
IGA,01 38%-10%=28% EASI75 51%-15%=36% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/4/4 ¤U¤È 10:20:46
²Ä 169 ½g¦^À³
|
Ó¤H¬Ýªk
Lebrikizumab(16¶g) VS Dupilumab(¤T´Á ¼Æ¾Ú¦©°£¹ï·Ó²Õ )
¦n®ø®§¬O§@¥Î¦bIL13 Lebrikizumab ¤T´Á(16¶g) ¥X²{¤@¥b¾÷·|¥i¯àÀu©óDupilumab ¤T´Á.
Lebrikizumab MOA : ±µ¦X IL13 ªºB¡BCÁ³±Û , IL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\, ¥iªý¤îIL13°T¸¹¶Ç»¼.
¦ýLebrikizumab , IL13 & IL-13R£\1 ±µ¦X¦û¾Ú ³¡¥÷IL-13R £\1, ¼vÅT³¡¥÷ IL4 °T¸¹¶Ç»¼¡C IL-13R £\1¥¼³Q¦û¾ÚªÌ,IL4°T¸¹¯à³Q¶Ç»¼¨ìTYPE II recepter ,¦Ó¨Ï¡«á°ªÀø®ÄÅÜ®t.
------------------------ ASLAN004 MOA ±µ¦X IL-13R£\1 ,¥i±æ¦³¾÷·|§óéwªºÂ¡«á°ªÀø®Ä, Àu©óLebrikizumab(16¶g)In ADvocate 1 ¾÷·|°ª.
------------------------------------------
¤@.Lebrikizumab(16¶g)
In ADvocate 1,
(IGA) 43%-13%=30% EASI 59%-16%-43%
In ADvocate 2,
(IGA) 33%-11%=22% EASI 51%-18%-33%
¤G.Dupilumab ¤T´Á(16¶g) In SOLO 1,
(IGA) 38%-10%=28% EASI 51%-15%=36%
In SOLO2 2,
(IGA) 36%-8%=28% EASI 44%-12%-32%
----------------------------------
Lebrikizumab ¤GÓ¤T´Á¥Dn«ü¼Ð16¶g¡«áÀø®Ä¡C¤@¤@¤@¤@2022AAD¦~·|¤fÀY³ø§i
In ADvocate 1, 43 percent of patients receiving lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks compared to 13 percent of patients taking placebo. Among those receiving lebrikizumab, 59 percent achieved an EASI-75 response, compared to 16 percent with placebo.
In ADvocate 2, 33 percent of patients taking lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared to 11 percent of patients on placebo. Among those receiving lebrikizumab, 51 percent achieved an EASI-75 response, compared to 18 percent taking placebo.
www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/4/4 ¤U¤È 09:11:19
²Ä 168 ½g¦^À³
|
Lebrikizumab ¤GÓ¤T´Á¥Dn«ü¼Ð16¶g¡«áÀø®Ä¡C¤@¤@¤@¤@2022AAD¦~·|¤fÀY³ø§i ¨âÓÁ{§É¤§¶¡ªºÀø®ÄÅܲ§©Ê¤j¬°±Ñµ§¡C
In ADvocate 1, 43 percent of patients receiving lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks compared to 13 percent of patients taking placebo. Among those receiving lebrikizumab, 59 percent achieved an EASI-75 response, compared to 16 percent with placebo.
In ADvocate 2, 33 percent of patients taking lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared to 11 percent of patients on placebo. Among those receiving lebrikizumab, 51 percent achieved an EASI-75 response, compared to 18 percent taking placebo.
¤@¤@¤@¤@¤@¤@ Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly¡¦s Pivotal Phase 3 Atopic Dermatitis Studies Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) NEWS PROVIDED BY Eli Lilly and Company Mar 26, 2022, 09:20 ET SHARE THIS ARTICLE Lebrikizumab rapidly improved skin and itch symptoms in four weeks
INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes compared to placebo.
Patients with atopic dermatitis experience persistent itch, dry skin, severe pain and inflammation, which can be unpredictable and affect their work, social relationships, mental and emotional health, said Emma Guttman-Yassky, M.D., Ph.D., Waldman professor and system chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, and senior author of the ADvocate analyses. Lebrikizumab is a novel treatment targeting the IL-13 pathway, which is the main cytokine driver of inflammation that is involved in AD. I¡¦m encouraged by today¡¦s data showing rapid improvements in skin, itch and quality-of-life measures.
Lebrikizumab is a monoclonal antibody (mAb) that binds to the interleukin 13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R£\1/IL-4R£\ (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway. 1-5 IL-13 plays the central role in Type 2 inflammation.6 In AD, IL-13 underlies the signs and symptoms including skin barrier dysfunction, itch, infection and hard, thickened areas of skin.7
In ADvocate 1, 43 percent of patients receiving lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks compared to 13 percent of patients taking placebo. Among those receiving lebrikizumab, 59 percent achieved an EASI-75 response, compared to 16 percent with placebo.
In ADvocate 2, 33 percent of patients taking lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared to 11 percent of patients on placebo. Among those receiving lebrikizumab, 51 percent achieved an EASI-75 response, compared to 18 percent taking placebo.
Within four weeks, patients receiving lebrikizumab experienced statistically significant improvements in skin clearance and itching, as well as improvements in interference of itch on sleep, and quality of life, as measured by key secondary endpoints.
The safety profile of the 16-week period was consistent with prior lebrikizumab studies in AD. Patients taking lebrikizumab, compared to placebo, reported a lower frequency of adverse events in ADvocate 1 (lebrikizumab: 45%, placebo: 52%) and ADvocate 2 (lebrikizumab: 53%, placebo: 66%). Most adverse events across the two studies were mild or moderate in severity and nonserious and did not lead to treatment discontinuation. The most common adverse events in ADvocate 1 and 2 for those on lebrikizumab were conjunctivitis (7% and 8%, respectively), common cold (nasopharyngitis) (4% and 5%, respectively) and headache (3% and 5%, respectively).
People¡¦s experiences and struggles with autoimmune diseases, such as atopic dermatitis, drive us at Lilly to pursue novel science and meaningful treatments that make life better, especially in areas where there is urgent unmet need, said Lotus Mallbris, M.D., Ph.D., vice president of global immunology development and medical affairs at Lilly. These data reinforce the positive results in our broader Phase 3 development program, and we believe lebrikizumab represents a new generation of biologics for AD.
Detailed 52-week results from ADvocate 1 and 2, as well as 16-week data from ADhere, the Phase 3 AD study of lebrikizumab with topical steroids, will be disclosed in coming months. Lilly and Almirall S.A. plan to submit filings to regulatory authorities around the world by the end of 2022 following completion of the ADvocate studies.
Patients need new treatment options that provide high efficacy and tolerability. These positive data demonstrate that lebrikizumab has the potential to be a leading treatment in AD, said Karl Ziegelbauer, Ph.D., Almirall¡¦s Chief Scientific Officer.
Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside Europe. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
*EASI=Eczema Area and Severity Index, EASI75=75 percent reduction in EASI from baseline to Week 16
www.prnewswire.com/news-releases/majority-of-patients-treated-with-lebrikizumab-achieved-skin-clearance-in-lillys-pivotal-phase-3-atopic-dermatitis-studies-301510964.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/20 ¤W¤È 06:30:19
²Ä 167 ½g¦^À³
|
CIBINQO
1¡A100mg °w¹ï¤¤-««× AD ¤@½uÃÄ
¬D¾Ô: A.Àø®Ä: 100mg/¤é Àø®Ä¡A ¤ñdupilumab ®t¡A ¥h°£¹ï·Ó组¼vÅT¡A¶È约dupikumab70%-80%
B.«¤j°Æ§@¥Î: ¦º¤`·ÀI:±wRA(Ãþ·ÀãÃö结ª¢)¸T¥Î ´c©Ê¸~½F Àù¯g ¦å®ê
Ó¤H§PÂ_:BININQO ,¦b¤@½u¥«³õ¤ñ¸ûµL§l¤Þ¤O¡C
2.200mg °w¹ï¤¤-««× AD ¤G½uÃÄ
¬D¾Ô 100mg.µL¤ÏÀ³¡A«á¤~¯à¥Î200mg
Y100mg¡A ¥Îªº¤H¤£¦h¡A则200mg¥çÃø¦³¦n销°â 3.Áo©úªº½÷·ç¥i¯àµ¦²¤ À³°µ¥t¤@ÓÁ{§É¡A©Û¶Ò¯u¥¿dupilumabµL¤ÏÀ³ªÌ¡A ª½±µ¥Î200mgªvÀø¡A¥h¦û领3¦¨ªº¤G½u¥«Ô·
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K CIBINQO ³Q§å㪺±ÀÂ˾¯¶q¬° 100 mg ©M 200 mg¡A
200 mg ¾¯¶q³Q±ÀÂ˥Ωó¹ï 100 mg ¾¯¶q¨S¦³¤ÏÀ³ªº±wªÌ¡C
¦¹¥~¡A50 mg ¾¯¶q³Q§åã¥Î©óªvÀø¤¤«×¦Ü««× AD¡A¯S§O¬O¦b¤¤«×µÇ¥\¯à¤£¥þ¡]µÇ°IºÜ¡^±wªÌ¡B
¬Y¨Ç±µ¨ü²ÓM¦â¯À P450 (CYP) 2C19 §í»s¾¯ªvÀøªº±wªÌ¡A©Î¤wª¾©ÎºÃ¦ü¬O CYP2C19 ªº®z¥NÁª̡C¹ï©ó¤¤«×µÇ¥\¯à¤£¥þªº±wªÌ¡A¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡A¤]¥i¥H¶}¥X¨C¤Ñ¤@¦¸ 100 ²@§Jªº³B¤è¡C
¡K¡K¡K¡K¡K¡K¡K
³æÁn¹D-1¡G IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 24%*¡B44%** ©M 8% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 40%**¡B62%** ©M 12% JADE MONO-2 IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 28%**¡B38%** ©M 9% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 44%**¡B61%** ©M 10% ¥É¥Û¤ñ¸û IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 36%**¡B47%** ©M 14% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 58%**¡B68%** ©M 27% ¦w¥þ©ÊÁÙ³q¹L¤@¶µÀH¾÷¾¯¶q½d³ò¸ÕÅç©M¤@¶µªø´Á¡B¶}©ñ¼ÐÅÒ¡BÂX®i¸ÕÅç¡]JADE EXTEND¡^¶i¦æ¤Fµû¦ô¡C ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/1/19 ¤U¤È 11:11:17²Ä 5072 ½g¦^À³ www-pfizer-com.translate.goog/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults?_x_tr_sl=en&_x_tr_tl=zh-TW&_x_tr_hl=zh-TW&_x_tr_pto=sc
¥ý¥Î100mgµL®ÄªÌ¡A¦A¥Î200mg¤@¤@¤@¤@FDA«Øij
100mgÀø®Ä«Ü¤£«ç»ò¼Ë¡C
¤@¤j°ï«¤j¥ÎÃÄĵ§i¡C
¤@¤@¤@¤@¤K¤@¤@¤@¤@Æ¿ ¬ü°ê FDA §åã½÷·çªº CIBINQO®¡]abrocitinib¡^¥Î©ó¦¨¤H¤¤««×¯SÀ³©Ê¥Öª¢ 2022 ¦~ 1 ¤ë 14 ¤é¬P´Á¤ - ¤U¤È 3:30 CIBINQO ¬O¤@ºØ¨C¤é¤@¦¸ªº¤fªAªvÀøÃĪ«¡A¸gÃÒ¹ê¥i¦³®Ä½w¸Ñ¥Ø«e©|¥¼½w¸Ñ¯gª¬ªº¦¨¦~¤Hªº¯gª¬
¯Ã¬ù--(BUSINESS WIRE)--(¬ü°ê°Ó·~¸ê°T)--½÷·ç¤½¥q (NYSE: PFE) ¤µ¤Ñ«Å¥¬¡A¬ü°ê (US) ¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) §åã¤F CIBINQO ® (abrocitinib)¡A³o¬O¤@ºØ¤fªA¡B¨C¤é¤@¦¸ªº Janus ¿E酶1 (JAK1) §í»s¾¯¡A¥Î©óªvÀø±w¦³Ãøªv©Ê¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ (AD) ªº¦¨¤H¡A³o¨Ç±wªÌªº¯e¯fµLªk³q¹L¨ä¥L¥þ¨©ÊÃĪ«²£«~¡]¥]¬A¥Íª«»s¾¯¡^±o¨ì¥R¤À±±¨î¡A©ÎªÌ¦b¤£«Øij¨Ï¥Î³o¨ÇÀøªk®É¡C
CIBINQO ³Q§å㪺±ÀÂ˾¯¶q¬° 100 mg ©M 200 mg¡A200 mg ¾¯¶q³Q±ÀÂ˥Ωó¹ï 100 mg ¾¯¶q¨S¦³¤ÏÀ³ªº±wªÌ¡C¦¹¥~¡A50 mg ¾¯¶q³Q§åã¥Î©óªvÀø¤¤«×¦Ü««× AD¡A¯S§O¬O¦b¤¤«×µÇ¥\¯à¤£¥þ¡]µÇ°IºÜ¡^±wªÌ¡B¬Y¨Ç±µ¨ü²ÓM¦â¯À P450 (CYP) 2C19 §í»s¾¯ªvÀøªº±wªÌ¡A©Î¤wª¾©ÎºÃ¦ü¬O CYP2C19 ªº®z¥NÁª̡C¹ï©ó¤¤«×µÇ¥\¯à¤£¥þªº±wªÌ¡A¹ï¨C¤Ñ¤@¦¸ 50 ²@§J¨S¦³¤ÏÀ³ªº±wªÌ¡A¤]¥i¥H¶}¥X¨C¤Ñ¤@¦¸ 100 ²@§Jªº³B¤è¡C
¡§The reality for patients living with chronic inflammatory skin disease such as moderate-to-severe atopic dermatitis is that many experience debilitating symptoms that are not managed by current treatment options. Today¡¦s approval of CIBINQO will provide an important new oral option that could help those who have yet to find relief,¡¨ said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. ¡§In multiple large-scale clinical trials, CIBINQO demonstrated strong efficacy at clearing skin, improving itch, and managing the extent and severity of eczema, offering a benefit-risk profile that supports the use of this treatment in the FDA-approved patient population.¡¨
FDA ªº§åã¬O°ò©ó 1,600 ¦h¦W±wªÌªº¤j³W¼ÒÁ{§É¸ÕÅçp¹ºªº¤¶µÁ{§É¸ÕÅ窺µ²ªG¡C CIBINQO ªº¦w¥þ©Ê©M¦³®Ä©Ê¦b¤T¶µÀH¾÷¡B¦w¼¢¾¯¹ï·Óªº 3 ´Á¸ÕÅ礤¶i¦æ¤Fµû¦ô¡C¦¹¥~¡A¦w¥þ©Ê³q¹L¤@¶µÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³ò¸ÕÅç©M¤@¶µ¥¿¦b¶i¦æªºªø´Á¶}©ñ¼ÐÅÒÂX®i¸ÕÅç¶i¦æ¤Fµû¦ô¡C¦b¾ãÓ¸ÕÅ礤¡ACIBINQO ÃÒ©ú¤F»P¦w¼¢¾¯¬Û¤ñ¡A¹ï©ó¤@¨Ç±w¦³ AD ªº¤H¨Ó»¡¡ACIBINQO ¨ã¦³¤@Pªº¦w¥þ©Ê©M¥Ö½§²M°£²v¡B¯e¯fµ{«×©MÄY«µ{«×ªºÅãµÛ§ïµ½¡A¥H¤Î¨â¶g«áæ±Äoªº§Ö³t§ïµ½¡C¦¹¥~¡A»P¦w¼¢¾¯¬Û¤ñ¡A¦b¨â¶µ³æ¤@Àøªk¸ÕÅ礤±µ¨ü CIBINQO ªvÀøªº¨ü¸ÕªÌ¦b²Ä 12 ¶gªºæ±Äo§ïµ½ªº¤ñ¨Ò§ó°ª¡C
¡§¬ü°ê¹«~©MÃĪ«ºÞ²z§½ªº§å㬰¬ü°ê¼Æ¦Ê¸U¨C¤Ñ¾D¨ü§K¬Ìª¢¯g¯e¯f§é¿iªº±wªÌ±a¨Ó¤F§Æ±æ¡A¦pªG¤£¥[¥H±±¨î¡A¥i¯à·|¾ÉP¼@¯P©M«ùÄòªºæ±Äo¡B¯kµh¡B¤£¾A©MµhW¡A¡¨¥þ²yÁ`µô Mike Gladstone »¡¡C½÷·çª¢¯g»P§K¬Ì¾Ç¡C ¡§CIBINQO ¬O¤@ºØ¦³®Äªº¨C¤é¤@¦¸ÃĤY¡A¬O½÷·ç¬ã¨s¤Hû©M°Ñ»P§ÚÌÁ{§É¸ÕÅ窺¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢±wªÌ¹ê²{ªºÂå¾Ç¬ð¯}¡C¡¨
¡§¯SÀ³©Ê¥Öª¢¤£¶È¶È¬O¥Ö¯l¡A¥¦¶W¶V¤F¥Ö½§ªí±¡C³o¬O¤@ºØºC©Ê¯f¡A·|ÄY«ÂZ¶Ã±wªÌªº¤é±`¥Í¬¡¡A¨Ã¹ï¥L̪º±¡ºü°·±d²£¥Ít±¼vÅT¡A¡¨¥þ°êÀã¯l¨ó·|¥D®uݺ®u°õ¦æ©x Julie Block »¡¡C¡§§ÚÌ·PÁ½÷·ç¹ï³oÓ´I¦³¼u©Êªº±wªÌªÀ°Ïªº©Ó¿Õ¡A¨Ã¼ö¤Á´Á«Ý CIBINQO ¥i¯à¹ï¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªºªvÀø«e´º²£¥Í¿n·¥¼vÅT¡C¡¨
≥5% ªº CIBINQO ±wªÌ³ø§iªº³Ì±`¨£¤£¨}¨Æ¥ó¥]¬A»ó«|ª¢¡]CIBINQO 100 mg ²Õ¬° 12.4%¡ACIBINQO 200 mg ²Õ¬° 8.7%¡A¦w¼¢¾¯²Õ¬° 7.9%¡^¡Bäú¤ß¡]6%¡B14.5% ©M 2.1% ¡A¤À§O¡^©MÀYµh¡]¤À§O¬° 6%¡B7.8% ©M 3.5%¡^¡C
CIBINQO ªº§¹¾ã³B¤è«H®§¥i¦b¦¹³B§ä¨ì¡CCIBINQO ±N¦b¥¼¨Ó´X¶g¤º´£¨Ñ¡C
CIBINQO Á{§É¸ÕÅçp¹ºªº¨ä¥L¸Ô²Ó«H®§
CIBINQO JAK1¯SÀ³©Ê¥Öª¢Àø®Ä©M¦w¥þ©Ê¡]JADE¡^¥þ²y¶}µop¹º¤¤ªº¤¶µÁ{§É¸ÕÅç³Q¯Ç¤J·sÃĥӽС]NDA¡^¥H¤ä«ùFDA§åã¡C
CIBINQO ªº¦w¥þ©Ê©M¦³®Ä©Ê¦b¤TÓ 3 ´Á¡BÀH¾÷¡B¦w¼¢¾¯¹ï·ÓÁ{§É¸ÕÅ礤¶i¦æ¤Fµû¦ô¡C³o¨Ç¸ÕÅçµû¦ô¤F¥Ö½§²M°£¡Bæ±Äo¡B¯e¯fµ{«×©MÄY«µ{«×ªº§ïµ½±¹¬I¡A¥]¬A½Õ¬dû¥þ²yµû¦ô (IGA)¡BÀã¯l±¿n©MÄY«µ{«×«ü¼Æ (EASI) ©M®pÈæ±Äo¼Æȵû©w¶qªí (PP-NRS)¡C¦b¨C¶µ¸ÕÅ礤¡A¶W¹L 40% ªº±wªÌ´¿±µ¨ü¹L¥þ¨ªvÀø¡G
JADE MONO-1 ©M JADE MONO-2¡G¤@¹ïÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¦®¦bµû¦ô 778 ¦W±wªÌ 12 ¦~ªº¨âºØ¾¯¶q¡]100 ²@§J©M 200 ²@§J¨C¤Ñ¤@¦¸¡^ªº CIBINQO ³æ¤@ÀøªkªºÀø®Ä©M¦w¥þ©Ê¦~Ä֤ΥH¤Wªº¤¤«×¦Ü««× AD¡C³o¨Ç¸ÕÅç¦b²Ä 12 ¶gµû¦ô¤F IGA ©M EASI-75 ¤ÏÀ³ªº¦@¦P¥Dn²×ÂI¡C JADE COMPARE¡G¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¦®¦bµû¦ô CIBINQO ¨â¾¯¡]100 ²@§J©M 200 ²@§J¡A¨C¤Ñ¤@¦¸¡^¦b 837 ¦WI´º§½³¡¥ÎÃĪº¤¤«×¦Ü««× AD ¦¨¤H±wªÌ¤¤ªºÀø®Ä©M¦w¥þ©ÊªvÀø¡C»P¦w¼¢¾¯¬Û¤ñ¡A¸Ó¸ÕÅçÁÙ¥]¬A¤@Ó±a¦³ dupilumab ªº¥D°Ê±±¨î²Õ¡Adupilumab ¬O¤@ºØ³q¹L¥Ö¤Uª`®g¶i¦æªº¥Íª«ªvÀø¡C¸Ó¸ÕÅç¦b²Ä 12 ¶gµû¦ô¤F IGA ©M EASI-75 ¤ÏÀ³ªº¦@¦P¥Dn²×ÂI¡C CIBINQO 100 mg¡B200 mg ©M¦w¼¢¾¯ªº¿ï¾Üµ²ªG¦p¤U¡]*p<0.01 ©Î **p<0.001¡^¡G
¥É³æÁn¹D-1¡G IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 24%*¡B44%** ©M 8% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 40%**¡B62%** ©M 12% JADE MONO-2 IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 28%**¡B38%** ©M 9% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 44%**¡B61%** ©M 10% ¥É¥Û¤ñ¸û IGA ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 36%**¡B47%** ©M 14% EASI-75 ÅTÀ³²v¡]²Ä 12 ¶g¡^¡G¤À§O¬° 58%**¡B68%** ©M 27% ¦w¥þ©ÊÁÙ³q¹L¤@¶µÀH¾÷¾¯¶q½d³ò¸ÕÅç©M¤@¶µªø´Á¡B¶}©ñ¼ÐÅÒ¡BÂX®i¸ÕÅç¡]JADE EXTEND¡^¶i¦æ¤Fµû¦ô¡C
¬ü°ê«n¦w¥þ«H®§
ĵ§i¡GÄY«·P¬V¡B¦º¤`²v¡B´c©Ê¸~½F¡B¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó©M¦å®ê§Î¦¨
ÄY«·P¬V
±µ¨ü CIBINQO ªvÀøªº±wªÌµo¥ÍÄY«·P¬Vªº·ÀI¥i¯à·|¼W¥[¡A±q¦Ó¾ÉP¦í°|©Î¦º¤`¡CCIBINQO ³Ì±`¨£ªºÄY«·P¬V¬O³æ¯Â¯p¯l¡B±aª¬¯p¯l©MªÍª¢¡C
¦pªGµo¥ÍÄY«©Î¾÷·|©Ê·P¬V¡A½Ð°±¤î CIBINQO ¨Ã±±¨î·P¬V¡C
¥Î©óªvÀøª¢¯gªº Janus ¿E酶 (JAK) §í»s¾¯³ø§iªº·P¬V¡G
¬¡°Ê©ÊªÍµ²®Ö¡A¥i¯àªí²{¬°ªÍ³¡©ÎªÍ¥~¯e¯f¡C¦bªvÀø«e©MªvÀø´Á¶¡ÀË´ú¼ç¥ñ©Êµ²®Ö¯f¡F¨Ï¥Î«eªvÀø¼ç¥ñ©Êµ²®Ö¯f¡C¦bªvÀø´Á¶¡ºÊ´ú©Ò¦³±wªÌªº¬¡°Ê©Êµ²®Ö¯f¡A§Y¨Ï¬O³Ìªì³±©Ê¡B¼ç¥ñ©Êµ²®Ö¯fÀË´úªº±wªÌ¡C «Iŧ©Ê¯uµß·P¬V¡A¥]¬AÁô²yµß¯f©MªÍÌU¤lÂίf¡C«Iŧ©Ê¯uµß·P¬V±wªÌ¥i¯à·|¥X²{¼½´²©Ê¦Ó«D§½³¡©Ê¯e¯f¡C ¥Ñ¾÷·|©Ê¯fìÅé¤Þ°_ªº²Óµß¡B¯f¬r¡]¥]¬A±aª¬¯p¯l¡^©M¨ä¥L·P¬V¡C ÁקK¦b¦³¬¡°Ê©Ê¡BÄY«·P¬V¡]¥]¬A§½³¡·P¬V¡^ªº±wªÌ¤¤¨Ï¥Î CIBINQO¡C¦b¶}©lªvÀøºC©Ê©Î½Æµo©Ê·P¬V±wªÌ©Î¦b¦a¤è©Êµ²®Ö¯f©Î¦a¤è©Ê¯uµß¯f¦a°Ï©~¦í©Î®È¦æªº±wªÌ¤§«e¡AÀ³¥J²Ó¦Ò¼{¨Ï¥Î CIBINQO ªvÀøªº·ÀI©M¯q³B¡C
À³±K¤ÁºÊ´ú±wªÌ¦b CIBINQO ªvÀø´Á¶¡©MªvÀø«á·P¬VÅé¼x©M¯gª¬ªºµo®i¡A¥]¬A¦b¶}©lªvÀø«e¹ï¼ç¥ñ©Êµ²®Ö·P¬VÀË´ú§e³±©Êªº±wªÌ¥i¯àµo®i¬°µ²®Ö¯f¡C
¦Ò¼{¨C¦~¹ïµ²®Ö¯f°ª«×¬y¦æ¦a°Ïªº±wªÌ¶i¦æ¿z¬d¡CCIBINQO ¤£±ÀÂ˥Ω󬡰ʩʵ²®Ö¯f±wªÌ¡C¹ï©ó·s¶EÂ_¬°¼ç¥ñ©Êµ²®Ö¯f©Î¥ý«e¥¼ªvÀøªº¼ç¥ñ©Êµ²®Ö¯f±wªÌ¡A©Î¼ç¥ñ©Êµ²®Ö¯fÀË´úµ²ªG¬°³±©Ê¦ý·P¬Vµ²®Ö¯f·ÀI°ªªº±wªÌ¡A¦b¶}©l CIBINQO ¤§«e¶}©l¹ï¼ç¥ñ©Êµ²®Ö¯f¶i¦æ¹w¨¾©ÊªvÀø¡C
¦b¨Ï¥Î CIBINQO ªºÁ{§É¬ã¨s¤¤³ø§i¤F¯f¬r¦A¿E¬¡¡A¥]¬A¯p¯l¯f¬r¦A¿E¬¡¡]¨Ò¦p¡A±aª¬¯p¯l¡B³æ¯Â¯p¯l¡^¡C¦pªG±wªÌ¥X²{±aª¬¯p¯l¡A¦Ò¼{¤¤Â_ CIBINQO ª½¨ìµo§@®ø°h¡C¦b±µ¨ü JAK §í»s¾¯ªº±wªÌ¤¤³ø§i¤F¤A«¬¨xª¢¯f¬r¦A¿E¬¡¡C¦b¶}©lªvÀø«e©M¨Ï¥Î CIBINQO ªvÀø´Á¶¡¡A®Ú¾ÚÁ{§É«ü«n¶i¦æ¯f¬r©Ê¨xª¢¿z¬d©M¦A¿E¬¡ºÊ´ú¡C¤£«Øij±N CIBINQO ¥Î©ó¬¡°Ê©Ê¤A«¬¨xª¢©Î¤þ«¬¨xª¢±wªÌ¡C
¦º¤`
¦b¤@¶µ°w¹ï 50 ·³¤Î¥H¤W¦Ü¤Ö¦³¤@ӤߦåºÞ¦MÀI¦]¯ÀªºÃþ·ÀãÃö¸`ª¢ (RA) ±wªÌ¶i¦æªº¤j«¬ÀH¾÷¤W¥««á¦w¥þ©Ê¬ã¨s¤¤¡A±N¥t¤@ºØ JAK §í»s¾¯»P TNF ªýº¢¾¯ªvÀø¶i¦æ¤ñ¸û¡Aµo²{§ó°ªªº¥þ¦]¦º¤`²v¡]¥]¬A¤ß¦åºÞÖ`¦º¡^ ) ¥Î JAK §í»s¾¯Æ[¹î¨ì¡CCIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C
´c©Ê¸~½F
¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F´c©Ê¸~½F¡A¥]¬A«D¶Â¦â¯À½F¥Ö½§Àù (NMSC)¡C¦b±µ¨ü¥Î©óªvÀøª¢¯gªº JAK §í»s¾¯ªº±wªÌ¤¤Æ[¹î¨ì²O¤Ú½F©M¨ä¥L´c©Ê¸~½F¡C¹ï¥Ö½§Àù·ÀI¼W¥[ªº±wªÌ¶i¦æ©w´Á¥Ö½§Àˬd¡CÀ³³q¹L¬ï¨¾Å@ªA©M¨Ï¥Î¼sÃШ¾ÅÎÁ÷¨Ó¨î¼ÉÅS¦b¶§¥ú©Mµµ¥~½u¤U¡C
¦b¤@¶µ°w¹ï RA ±wªÌªº¥t¤@ºØ JAK §í»s¾¯ªº¤j«¬ÀH¾÷¤W¥««á¦w¥þ©Ê¬ã¨s¤¤¡A»P±µ¨ü TNF ªýº¢¾¯ªvÀøªº±wªÌ¬Û¤ñ¡A±µ¨ü JAK §í»s¾¯ªvÀøªº±wªÌªº´c©Ê¸~½F¡]¤£¥]¬A«D¶Â¦â¯À½F¥Ö½§Àù [NMSC]¡^ªºµo¥Í²v§ó°ª¡C CIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C»P±µ¨ü TNF ªýº¢¾¯ªvÀøªº±wªÌ¬Û¤ñ¡A±µ¨ü JAK §í»s¾¯ªvÀøªº±wªÌªº²O¤Ú½Fµo¯f²v§ó°ª¡C»P±µ¨ü TNF ªýº¢¾¯ªvÀøªº§l·ÏªÌ¬Û¤ñ¡A±µ¨ü JAK §í»s¾¯ªvÀøªº·í«e©Î¹L¥h§l·ÏªÌªºªÍÀùµo¯f²v§ó°ª¡C¥Ø«e©Î¹L¥h§l·Ïªº±wªÌ±Á{ÃB¥~¼W¥[ªº·ÀI¡C
¦b¶}©l©ÎÄ~Äò¨Ï¥Î CIBINQO ªvÀø¤§«e¦Ò¼{ÓÅé±wªÌªº¯q³B©M·ÀI¡A¯S§O¬O¹ï©ó¤wª¾´c©Ê¸~½F¡]¦¨¥\ªvÀøªº NMSC °£¥~¡^ªº±wªÌ¡B¦bªvÀø®Éµo¥Í´c©Ê¸~½Fªº±wªÌ¥H¤Î·í«e©Î¹L¥hªº±wªÌ§l·ÏªÌ¡C
¥Dn¤ß¦åºÞ¤£¨}¨Æ¥ó
¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó¡C¦b 50 ·³¤Î¥H¤W¥B¦Ü¤Ö¦³¤@ӤߦåºÞ¦MÀI¦]¯À¥B¨Ï¥Î¥t¤@ºØ JAK §í»s¾¯ªvÀøªº RA ±wªÌ¤¤¡AÆ[¹î¨ì¸û°ªªº¥Dn¤£¨}¤ß¦åºÞ¨Æ¥ó (MACE)¡]©w¸q¬°¤ß¦åºÞ¦º¤`¡B¤ß¦Ù±ð¶ë©M¤¤·¡^µo¥Í²v»P TNF ªýº¢¾¯¡C CIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C¥Ø«e©Î¹L¥h§l·Ïªº±wªÌ±Á{ÃB¥~¼W¥[ªº·ÀI¡C¦b¸g¾ú¹L¤ß¦Ù±ð¶ë©Î¤¤·ªº±wªÌ¤¤²×¤î CIBINQO¡C
¦b¶}©l©ÎÄ~Äò¨Ï¥Î CIBINQO ªvÀø¤§«e¦Ò¼{ÓÅé±wªÌªº¯q³B©M·ÀI¡A¯S§O¬O¦b·í«e©Î¹L¥h§l·ÏªÌ©M¨ã¦³¨ä¥L¤ß¦åºÞ¦MÀI¦]¯Àªº±wªÌ¤¤¡CÀ³§iª¾±wªÌÄY«¤ß¦åºÞ¨Æ¥óªº¯gª¬¥H¤Îµo¥Í®ÉÀ³±Ä¨úªº±¹¬I¡C
¦å®ê§Î¦¨
¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F²`ÀR¯ß¦å®ê§Î¦¨ (DVT) ©MªÍ®ê¶ë (PE)¡C¦b±µ¨ü¥Î©óªvÀøª¢¯gªº JAK §í»s¾¯ªº±wªÌ¤¤³ø§i¤F¦å®ê§Î¦¨¡A¥]¬A PE¡BDVT ©M°Ê¯ß¦å®ê§Î¦¨¡C³\¦h³o¨Ç¤£¨}¤ÏÀ³¬OÄY«ªº¡A¦³¨Ç¾ÉP¦º¤`¡C»P TNF ªýº¢¾¯¬Û¤ñ¡A¦b 50 ·³¤Î¥H¤W¥B¦Ü¤Ö¦³¤@ӤߦåºÞ¦MÀI¦]¯À¥B¨Ï¥Î¥t¤@ºØ JAK §í»s¾¯ªvÀøªº RA ±wªÌ¤¤¡AÆ[¹î¨ì§ó°ªªºÁ`Åé¦å®ê§Î¦¨¡BDVT ©M PE µo¥Í²v¡CCIBINQO ¥¼³Q§åã¥Î©ó RA ±wªÌ¡C
¦b¦å®ê§Î¦¨·ÀI¥i¯à¼W¥[ªº±wªÌ¤¤ÁקK¨Ï¥Î CIBINQO¡C¦pªG¥X²{¦å®ê§Î¦¨¯gª¬¡A²×¤î CIBINQO ¨Ã¾A·íªvÀø±wªÌ¡C
¸T§Ò¯g
¦bªvÀøªº«e 3 Ó¤ë¡A°£§C¾¯¶qªü¥q¤ÇªL¡]¨C¤Ñ≤81 mg¡^¥~¡ACIBINQO ¸T¥Î©ó±µ¨ü§Ü¦å¤pªOªvÀøªº±wªÌ¡C
¹êÅç«Ç²§±`
¦å²G¾Ç²§±`¡GCIBINQO ªvÀø»P¦å¤pªO´î¤Ö¯g©M²O¤Ú²ÓM´î¤Ö¯gªºµo¥Í²v¼W¥[¦³Ãö¡C¦b CIBINQO ¶}©l¤§«e¡A°õ¦æ¥þ¦å²ÓMp¼Æ (CBC)¡C«Øij¦b¶}©l«á 4 ©P©M CIBINQO ¾¯¶q¼W¥[«á 4 ¶g¶i¦æ CBC µû¦ô¡C¬Y¨Ç¹êÅç«Ç²§±`»Ýn°±¤î CIBINQO ªvÀø¡C
¦å¯×¤É°ª¡G¦b±µ¨ü CIBINQO ªvÀøªº±wªÌ¤¤³ø§i¤F¦å¯×°Ñ¼Æªº¾¯¶q¨Ì¿à©Ê¼W¥[¡CCIBINQO ªvÀø¶}©l«á¬ù 4 ¶gÀ³µû¦ô¦å¯×°Ñ¼Æ¡A¦¹«áÀ³®Ú¾Ú°ª¯×¦å¯gÁ{§É«ü«n¹ï±wªÌ¶i¦æºÞ²z¡C³o¨Ç¯×½è°Ñ¼Æ¤É°ª¹ï¤ß¦åºÞµo¯f²v©M¦º¤`²vªº¼vÅT©|¥¼½T©w¡C
§K¬Ì±µºØ
¦b¶}©l CIBINQO ¤§«e¡A«ö·Ó·í«e§K¬Ì«ü«nªº«Øij§¹¦¨©Ò¦³¾A¦X¦~ÄÖªº¬Ì]±µºØ¡A¥]¬A¹w¨¾©Ê±aª¬¯p¯l¬Ì]±µºØ¡CÁקK¦b CIBINQO ªvÀø¤§«e¡B´Á¶¡©M¤§«á¥ß§Y±µºØ¬¡¬Ì]¡C
µÇ¥\¯à¤£¥þ
ÁקK¥Î©ó±w¦³ÄY«µÇ¥\¯à¤£¥þ©Î²×¥½´ÁµÇ¯fªº±wªÌ¡A¥]¬A±µ¨üµÇŦ´À¥NªvÀøªº±wªÌ¡C
¨x¥\¯à·l®`
ÁקK¦bÄY«¨x¥\¯à¤£¥þªº±wªÌ¤¤¨Ï¥Î¡C
¤£¨}¤ÏÀ³
±µ¨ü 100 mg ©M 200 mg ªº¨ü¸ÕªÌ³Ì±`¨£ªº¤£¨}¤ÏÀ³ (≥1%) ¥]¬A¡G»ó«|ª¢¡Bäú¤ß¡BÀYµh¡B³æ¯Â¯p¯l¡B¦å¦ÙÓþÁC»Ä¿E酶¤É°ª¡BÀY·w¡B§¿¸ô·P¬V¡B¯h³Ò¡BÚµ½H¡B¹Ã¦R¡B¤f«|µh¡B¬y·P¡B¸zGª¢¡C
±µ¨ü 100 mg ©Î 200 mg ªº¨ü¸ÕªÌ³Ì±`¨£ªº¤£¨}¤ÏÀ³ (≥1%) ÁÙ¥]¬A¡GÁw¯p¯f¡B°ª¦åÀ£¡B±µÄ²©Ê¥Öª¢¡B¤W¸¡µh¡B¸¡³¡¤£¾A¡B±aª¬¯p¯l©M¦å¤pªO´î¤Ö¯g¡C
Ãh¥¥´Á¶¡¨Ï¥Î
CIBINQO Á{§É¸ÕÅ礤³ø§iªº§³®Wªº²{¦³¼Æ¾Ú¤£¨¬¥H½T©w«¤j¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}¥ÀÅé©ÎL¨àµ²§½ªºÃĪ«¬ÛÃö·ÀI¡C©¾§i¦³¥Í´Þ¼ç¤Oªº¤k©Ê CIBINQO ¥i¯à·|·l®`¥Í¨|¯à¤O¡C
±N¦³¤@Ó§³®W¼ÉÅSµn°O³B¡AºÊ´úÃh¥¥´Á¶¡¼ÉÅS©ó CIBINQO ªº°ü¤kªº§³®Wµ²ªG¡C¹ªÀy±µÄ² CIBINQO ªº¥¥°ü©MÂåÀø«O°·´£¨ÑªÌP¹q1-877-311-3770¡C
÷¨Å´Á
«Øij¤k©Ê¦b¥Î CIBINQO ªvÀø´Á¶¡©M³Ì«á¤@¦¸µ¹ÃÄ«á¤@¤Ñ¤£n¶i¦æ¥À¨Å³Þ¾i¡C
¾AÀ³¯g
CIBINQO ¾A¥Î©óªvÀø±w¦³Ãøªv©Ê¡B¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢ªº¦¨¤H¡A¨ä¯e¯fµLªk³q¹L¨ä¥L¥þ¨©ÊÃĪ«²£«~¡]¥]¬A¥Íª«»s¾¯¡^±o¨ì¥R¤À±±¨î¡A©ÎªÌ¦b¤£«Øij¨Ï¥Î³o¨ÇÀøªk®É¡C
¨Ï¥Î¨î¡G¤£«Øij±N CIBINQO »P¨ä¥L JAK §í»s¾¯¡B¥Íª«§K¬Ì½Õ¸`¾¯©Î¨ä¥L§K¬Ì§í»s¾¯Áp¦X¨Ï¥Î¡C
Ãö©ó CIBINQO ® (abrocitinib)
CIBINQO ¬O¤@ºØ¿ï¾Ü©Ê§í¨î Janus ¿E酶 (JAK) 1 ªº¤fªA¤p¤À¤l¡C§í¨î JAK1 ³Q»{¬°¥i½Õ¸`°Ñ»P AD ¯f²z¥Í²z¾Çªº¦hºØ²ÓM¦]¤l¡A¥]¬A¥Õ²ÓM¤¶¯À IL-4¡BIL-13¡BIL-31¡BIL-22 ©M¯Ý¸¢°ò½è²O¤Ú²ÓM¥Í¦¨¯À (TSLP)¡C
°£¤F¦b¬ü°êÀò±oºÊºÞ§åã¥~¡ACIBINQO ÁÙ¦b¼Ú·ù¡B^°ê¡B¤é¥»¡BÁú°ê¡Bªü©Ô§BÁp¦X©ªø°ê¡B®¿«Â¡B¦B®q©M·s¥[©YÀò±o¤FÀç¾P³\¥i¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2022/1/5 ¤W¤È 06:05:58
²Ä 166 ½g¦^À³
|
LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022.
Tralokinumab is marketed outside of the U.S. under the tradename Adtralza® and is currently approved in the European Union, Great Britain, Canada and the United Arab Emirates.
BALLERUP, Denmark, December 28, 2021 ¡V LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids.1 Adbry is the first and only FDA approved biologic that specifically binds to and inhibits the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,2,3 ¡§Today¡¦s FDA approval of Adbry is a major milestone for LEO Pharma and for the millions of people living with moderate-to-severe atopic dermatitis who struggle to find a suitable treatment option for this chronic and debilitating disease,¡¨ said Anders Kronborg, Chief Financial Officer and Acting Chief Executive Officer of LEO Pharma A/S. ¡§As our first biologic in the U.S., Adbry signifies important progress in our mission of advancing the standard of care in medical dermatology.¡¨
The approval of Adbry is based on safety and efficacy results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase 3 trials, which included nearly 2,000 adult patients with moderate-to-severe atopic dermatitis.1 Safety data was evaluated from a pool of five randomized, double-blind, placebo-controlled trials, including ECZTRA 1, 2 and ECZTRA 3, a dose-finding trial, and a vaccine response trial.1
¡§Atopic dermatitis can be severe and unpredictable, which makes it not only challenging for patients to achieve long-term disease control, but also for clinicians to treat, since there are limited treatment options for this burdensome chronic skin disease,¡¨ said Jonathan Silverberg, MD, PhD, MPH, Associate Professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator. ¡§Adbry will be an important addition to our therapeutic armamentarium as a treatment designed to specifically target and neutralize the IL-13 cytokine, thereby, helping patients manage their atopic dermatitis¡¨
Adbry will be available in a 150 mg/mL prefilled syringe for subcutaneous injection with an initial dose of 600 mg followed by 300 mg every other week. Adbry can be used with or without TCS.1 A dosage of 300 mg every four weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment.1
To help eligible patients have access to Adbry, LEO Pharma will introduce the Adbry™ Advocate™ Program to support U.S. patients at diagnosis and through treatment with Adbry.
¡§For people living with atopic dermatitis, the experience goes beyond the skin, often impacting important psychosocial aspects of their life,¡¨ said Julie Block, President and CEO of the National Eczema Association. ¡§It¡¦s exciting to see a new, targeted therapeutic option for adult patients living with moderate-to-severe atopic dermatitis. Therapeutic advances like this provide much needed hope for those who may have spent years struggling to find a suitable therapy to alleviate the burden of this disease.¡¨
The FDA approval marks the fifth global regulatory approval for tralokinumab in 2021. Tralokinumab is marketed outside of the U.S. under the tradename Adtralza® and is currently approved in the European Union, Great Britain, Canada and the United Arab Emirates.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/11/14 ¤W¤È 10:19:30
²Ä 165 ½g¦^À³
|
.¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù:
(a)11/(b)50*(c)120*(d)2=52.8»õ¬ü¤¸(¨È·à¿W±o)
(a)Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/(b)2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*(c)2021¦~dupilumab 120»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *(d)2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2022¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù.
52.8»õ¬ü¤¸/70,000,000ªÑ(ADR ¥Ø«eªÑ¥»70,000,000ªÑ)=75 ¬ü¤¸/ªÑ---(2023¦~Q1«e³Q¨ÖÁÊ) -------------------------------------------------------------------------------- ¥¼¨Ó¦AÄw¸ê°µ¤T´Á, ¦ô (1)µo¦æ·sªÑ30,000,000ªÑ*6.4¬ü¤¸=1.92»õ¬ü¤¸ (2)«D¬ü°ÏAD±ÂÅv 1.98*120/50=4.75»õ¬ü¤¸(«eª÷+¨úµýùµ{ª÷)
52.8»õ¬ü¤¸/100,000,000ªÑ(ADR ¥¼¨ÓªÑ¥»(2023/Q2)100,000,000ªÑ)=52.8 ¬ü¤¸/ªÑ(2023¦~Q2«á³Q¨Ö)
------------------------------------------------------------------
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/11/13 ¤W¤È 10:51:32
²Ä 164 ½g¦^À³
|
1.ªvÀø¤¤-««×ADÀø®Ä¶È¬ùDUPILUMAB 75%, Lebrikizumab¦ô,°ª®p¦~¾P°â25»õ¬ü¤¸.
2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements \Almirall Agreement
·í®ÉAlmirall CEO ¦ô¼Ú¬w³Ì°ª¾P°â5»õ¬ü¤¸, (¦û¥þ²y¬ù20%)
5/20%=25»õ¬ü¤¸,---¦ôp¥þ²y¾P°â°ª峄.
2.ªvÀø¤¤-««×ADÀø®Ä¶È¬ùDUPILUMAB 50%, Adtralza (tralokinumab)¦ô,2027 ¦~¾P°â16»õ¬ü¤¸.
---------------------------------
remapconsulting.com/blockbuster-drugs-of-the-next-decade/
ªü¯S©Ô¤ã¡]¯S©Ô¬¥°ò§V°¨¥¬¡^ Adtralza ©ó 2021 ¦~ 6 ¤ëÀò±o EMA §åã¡A¥Î©óªvÀø¦¨¤H±wªÌ¤¤«×¦Ü««×¯S²§©Ê¥Öª¢¡A³o¨Ç±wªÌ¬O¥þ¨ªvÀøªºÔ¿ïªÌ¡C¥¿¦b¦V¬ü°ê¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^©M¥þ²y¨ä¥L½Ã¥Í·í§½´£¥æ§ó¦hºÊºÞÀÉ¡C¸ÓÃĪ«¤w¸g¶}µo¡A±N¥ÑLEO»sÃĤ½¥q¾P°â¡A³o¬O¥Ö½§¬ì»â°ì³Ì±j¤jªº°Ñ»PªÌ¤§¤@¡CAdtralzaªº§åã¬O°ò©óECZTRA 1¡A2©M3ÃöÁ䶥¬q3¸ÕÅ窺Àø®Ä©M¦w¥þµ²ªG¡A¨ä¤¤¥]¬A1¡A900¦h¦W¦¨¤H±wªÌ¤¤«×¦Ü««×¥Öª¢9¡C ¸ÓÃĪ«¦b16©PªºªvÀø¤¤ªí²{¥XÀu©ó¦w¼¢¾¯ªºÀu¶V©Ê¡A¦b¦hÓµ²ªG±¹¬I¤Ï¬M¯S²§©Ê¥Öª¢10ªº¸ñ¶H©MÄpª¬¡C¹wp¨ì2027¦~¡AAdtralzaªº¾P°âÃB±N¹F¨ì16»õ¬ü¤¸
7. Adtralza (tralokinumab) Adtralza was approved in June 2021 by the EMA for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. Additional regulatory filings are underway with the US FDA and other health authorities worldwide. The drug has been developed and will be marketed by LEO Pharma, one of the strongest players in the field of dermatology. Adtralza¡¦s approval was based on efficacy and safety results from the ECZTRA 1,2 and 3 pivotal Phase 3 trials, which included more than 1,900 adult patients with moderate-to-severe dermatitis9. The drug demonstrated superiority over placebo during 16 weeks of treatment across multiple outcome measures reflecting the signs and symptoms of atopic dermatitis10. Adtralza is projected to generate $1.6 billion in sales by 2027.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/11/4 ¤U¤È 09:12:54
²Ä 163 ½g¦^À³
|
ªø§ë«H¤ß¨Ó·½¤G¡GÀø®Ä¦³Àu©ódupilumab¤T´Á(¼Ð·Ç¤W¥«Àøªk)ªº谮¤O¡C/°Æ§@¥ÎµLdupilumabªº结½¤ª¢¡B¤@¤ë¤@°wªvÀøªk¡A±`温«O¦sÃĪ«¡C
¤@¡B¨Ì¾ÚDupilunab 3´Á°ò½uTRAC¤ÀªR vs ¡«á¥§¡EASI°´T ¾ãÅé¤T´ÁITT¤À§é ¡«á ¥§¡EASI°70%vsEASI34(¹ï·Ó组) EASI75 49%vs13% IGA0,1 37%vs9% ...¤¤断²v6.3%
1.°ò½uTRAC<1115 pg/ml¡AEASI=25.5,¦û1/3©Û¶Ò¤H¼Æ¡C
¡«á¥§¡EASI°´T78%
EASI25.5¤À¡Ñ78%=EASI20¤À¡K¡K¤w®ø°£Àã¯l¯gª¬ ³Ñ¤U¥§¡EASI5.5¤À¡K¡K´Ý¯d¤UÀã¯l¯gª¬.
³oÓ±Ú¸s¦³«Ü¤j¤ñ¨Ò¡«á¹FEASI75/IGA0,1
¦]¬°»´¯g¤¤Â_²v¦ô¯S§O§C,±µªñ0%¡C¹ï·Ó组¥§¡EASI°´T42% ¦ô EASI75 »·>55%(78%/70%¡Ñ49%) IGA0,1 »·>41%
2.°ò½uTRAC>1115(约6000)pg/ml,°ò½uEASI31/EASI41¡A¬ù2/3©Û©Û¶Ò¤H¼Æ¡C
¡«á ¥§¡EASI°´T66% ¦ôEASI75 »·<46%(66%/70%¡Ñ49%) ¦ôIGA0,1 »·<35%(66%/70%¡Ñ37%)
¥»组¤¤断²v¦ô6.3%/67%=9.4% ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
¤G¡BASLAN004-RITT¤ÀªR ¡K¡Kç°£x¤¤¤ß9(6+3)¤H«D¶Ç²ÎAD ¹êÅç组¤¤断²v3/16=19%(Áô§t13%«D¶Ç²ÎAD) °ò½uTRAC=4600pg/ml °ò½uEASI30.5 ¡«á ¥§¡EASI°´T EASI75 69%(11/16) vs15%(2/13)(¹ï·Ó组) IGA0,1 44%(7/16) vs15%
¤T¡BÀø®ÄPK
Dupilumab TRAC>1115(=6000)组 vs ASLAN004 TRAc>1115(=4600)pg/ml
¡«á(½Õ¾ã¹ï·Ó组Àø®Ä)
¥§¡EASI°´T Dupilumab vd ASLAN004 EASI75 33%(46%-13%) vs 54%(69%-15%) IGA0¡A1 25%(35%-10%) vs 29%(44%-15%)
¥H¤WDupilumab©ÒÁôÂä@©w¤ñ²vªº«D¶Ç统AD¡C ASLAN004 9-16¶g¤´·|¤j´T©Ô°ªIGA0,1 10%-12%ªºÀø®Ä¡C ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/11/4 ¤W¤È 07:03:57²Ä 4854 ½g¦^À³
ªø§ë«H¤ßªº³Ì«n¨Ó·½:MOA
¤w³QÅçÃÒ¹LªºII«¬ª¢¯g¾÷Âà¡A ·ÓµÛdupilumabÁ{§É³]p°µ¡C ¦Ü¤ÖÀø®Ä¬Û·í¡C
¥Ñ©ódupilumab¤T´ÁÁ{§É¥Dn¡«áÀø®Ä®Ä«ü¼ÐEASI75,IGA0,1©M¹ï·Ó组¤ñȹF3-4¿¡C ASLAN004,¥¼¨Ó100%¥i¨ú±o©Mdupilumab¤@¼Ëªº©Ò¦³¾AÀ³¯gªºÃĵý¡C
¥Ø«e10¦~¤º°£ASLAN004¥~¡AµL¨ä¥L¼Ä¤â¥i¤j´T§ð¦û¨ä¥«³õ¡C
Dupilumab ªº¥é¥ÍÃĦô11-12¦~«á¤~·|¦b³°Äò¬ü¤W¥«¡A ³Ì§Öªº¥i¯à¬OCNTB,CBP201,¤G´ÁADÁ{§É¤§µ²ªG§Ö¤½§G¤F¡A¤µ¦~¥|¤ë¤w¦¬®×287¤H§¹¦¨¡C
³ÌªñªÑ»ù¤j¶^30%¥H¤W¡C
Àø®Ä©M°Æ§@¥ÎÀ³©MDupilumab ¬Ûªñ¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K M0A«D±`¡B«D±`«n¡I
¤@¡B§ùÁת¢¡K¡KDupilumab ¤¤¤å¥é³æ¡C
§@¥Î¾÷Âà(M0A)
Dupilumab ¬O¤@ºØ IgG4 ¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤Wªº IL-4R£\ ¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T ®§¶Ç»¼¡C
Dupilumab ¥iÂǥѻP²Ä I Ãþ¨üÅéµ²¦X¦Ó§í¨î IL-4 °T®§¶Ç»¼¡A¥H¤ÎÂǥѻP²Ä II Ãþ¨ü Åéµ²¦X¦Ó¦P®É§í¨î IL-4 ¤Î IL-13 ¤§°T®§¶Ç»¼¡C
Dupilumab ªýÂ_¤¶¥Õ¯À-4 £\ ¨üÅé(IL-4R£\)¥i§í¨î IL-4 ¤Î IL-13 ²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥] ¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥Õ E (IgE)¡C
¤G¡BASLAN004 §@¥Î¾÷Âà(M0A)
ASLAN004 ¬O¤@ºØ IgG4 ¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-13 (IL-13)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤Wªº IL-13R£\1 ¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T ®§¶Ç»¼¡C ÂǥѻP²Ä II Ãþ结Åéµ²¦X¦Ó¦P®É§í¨î IL-4 ¤Î IL-13 ¤§°T®§¶Ç»¼¡C ASLAN004 ªýÂ_¤¶¥Õ¯À-13R£\1¨üÅé(IL-13R£\1)¥i§í¨î IL-4 ¤Î IL-13 ²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥] ¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥Õ E (IgE)¡C
¤T¡B¥H¤WDupilumab ¤ÎASLAN004 ,§í¨îÂI¤£¦P¡A¦ý¦³¦@¦P®ÄªG: Dupilumab ªýÂ_¤¶¥Õ¯À-4R£\¨üÅé(IL-4R£\) ¡A
ASLAN004 ªýÂ_¤¶¥Õ¯À-13R£\1¨üÅé(IL-13R£\1) ¡A
¦@¦P§í¨î®ÄªG:
¥i§í¨îIL-4 ¤Î IL-13 ²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥] ¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥Õ E (IgE)¡C
¥|¡BDupilumab ¥i»PIÃþ结Åé结¦X¡A¥i¯à²£¥Í结½¤ª¢°Æ§@¥Î¤§ì¦]¡C
¦ýASLAN004¨S»PIÃþ结Åé结¦X¡C
¤¡B 1.ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action <¥H¤W¥]§t¤¶²ÐYASLAN004±µ¦XIL-13R£\1«á¦P结¦XR-4R£\®ÄªG> |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/11/2 ¤W¤È 11:20:42
²Ä 162 ½g¦^À³
|
ibmi.taiwan-healthcare.org/zh/news_detail.php?REFDOCTYPID=0o4dd9ctwhtyumw0&REFDOCID=0qzjyul88xy298vv
2021/09/17 ¤¤¤å³ø¾É
abrocitinib monotherapy in the Janus kinase 1 (JAK1) atopic dermatitis
©M¨ä¥L¤fªAJAK1§í¨î¾¯¤@¼Ë, ¥¼¨Ó½÷·çªºªü¥¬Ã¹´À¥§/abrocitinib¤W¥«, FDA¥i¯à·|µo¥X¥ÎÃÄ(¶Â®Ø)ĵ§i:¤ßŦ¯e¯f¡BÀù¯g
Evaluate ¦ô2026¦~¾P 10»õ¬ü¤¸,¥u¦³½÷·ç¦Û¦ôªº1/3. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/30 ¤W¤È 07:38:55
²Ä 161 ½g¦^À³
|
KHK4083 15.2»õ¬ü¤¸vs Lebrikiumab 20»õ¬ü¤¸ ¥þ²y±ÂÅvª÷»ùÈ
A/B=15.2»õ¬ü¤¸/20»õ¬ü¤¸¡C =76%
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¤@¡B¤é¥»ÄQÅï±ÂÅv¦w¶iKHK4083 ¤é¥»ÄQÅ綠¥q2021/06±ÂÅvKHK4083 给¦w¶i¡A°£¤é¥»¥~¥þ²y¾P°âÅv¡C¤T´Á¦¨¥»¦ô4»õ¬ü¤¸¡A¦U¥b¡A
±ÂÅv¦X约=4»õ¬ü¤¸«eª÷+2»õ¬ü¤¸¤T´Á¦¨¥»+8.5»õ¬ü¤¸ùµ{ª÷+¾P°â¤À¼í
14.5»õ¬ü¤¸±ÂÅvª÷/«D¤é¥»95%=15.2»õ¬ü¤¸¡K¡K¾ãÅéKHK4083»ùÈ¡K¡KA
¤G¡B®Ú¾ÚLebrikiumab³Q±ÂÅvAlmirall ¦X约 ¡K¡KCEO«ÅºÙ欧¬w区AD³Ì°ª¥i¾P5»õ¬ü¤¸¡C ¡K¡K«eª÷+¶}µoùµ{ª÷1.98»õ¬ü¤¸+12.5»õ¬ü¤¸¡A³Ì°ª¾P°âùµ{ª÷(30»õ¬ü¤¸³Ì°ª¾P°â) +¾P°â¤À¼í10%-20%
±ÂÅvª÷1.98+2.1(5/30*12.5¡K¡K5»õ¬ü¤¸销°â°ò¦)¡A约4»õ¬ü¤¸¡C
4»õ¬ü¤¸/20%(欧¬w区)=20»õ¬ü¤¸¡K¡K¾ãÅéLebrikiumab±ÂÅvª÷AD»ùÈ¡K¡KB
Lebrikizumab ¼Ú¬w°Ï±ÂÅv¦X¬ù(2019/02) www.sec.gov/edgar/search/?r=el#/q=Dermira
ùµ{ª÷(1)3000+(1.1)5000+(2)3000+(3)4000+(4)4500=19,500(¸U¬ü¤¸) +(5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A ¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î
¾P°â¤À¼í(6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¥[¨ì§C¤G¤Q¦ì数¡C
®ÚÕu该协议¡AAlmirall将对Dermira©Óü®¥H¤U¥I´Úúå务¡C
(1)3,000ÉE¬ü¤¸ªº´Á权费¡A¦b¥Í®Ä¤é´Á¦Z¼w¦Ì©Ô¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(1.1)¦pªGAlmirall¦b¦¬¨ì数Õu¥]©M开发计¦E¦Zªº45¤Ñ内¦æ¨Ï¨ä选择权¥H获±o许¥i证¡A则应¤ä¥I5,000ÉE¬ü¤¸ªº选择权¦æ¨Ï费¡A该费¥Î应¦bDermira¦b选择权¦æ¨Ï¦Z¥æ¥I该ª÷额ªº发²¼¦Z¤Q¡]10¡^个¤u§@¤é内¤ä¥I¡C
(2)¼w¦Ì©ÔûD动¬Y¨Ç3´Á临§É¬ã¨s¡]¨C项§¡为 3´Á试验¡^¡A¥i额¥~获±o3000ÉE¬ü¤¸¡A¨C项试验¦b达¨ì该¨½µ{¸O¦Z¤G¤Q¤¡]25¡^¤Ñ内¤ä¥I¡C
(3)Almirall实现¬Y¨Ç监ºÞ¨½µ{¸O¦Z¡A¥i额¥~获±o4,000ÉE¬ü¤¸¡A¨C笔´Ú项§¡应¦b实现该¨½µ{¸O¦Z¼w¦Ì©Ô¥æ¥I发²¼¦Z¤G¤Q¤(25)¤Ñ内¤ä¥I¡C
(4)¦b欧·ùº¦¸°Ó业¤Æ销°âlebrikizumab¦Z¡A获±o4500ÉE¬ü¤¸ªº¦¬¤J¡C
(5)®ÚÕulebrikizumab¦b欧¬wªº¦~净销°â额达¨ì8600ÉE¬ü¤¸¦Ü30亿¬ü¤¸ªº¬Y¨Ç门槛¡A¤ä¥I³Ì¦h12.5亿¬ü¤¸ªº´Ú项¡A¨C笔ýͦbªº¨½µ{¸O¦¡¥I´Ú约¥eÓì¥Î净销°â额门槛ªº7%¦Ü15%¡F¥H¤Î
(6)°ò¤_欧¬wlebrikizumab¦~净销°â额¬Û应S围ªº层级¦Ê¤À¤ñS围ªº¯S许权¨Ï¥Î费¤ä¥I¡A¨ä¤¤²Ä¤@¦~净销°â额层级ªº¦Ê¤À¤ñ从§C两¦ì数开©l¡A³Ì°ª净销°â额层级ªº¦Ê¤À¤ñ¼W¦Ü20% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/28 ¤U¤È 10:51:49
²Ä 160 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT03703102
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
www.prnewswire.com/news-releases/amgen-and-kyowa-kirin-present-positive-late-breaking-data-from-phase-2-study-of-amg-451khk4083-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-at-eadv-congress-301391185.html
Amgen ©M Kyowa Kirin ¦b EADV ¤j·|¤W¤¶²Ð¤F¦b¦¨¤H±wªÌ¤¤«×¦Ü««×¯S²§©Ê¥Öª¢ªº AMG 451/KHK4083 ²Ä 2 ¶¥¬q¬ã¨sªº¶§©Ê±ß´Á¼Æ¾Ú ¸Ó¬ã¨s¹F¨ì¤F¨ä¥Dn¥Ø¼Ð¡A¦b16©P»P¦w¼¢¾¯¬Û¤ñ¡A±qÀã¯l°Ïªº°ò½u©MÄY«©Ê«ü¼Æ±o¤À¤WÃÒ©ú¦b²Îp¤W¦³§ó¤jªº§ïµ½
±µ¨üAMG 451/KHK4083ªº±wªÌ¦b²Îp¾Ç¤W¹ï¦w¼¢¾¯ªº»²§UÀø®Ä²×ÂI¦³¸û¤j§ïµ½
AMG 451/KHK4083 ¦b16©P«áªºÀø®Ä¤]³vº¥´£°ª
¦w®Ú¼Ð»x¡C¡]°OªÌºÖ¦«/¦w®Ú¡^¡]°OªÌ ºÖ¦«/¡^ ·s»D´£¨ÑªÌ
¦w®Ú ¤Q¤ë 02¡A 2021¡A 06¡G00 ET
¤À¨É¥»¤å ¤d¾ó¾ð¡A¥[§QºÖ¥§¨È¦{¡CªF¨Ê¡A2021¦~10¤ë2¤é /PRNewswire/ -- Amgen¡]¯Ç´µ¹F§J¡GAMGN¡^©MKyowa Kirin¦³¤½¥q¡]TSE¡G4151¡^¤µ¤Ñ«Å§G¡AAMG 451/KHK4083²Ä¤G¶¥¬q¬ã¨sªº¶§©Ê¼Æ¾Ú¦b¼Ú¬w¥Ö½§¯f¾Ç©M¬ü®e¾Ç¾Ç·|30¤é¤½§GthµêÀÀ°ê·|¦b2021¦~10¤ë2¤é¡CAMG 451/KHK4083 ¬O¤@ºØ¼ç¦bªº¤@¬y§ÜOX40¥þ¤H³æ§J¶©§ÜÅé¡A¥Î©óªvÀø¤¤«×¦Ü««×¯S²§©Ê¥Öª¢¡C
¨ÊµØ°òªL¼Ð»x¡]´¶·ç´µºÖ¦«/¦w®Ú¡^ ¨ÊµØ°òªL¼Ð»x¡]´¶·ç´µºÖ¦«/¦w®Ú¡^ ²Ä¤G¶¥¬q¡A¦h¤¤¤ß¡AÀH¾÷¡AÂùª¼¡A¦w¼¢¾¯¹ï·Ó¸ÕÅç½Õ¬d¤FAMG 451/KHK4083ªºÀø®Ä©M¦w¥þ©Ê¡A¦b¦¨¤H»P¤¤«×¦Ü««×¯S²§©Ê¥Öª¢½Ö¨S¦³¥R¤À±±¨î»P§½³¡¥N²z¡C¸Ó¬ã¨s¹F¨ì¤F¥Dn¥Ø¼Ð¡AÅã¥Ü»P¦w¼¢¾¯¡]¨C¨â©P600²@§J¡]Q2W¡^=-57.4%¬Û¤ñ¡A©Ò¦³¥|ºØ¥Ö¤U¾¯¶qªºAMG 451/KHK4083¦b16©P¤º±qÀã¯l°Ï°ò½u©MÄY«©Ê«ü¼Æ¡]EASI¡^±o¤Àªº²Îp¾Ç¤W¦³¸û¤j§ïµ½; 600 ²@§J Q4W = -49.7%; 300 ²@§J Q2W = -61.1%; 150 ²@§J Q4W = -48.3% »P¦w¼¢¾¯ = -15%;P<0.001¡^¡C
±µ¨üAMG 451/KHK4083ªº©Ò¦³ªvÀø²Õ»P²Ä16©P¦w¼¢¾¯¬Û¤ñ¡A¦bÃöÁä¤G¯Å²×ÂI´¶¹M¨ú±o¤F§ïµ½¡A ¨Ò¦p¡A¦bEASI¤À¼Æ ¡]EASI-75¡^ ªº°ò½u¤W¦Ü¤Ö´î¤Ö 75%¡A½Õ¬dû¥þ²yµû¦ô ¡]IGA¡^ ±o¤À¬° 0¡]²M´·¡^©Î 1¡]´X¥G²M´·¡^¡A°ò½u¡]IGA 0/1¡^¦Ü¤Ö´î¤Ö 2 ¤À¡A±q´¶¾|¨½¹Ï´µ¼Æ¦ìµû¤Àªí ¡]NRS¡^ ¤À¼Æªº°ò½u¦Ü¤Ö°§C 4 ¤À¡]PNRS-4¡^¡C©Ò¦³AMG 451/KHK4083¾¯¶qªºÀø®Ä±¹¬I¦b16©P«áÄ~Äò§ïµ½¡C
³Ì±`³ø§iªº¤£¨}¨Æ¥óµo¥Í¦b¦Ü¤Ö5%ªº±wªÌ¬O¤õ¼ö¡A»ó«|ª¢¡A¯S²§©Ê¥Öª¢´c¤Æ©M´H·N¡C¤õ¼ö©M´H¬yªº±j«×¬°»´«×¦Ü¤¤«×¡A¥¼¾ÉPªvÀø¤¤Â_¡C
²Ä¤G¶¥¬qªºµ²ªG¬J¿n·¥¤S¥O¤H¿³¾Ä¡C»P¦w¼¢¾¯¬Û¤ñ¡A©Ò¦³4¾¯²Õ³£Åã¥Ü¥X§ïµ½¡A¨Ã¬ð¥X¤FOX40¹ï§Ü説©ú±wªÌªº¼ç¤O¡A³o¶µ¬ã¨sªºº®u¬ã¨sû¡B¥Ö½§¯f¾Ç¨t¥D¥ô¡B¦è©`¤s¥ì§¢Âå¾Ç°|¥Ö½§¯f¾Ç©M§K¬Ì¾Ç±Ð±Â¡BÀã¯l¨ô¶V¤¤¤ß¥D¥ô¦ãº¿¡P¥j¯S°Ò-¨È´µ°ò³Õ¤h»¡¡A ¦è©`¤sª¢¯g©Ê¥Ö½§¯f¹êÅç«Ç§Ú§Æ±æ¥¼¨ÓªºÁ{§Éµo®i¼Æ¾Ú±N¶i¤@¨BÄÄ©úAMG 451/KHK4083¦bªvÀø¤¤«×¦Ü««×¯S²§©Ê¥Öª¢¤è±ªº«n©Ê©M¼ç¤O¡C
Kyowa Kirin °õ¦æ©x¡B°ÆÁ`µô¡B¬ãµo³¡ªùt³d¤HYoshifumi Torii³Õ¤h»¡¡G§ÚÌ«D±`°ª¿³¦a¦b²Ä¤G¶¥¬qªº¬ã¨s¤¤´£¨Ñ¼Æ¾Ú¡Aµû¦ô AMG 451/KHK4083 ¦b EADV ¤j·|¤WºC©Ê¡B´_µo©Ê¡B¤¤«×¦Ü««×¯S²§©Ê¥Öª¢ªºÀø®Ä©M¦w¥þ©Ê¡Cµ²ªGÅã¥Ü¡A§í¨î©M§R°£OX40ªí¹F²ÓM¥i¯à¬°ªvÀø¤¤«×¦Ü««×¯S²§©Ê¥Öª¢´£¨Ñ¤@ºØ«nªº·s¤èªk¡A¨Ã¦³¥i¯à説©ú±wªÌºû«ù¤ÏÀ³¡C
¦w®Ú¬ãµo°õ¦æ°ÆÁ`µô¤j½Ã¡P¸Ì´µ¡]David M. Reese¡^»¡¡G¯S²§©Ê¥Öª¢¨C¦~¼vÅTªñ3000¸U¤H¡A¤wª¾¹ï±wªÌªº¥Í¬¡¦³µÛ·¥¨ät±ªº¼vÅT¡C³o¨Ç¼Æ¾Ú¦³¤O¦aÃÒ©úÁAAMG 451/KHK4083¹ï±wªÌªº¼ç¤O¡A§ÚÌ´Á«ÝµÛ¦b²Ä¤T¶¥¬qÁ{§É¸ÕÅ礤¶i¤@¨B¬ã¨s³oºØªvÀø¡A§Ú̹wp¸ÓÁ{§É¸ÕÅç±N©ó2022¦~¤W¥b¦~¶}©l¡C
Ãö©óAMG 451/KHK4083 ²Ä ¤G¶¥¬q ¬ã¨s²Ä¤G¶¥¬q¡A¦h¤¤¤ß¡AÀH¾÷¡AÂùª¼¡A¦w¼¢¾¯¹ï·Ó¸ÕÅç¡]NCT03703102¡^½Õ¬d¤FAMG 451/KHK4083¦b¤¤«×¦Ü««×¯S²§©Ê¥Öª¢ªº¦¨¤Hªº¥\®Ä©M¦w¥þ©Ê¡A³o¨Ç¦¨¤H¨S¦³¥R¤À±±¨î§½³¡ÃĪ«¡C³o¶µ¬ã¨sÀH¾÷½Õ¬d¤F¬ü°ê¡B¤é¥»¡B¥[®³¤j©M¼w°êªº274¦W±wªÌ¡A¥Ḻµ¨ü¤F¥Ö¤UAMG 451/KHK4083¡]600mg Q2W¡B600mg Q4W¡B300mg Q2W¡B150mg Q4W¡^©M¤ñ¸û¦w¼¢¾¯¤âÁu¡C
¥Dn²×ÂI¬O²Ä 16 ©P EASI ¤À¼Æ¤¤ªº°ò½u¦Ê¤À¤ñÅܤơC¨ä¥L²×ÂI¥]¬A¡G±q EASI ¤À¼Æªº°ò½u¤¤¹ê²{ ≥75% ªº´î¤Ö¡]§ï¶i¡^¡AIGA ¤À¼Æ¬° 0¡]²M´·¡^©Î 1¡]´X¥G²M´·¡^¡A°ò½uªº¤À¼Æ´î¤Ö≥ 2 ¤À¡A±q´¶¾|¨½¹Ï´µ¼Æ¦ìµû¤Àªí ¡]NRS¡^ ¤À¼Æªº°ò½u°§C ≥ 4 ¤À¡C¬ã¨s¤¤ªº±wªÌ³Q¸òÂܨì²Ä56©P¡C
®i¥Ü§ë¼v¤ù¥i¦b EADV ºô¯¸¤W§ä¨ì¡Gwww.eadvcongress2021.org/¡C
¦ãº¿¡P¥j¯S°Ò-¨È´µ°ò³Õ¤h¬O³o¶µ¬ã¨sªºº®u¬ã¨sû¡A¤]¬OKyowa Kirin¶}µoAMG 451/KHK4083ªº¥I¶OÅU°Ý¡C
Ãö©ó¯S²§©Ê¥Öª¢ ¯S²§©Ê¥Öª¢¬O¤@ºØºC©Êª¢¯g©Ê¯e¯f¡A·|¾ÉP¥Ö½§¹L«×°®Àê¡Bæ±Äo¡A¥i¯à«ÜµhW¡C¤ÏÂЧì¶Ë·|¾ÉP¥Ö½§ÅÜ«p¡BÅܵw©Î©ö¨ü·P¬V¡C¯S²§©Ê¥Öª¢¬OÀã¯l³Ì±`¨£ªº§Î¦¡ - ¼vÅT¥þ²y 1-3% ªº¦¨¦~¤H¡A±w¯f²v¥¿¦b¤W¤É¡C³oºØ¯e¯f³q±`ªí²{¦b¨àµ£®É´Á¡AµM«á¬O¨ä¥L¹L±ÓÄpª¬¡C
Ãö©óAMG 451/KHK4083 AMG 451/KHK4083 ¬O¤@ºØ§ÜOX40¥þ¤H³æ§J¶©§ÜÅé¡A±Ä¥Î¨ÊµØ Kirin ªº±M§Q POTELLIGENT ²æ²¸§Þ³N³]p¡A¥H¼W±j¨ä§ÜÅé¨Ì¿à©Ê²ÓM¬r©Ê ¡]ADCC¡^ ¬¡©Ê¡C³ÌªìªºAMG 451/KHK4083§ÜÅé¬O¦b¬ü°ê¨ÊµØ°òªL¬ã¨s©Ò©M©ÔÀN¨È§K¬Ì¾Ç¬ã¨s©Ò¦X§@¤Uµo²{ªº¡C®
AMG 451/KHK4083 ¹vÂI¨Ã§í¨î¿E¬¡®ÄÀ³¾¹ T ²ÓMªí±ªí¹Fªº OX40 ¨üÅ骺¬¡°Ê¡A¨Ã¤w³Q ADCC ÃÒ©ú¥i¼W±j±Ò°Ê OX40+ T ²ÓMªº¯ÓºÜ¡C¾Ú³ø¾É¡Aªí¹FOX40ªº®ÄÀ³T²ÓM¦s¦b©ó¯S²§©Ê¥Öª¢±wªÌªº¯fÅܤ¤¡A¦b¯e¯f¯f²z¥Í²z¾Ç¤¤¦ÜÃö«n¡C
¦w®Ú©M¨ÊµØ°òªL¦X§@ 2021¦~6¤ë1¤é¡A¦w®Ú»P¨ÊµØ°òªL¹F¦¨¨ó©w¡A¦@¦P¶}µoAMG 451/KHK4083¨Ã¹ê²{°Ó·~¤Æ¡C®Ú¾Ú¨óij±ø´Ú¡AAmgen ±N»â¾ÉAMG 451/KHK4083¦b¥þ²y©Ò¦³¥«³õªº¶}µo¡B»s³y©M°Ó·~¤Æ¡A¦ý¤é¥»°£¥~¡A¤é¥»±N«O¯d©Ò¦³Åv§Q¡C¦pªGÀò±o§åã¡A¨â®a¤½¥q±N¦b¬ü°ê¦@¦P±À¼s¸Ó¸ê²£¡A¦ÓKyowa Kirin¾Ö¦³¦b¥]¬A¼Ú¬w©M¨È¬w¦b¤ºªº¬Y¨Ç¨ä¥L¥«³õ¦@¦P±À¼s¸Ó¸ê²£ªºÅv§Q¡C
Ãö©ó¦w®Ú Amgen P¤O©ó³q¹Lµo²{¡B¶}µo¡B»s³y©M´£¨Ñ³Ð·sªº¤HÃþªvÀø¤èªk¡A¬°±w¦³ÄY«¯e¯fªº±wªÌÄÀ©ñ¥Íª«¾Çªº¼ç¤O¡C³oºØ¤èªkº¥ý¨Ï¥Î¥ý¶iªº¤HÃþ¿ò¶Ç¾Çµ¥¤u¨ã¨Ó¸Ñ¶}¯e¯fªº½ÆÂø©Ê¡A¨ÃÁA¸Ñ¤HÃþ¥Íª«¾Çªº°ò¥»ì²z¡C
Amgen ±Mª`©óÂåÀø»Ý¨D¥¼±o¨ìº¡¨¬ªº°ª»â°ì¡A¨Ã§Q¥Î¨ä±M·~ª¾ÃѧV¤O´M¨D§ïµ½°·±dµ²ªG©MÅãµÛ§ïµ½¤H̥ͬ¡ªº¸Ñ¨M¤è®×¡CAmgen ¦Û 1980 ¦~¥H¨Ó¤@ª½¬O¥Íª«§Þ³Nªº¥ýÅX¡A²{¤w¦¨ªø¬°¥@¬É»â¥ýªº¿W¥ß¥Íª«§Þ³N¤½¥q¤§¤@¡A¤w´f¤Î¥þ²y¼Æ¦Ê¸U±wªÌ¡A¨Ã¥¿¦b¶}µo¨ã¦³¤ÀÂ÷¼ç¤OªºÃĪ«ºÞ¹D¡C
±ýÁA¸Ñ§ó¦h¸ê°T¡A½Ð¦s¨ú www.amgen.com¡A¨ÃÃöª`§ÚÌwww.twitter.com/amgen¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/28 ¤U¤È 10:40:45
²Ä 159 ½g¦^À³
|
www.pharmaceutical-technology.com/news/amgen-deal-kyowa-kirin/
Amgen enters up to $1.2bn atopic dermatitis drug deal with Kyowa Kirin 02 Jun 2021 (Last Updated October 27th, 2021 11:40) Amgen will make an upfront payment of $400m to Kyowa Kirin and milestone payments worth up to nearly $850m.
Share Article Amgen enters up to $1.2bn atopic dermatitis drug deal with Kyowa Kirin Amgen headquarters in Thousand Oaks, California, US. Credit: Coolcaesar / Wikipedia. Amgen and Kyowa Kirin have entered an agreement to co-develop and co-commercialise the latter¡¦s anti-OX40 fully human monoclonal antibody, KHK4083 to treat atopic dermatitis and potentially other autoimmune diseases.
Discovered by Kyowa Kirin, KHK4083 demonstrated the ability to specifically reduce activated T cells that are vital in atopic dermatitis development.
According to the deal, Amgen will handle the development, production and marketing of KHK4083 for all worldwide markets, excluding Japan. Kyowa Kirin will retain all rights in Japan.
The partners will co-promote KHK4083 and Kyowa Kirin holds opt-in rights to co-promote the therapeutic in some other markets outside the US, including Europe and Asia.
As part of this transaction, Kyowa Kirin will receive an upfront payment of $400m from Amgen and prospective contingent milestone payments up to worth $850m.
Kyowa Kirin is also eligible to receive royalty payments emerging from worldwide sales.
The global development costs, except in Japan, as well as US marketing costs, will be shared by the companies.
Furthermore, Amgen plans to utilise data from the company¡¦s deCODE Genetics subsidiary to analyse the possible use of KHK4083 in therapy areas other than atopic dermatitis.
KHK4083 is set for Phase III trials after Kyowa Kirin reported in February that the antibody met the primary goal in a Phase II trial in moderate-to-severe atopic dermatitis subjects.
Kyowa Kirin president and CEO Masashi Miyamoto said: ¡§KHK4083 is an important asset in our global pipeline.
¡§We know Amgen well and this alliance will build on the past success and trust we have, bringing additional resources and therapeutic expertise to KHK4083¡¦s development and commercialisation, to meet the needs of patients living with atopic dermatitis who seek alternative treatment options.¡¨ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/28 ¤W¤È 05:33:17
²Ä 158 ½g¦^À³
|
Dupilumab 2Ó¤T´Á *16¶g*300mg,¹êÅç²Õ N=900¤H
¤@.¤À²Õ&ITT¤ÀªR
1.¤¤Â_ ,¹êÅç²Õ 6.3%
EASI 50 , 0% EASI 75 , 0% EASI 90 , 0% IGA 0,1 , 0%
2.¦©°£ ¤¤Â_6.3%¤H¼Æ«á ¹êÅç²Õ 93.7%¤H¼Æ
EASI 50 , 68% EASI 75 , 52% EASI 90 , 35% IGA 0,1 , 39%
3.ITT ,100%¤H¼Æ(¬ù900¤H)
EASI 50 , 64% EASI 75 , 49% EASI 90 , 33% IGA 0,1 , 37%
Dupilumab ITT¤ÀªR¡A¥]§t¦h¤Ö¤ñ²vªº«D¶Ç²ÎAD(«DIL4/IL3ªºP¯f¤Hû¡A¤£ª¾¹D¡C
REGN ¤½¥q¤@ª½¦b§ä¥Íª««ü¼Ð¨Ó©w¸q·sAD¾÷Âà¡A¦]¬°ÁÙ¦³¨Ï¥Îdupilumab ªÌ¡A¤´¦³60%¥H¤W¥¼Àò³Ì¨ÎªvÀø¡A¡«á¹FIGA0,1 IL32¤w©ñ±ó(¤GÓ¤G´ÁÁ{§É§¹¦¨«á¡A¤¤¤î¬ã¨s)¡C¡A¥Ø«e¦b±´¯ÁIL31¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/27 ¤U¤È 08:23:51²Ä 4827 ½g¦^À³ ASLAN004 1b *8¶g*600mg
¤@.¤À²Õ&ITT¤ÀªR 1.3/1«e 600mg ¹êÅç²Õ 3¤H
EASI 50 , 100%(3/3) EASI 75 , 67%(2/3) EASI 90 , 33%(1/3) IGA 0,1 , 33% (1/3)
2.3/1«á 600mg ¹êÅç²Õ 10¤H
EASI 50 , 100%(10/10) EASI 75 , 90%(9/10) EASI 90 , 50%(5/10) IGA 0,1 , 60%(6/10)
3.¥H¤W¦b¤ÀªRASLAN004¯u¥¿¯à¤O.(¤w¦©°£«D¶Ç²ÎAD 6¤H¡B¤¤Â_3¤H ¼vÅT)
4.«D¶Ç²ÎAD 6¤H EASI 50 , 66%(4/6) EASI 75 , 0%(0/6) EASI 90 , 0%(0/6) IGA 0,1 , 0%(0/6)
5.¤¤Â_3¤H EASI 50 , 0%(0/3) EASI 75 , 0%(0/3) EASI 90 , 0%(0/3) IGA 0,1 , 0%(0/3)
6.¥»¦¸ITT¤ÀªR ,¨ü«D¶Ç²ÎAD6¤H¡B¤¤Â_3¤H ,9(3+6)/22=41%¼vÅT.
EASI 50 , 77%(17/22) EASI 75 , 50%(11/22) EASI 90 , 27%(6/22) IGA 0,1 , 32%(7/22)
----------------------------------------------------- ------------ ¤G.2b ±N±´¯ÁIL22
.ASLAN004 ,2b ,300¤H,±N±´¯ÁIL22 ¬O§_·|¼vÅTÀø®Ä. ¬O§_¬°«D¶Ç²ÎADªº¥Dn¼vÅT¦]¯À.
¦p¶Ý»Ä©Ê²ÓM<150/ml,¥Îdupilumab ªvý³ÝµL®Ä,
«D¶Ç²ÎAD,¥Ø«eDupilumab/Lebrikiumab/Traloikumab ¥ç©M¹ï·Ó²ÕµL®t²§.¦]¬°¤£¬OIL4/IL13©Ò¤Þ°_¤§¾÷¨î.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/24 ¤U¤È 05:43:05
²Ä 157 ½g¦^À³
|
ASLAN004 VS DUPILUMAB
¤@.ASLAN004*8 ¶g *1b N=22+16¤H
EASI75 ¹êÅç²Õ50%/¹ï·Ó²Õ13% = 380%, HR(·ÀI¤ñ): 13%/50%=0.26 ,p =0.018------ITT¤ÀªR
¹êÅç²Õ EASI75------¤À²Õ¤ÀªR A.¤¤Â_ N=13.6%(3/22) , 0%(0/3) B.TRAC <1115 N=27.3%(6/22), 0%(0/6)----------(¥»²Õ6¤H¬Ò«D¶Ç²ÎAD,ªvÀø©M¹ï·Ó²ÕµL®t²§,0%¹FEASI75) C.TRAC >1115 N=59%(13/22) , 85%(11/13) ----------------------------------------------- ¤pp N=100%(22/22), 50%(11/22 )------
¤G.Dupilumab*16¶g,P3 ,N=900+450 ¤H
EASI75 ¹êÅç²Õ49%/¹ï·Ó²Õ14% = 350%, HR(·ÀI¤ñ): 14%/50%=0.28----ITT¤ÀªR
¹êÅç²Õ EASI75------¤À²Õ¤ÀªR
A.¤¤Â_ N=6.3% ,¦ô 0% B.TRAC <1115 N=30.7%,¦ô 58% (49%*(78%/70%)/93.7%)=58% (¨Ì¥§¡°´T¤ñ²v¦ô/¤¤Â_²v) C.TRAC >1115 N=62.5%,¦ô 49%(49%*(66%/70%)/93.7%)=49% ¤pp N=100% , 49%
------------------------------------------ TRAC <1115 ,EASI ¥§¡°´T78% TRAC >1115 ,EASI ¥§¡°´T66%
---------------------------------------------
Dupilumab ²Õ¥]§t¤@©w¤ñ²vªº«D¶Ç²ÎAD. -----------------------------------------------
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/24 ¤W¤È 11:36:02
²Ä 156 ½g¦^À³
|
Tralokinumab 12-17·³¡A¤¤-««×AD¡A¤T´Á¹LÃö¡A N=98/150mg:97/300mg:94¹ï·Ó组, «Å¥¬¹LÃö¡A2021/10/22
¥Dn«ü¼ÐÀø®Ä¡A约Dupilumab ¤@¥b¡C
Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis Sixteen-week results from the Phase 3 ECZTRA
6 trial in adolescents showed tralokinumab 150 mg and 300 mg significantly improved measures of efficacy compared to placebo1 Tralokinumab was generally well-tolerated with an overall frequency and severity of adverse events comparable with placebo, consistent with that observed in adults in Phase 3 trials1 October 22, 2021 07:00 AM Easter
Tralokinumab is a high-affinity, human monoclonal antibody that specifically binds to and inhibits IL-13, a key driver of atopic dermatitis signs and symptoms.2,3 It is an investigational therapy in clinical development in the United States and has not been approved by the U.S. Food and Drug Administration. It has been approved for the treatment of adults with moderate-to-severe atopic dermatitis by the European Commission and the MHRA in June 2021 and by Health Canada in October 2021.
¡§After 16 weeks, adolescents who received either dose of tralokinumab, without rescue therapy, showed significantly greater improvement in atopic dermatitis signs and symptoms and quality of life compared to those receiving placebo,¡¨ said Amy Paller, M.D., Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University in Chicago, Illinois, and the international coordinating investigator for ECZTRA 6. ¡§These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.¡¨
The 16-week initial treatment period of the ECZTRA 6 trial (NCT03526861) assessed the efficacy and safety of tralokinumab 150 mg (n=98) or 300 mg (n=97) every two weeks (Q2W) compared to placebo (n=94) in adolescents.1 At week 16, tralokinumab met its primary and secondary endpoints, showing significantly more patients treated with tralokinumab achieved a clinical response, compared to placebo, defined as achieving an IGA 0/1 and/or an EASI-751:
21.4% (p<0.001) of the tralokinumab 150 mg group and 17.5% (p=0.002) of the tralokinumab 300 mg group achieved clear or almost-clear skin compared to 4.3% with placebo as measured by IGA.1 28.6% (p<0.001) of the tralokinumab 150 mg group and 27.8% (p=0.001) of the tralokinumab 300 mg group achieved 75% or greater disease improvement from baseline compared to 6.4% with placebo as measured by EASI.1 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/24 ¤W¤È 09:39:53
²Ä 155 ½g¦^À³
|
ASLAN004 ADÃĵý¥²¨ú¡C
¤@¡B¦w¥þ©Ê¹LÃö¡A©Mdupilumab/leri/trolµ¥§í¨îIL4/IL13¤§¾÷¨î¬Û¦ü¡A¬Gªø´Á¦w¥þ©Ê¤w¥i³Q预测¡C ¤G¡BÀø®Ä¡A¥Ñ©ó¥Dn«ü¼ÐEASI75/IGA0,1 ©M¹ï·Ó组Àø®Ä¤ñÈ3.5-4¿¥H¤W¡AHR= 0.3-2.5,p<0.00001
1.ASLAN004*8 ¶g *1b¡CN=22:16,ITT¤ÀªR
EASI75 ¹êÅç²Õ50%/¹ï·Ó²Õ13% = 380%, HR(·ÀI¤ñ): 13%/50%=0.26 ,p =0.018
2.Dupilumab*16 ¶g,phase 3 solo 1&2 N=¬ù900:450¡AITT¤ÀªR
EASI75 ¹êÅç²Õ49%/¹ï·Ó²Õ14% = 350%, HR(·ÀI¤ñ): 14%/50%=0.28
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 p.18//p.25
EASI75 ¬O¤T´Á«ü¼Ð. ¦b²Ä8¶g¤w±µªñ12¶g®pÈ.¤j¬ù®t5%¤§¤º.
IGA 0,1¡A«ü¼ÐªºÀø®Ä¦b 16¶g±NÀHEASI75 ¦³¤@©w¤§¤ñ²v®t(约12%)¡C
¦bDupilumab ¤T´ÁEASI75 49%,IGA0,1 37%¡A ¨â«ü¼Ð®t12%
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
¤p«¬·sÃĤ½¥q¡K¡KªÑ»ù vs ¨ÖÁÊ»ù
¨ÖÁÊ»ùªºpºâ¤½¦¡¡A ·½¦Û预¦ô³Ì°ª¦~¾P°â¡A³v¦~ºâ预¦ô税«áÀç¾l¡A§é现«á»ù®æ¡C ¡K¡K ³Q¨Ö¤½¥qªÑ»ù¤£¦b¨ÖÁÊ»ùªº¤½¦¡¤§内 ¡K¡K
µu½u¨Ì§Þ³N±¶i¥X谮¤O¤jªº¤p«¬·sÃĪѡA ¤@¦ý¿ù¹L«Å¥¬¨ÖÁʪº·í¤Ñ¤@»ù¨ì顶¡A 将¿ù¹L³Ì¤j§ë¸ê«O¹S¾÷·|¡C ¡K¡K¡K¡K ¤p·sÃĤ½¥q³Ì¨Î§ë¸êµ¦²¤ µû¦ô: ¡iÁ{§É¼Æ¾Ú+MOA=¦ô¨úÃĵý¦¨¥\²v¡j+¡i¼ç¦b¥«³õ³Ì°ªÀ禬¡j
¨ä¥L´N¬Oµ¥«Ý³Q¨ÖÁÊ ¡K¡K¡K ASLAN004 vs Dupilumab
MoA:¨âªÌ¬Ò¥i¦P®É§í¨îIL4/IL13
1.Àø®Ä>=Dupilumab ªº¼Ð·ÇÀøªk¡A (¤£·|ūܦh¡AEASI75,¦ô110%-130%,HR=0.7-0.9)
2.°Æ§@¥Î§C(µL结½¤ª¢)¡B¤@¤ë¤@¦¸¥ÎÃÄ频²v¡A«Ç温«O¦s¡A ¥H¤W¬ÒÀu©óDupilumab
3.¦ô¥«³õ渗³z:50%, 60»õ¬ü¤¸
4.¦ô³Q¨ÖÁÊ»ù52-60 »õ¬ü¤¸
11/50¡Ñ120¡Ñ2=52 Lebrikiumab (AD)ªºDERM¤½¥q¡A2020/02³Q¨ÖÁÊ»ù11»õ¬ü¤¸¡C 2019¡A11¤ë¥H«eDupilumab ¥«³õ»{¦P³Ì°ª¾P°â¥i¹F50»õ¬ü¤¸ 2019.12¤ë¡AREGN CEO«Å¥¬¡A¦ôdupilumab ³Ì°ª¾P°â100»õ¼Ú¤¸/120»õ¬ü¤¸¡C Lebrikiumab¦bý³Ý/COPD 3´ÁÁ{§É¬Ò¥¼¦¨¥\¡A ASLAN004¾Ö¦³ý³Ý¡BCOPD...µ¥¦PDupilumabªº¾AÀ³¯g¦¨¥\ªº¥i¯à¡C+ASLAN003,¦ôµ¥¦PAD»ùÈ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/24 ¤W¤È 09:05:18
²Ä 154 ½g¦^À³
|
¤p«¬·sÃĤ½¥q¡K¡KªÑ»ù vs ¨ÖÁÊ»ù
¨ÖÁÊ»ùªºpºâ¤½¦¡¡A ·½¦Û预¦ô³Ì°ª¦~¾P°â¡A³v¦~ºâ预¦ô税«áÀç¾l¡A§é现«á»ù®æ¡C ¡K¡K ³Q¨Ö¤½¥qªÑ»ù¤£¦b¨ÖÁÊ»ùªº¤½¦¡¤§内 ¡K¡K
µu½u¨Ì§Þ³N±¶i¥X谮¤O¤jªº¤p«¬·sÃĪѡA ¤@¦ý¿ù¹L«Å¥¬¨ÖÁʪº·í¤Ñ¤@»ù¨ì顶¡A 将¿ù¹L³Ì¤j§ë¸ê«O¹S¾÷·|¡C ¡K¡K¡K¡K ¤p·sÃĤ½¥q³Ì¨Î§ë¸êµ¦²¤ µû¦ô: ¡iÁ{§É¼Æ¾Ú+MOA=¦ô¨úÃĵý¦¨¥\²v¡j+¡i¼ç¦b¥«³õ³Ì°ªÀ禬¡j
¨ä¥L´N¬Oµ¥«Ý³Q¨ÖÁÊ ¡K¡K¡K ASLAN004 vs Dupilumab
MoA:¨âªÌ¬Ò¥i¦P®É§í¨îIL4/IL13
1.Àø®Ä>=Dupilumab ªº¼Ð·ÇÀøªk¡A (¤£·|ūܦh¡AEASI75,¦ô110%-130%,HR=0.7-0.9)
2.°Æ§@¥Î§C(µL结½¤ª¢)¡B¤@¤ë¤@¦¸¥ÎÃÄ频²v¡A«Ç温«O¦s¡A ¥H¤W¬ÒÀu©óDupilumab
3.¦ô¥«³õ渗³z:50%, 60»õ¬ü¤¸
4.¦ô³Q¨ÖÁÊ»ù52-60 »õ¬ü¤¸
11/50¡Ñ120¡Ñ2=52 Lebrikiumab (AD)ªºDERM¤½¥q¡A2020/02³Q¨ÖÁÊ»ù11»õ¬ü¤¸¡C 2019¡A11¤ë¥H«eDupilumab ¥«³õ»{¦P³Ì°ª¾P°â¥i¹F50»õ¬ü¤¸ 2019.12¤ë¡AREGN CEO«Å¥¬¡A¦ôdupilumab ³Ì°ª¾P°â100»õ¼Ú¤¸/120»õ¬ü¤¸¡C Lebrikiumab¦bý³Ý/COPD 3´ÁÁ{§É¬Ò¥¼¦¨¥\¡A ASLAN004¾Ö¦³ý³Ý¡BCOPD...µ¥¦PDupilumabªº¾AÀ³¯g¦¨¥\ªº¥i¯à¡C+ASLAN003,¦ôµ¥¦PAD»ùÈ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/22 ¤W¤È 09:10:31
²Ä 153 ½g¦^À³
|
II«¬ª¢¯gªºµo¯fì²z¾ú经Dupilumab/Berikiumab/Tralokiumab 3ÃÄ¡A6Ó¤T´ÁÁ{§ÉÅçÃÒ¡A¥DnÀø®Ä«ü¼ÐIGA0,1/EASI75¡A¹êÅç组Àø®Ä¬Ò¬O¹ï·Ó组2-4¿¡CP<0.001 ASLAN004Àø®Ä¡A¦bRITT-EEPP,¤U >=Dupilumab Àø®Ä¡C
¥¼¨Ó2b¡Aphase3 ,¥²®i²{¨äMOA¡AÀ³¦³Àø®Ä¡C
¤é«á°ªTRAC组¥§¡12000pg/ml,¥§¡EASI 41¡A¦û©Û¶Ò¤Hû 1/3, ¡«á¹êÅç组¥§¡°约EASI65-70(26-29)/41% vs¹ï·Ó组°EASI28%(11.5/41)
¦Û°Ê¥¿Å±¼«D¶Ç²ÎAD¤§¤ñ²v¡C
¦Ó¦³Dupilumab ¤T´Á¡A ¥§¡Â¡«á°´T 70% vs 34% (¤¤断²v6.3%) -----------------
Dupilumab ¤T´ÁÁ{§É
TRAC// ¤H¼Æ// °ò½u¥§¡EASI//ªvÀø«áEASI¥§¡°´T(¤ñ²v)//¥§¡°ªºEASI¤À¼Æ¡C
Dupilumab 组 solo1
¤pp 457¤H //32.4//70%//22.6
<1115 //154¤H//24.1//77.9%//19.5 1115~4300//153¤H//32.4//67.4%//21.9 >4300. //149¤H//41.1/63.1%//26.2
Solo2 ¤pp //462¤H//32.5//70.7%//23,1 <1115 //160¤H//25.8//75.4%//19.1 1115~4300//147¤H//31.2//66.4%//21.9 >4300. //152¤H//40.9//67.5%//27.5
Dupilumsb ¹êÅç组:¤¤断²v6.3%¡K¡K¡K¡K ¡K¡K¡K¡K ¹ï·Ó组 ¤pp460 //34.1//34.3%//11.5
143 //25.3//43.7%//11.5 157//32.4//23.3%//8.7 156//43.9//27.1%//11.5 ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/21 ¤W¤È 07:38:10²Ä 4770 ½g¦^À³ Lebrikiumab 2b °ò½u EASI 25.5 -------------------------------------------------------------- ¡«á
²Ä¥|¶gvs ²Ä¤K¶gvs ²Ä16¶g EASI°´T 50% vs 64% vs 73%
EASI¥h°£ EASI 12.8 vs EASI 16.3 vs EASI 18.6 EASI´Ý¯d EASI 12.8 vs EASI 9.2 vs EASI 6.9
EASI 50, NA vs NA vs 81% EASI 75, 30% vs 46% vs 61% (¤T´Á>50%) EASI 90, 14% vs 30% vs 44% IGA 0,1, 14% vs 31% vs 45%
¡K¡K¤¤Â_²v 19/75=25.3%
clinicaltrials.gov/ct2/show/results/NCT03443024 ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/20 ¤U¤È 08:19:06²Ä 4769 ½g¦^À³ ¼ÒÀÀ---ITTì´Á±æ22¦ì ASLAN004 600mg*8¶g
6¦ì«D¶Ç²ÎAD vs 13¦ì(RITT/EEPP) vs ITT22 ¦ì vs ¼ÒÀÀITTì´Á±æ22¦ì
°ò½u EASI 18 vs EASI30.5 vs EASI27.6 vs EASI27.6 -------------------------------------------------------------- ¡«á EASI°´T 50% vs 80%vs 61% vs 74%
EASI¥h°£ EASI1 9 vs EASI1 24.4 vs EASI 16.8 vs EASI 20.4 EASI´Ý¯d EASI1 9 vs EASI1 6.1 vs EASI 10.7 vs EASI 7.1
EASI 50, 67% vs 100% vs 77% vs 86% EASI 75, 0% vs 85% vs 50% vs 77% EASI 90, 0% vs 46% vs 27% vs 54% IGA 0,1, 0% vs 54% vs 32% vs 59%
¼ÒÀÀITTì´Á±æÈ22¦ì¡K¡K§ï«D¶Ç统6¦ì¡A¬°¶Ç统AD¡A°ò½uEASI18,¡«á¬°100%¹F¡AEASI90¡AIGA0,1¡A¥HASLAN004¤§¯à¤O预¦ô¬°°ò¦¡C¤¤Â_²v «O¯d3/22=13.6% . ----13¦ì(RITT/EEPP) : ITT 22¦ì-¤¤Â_3¦ì-6¦ì«D¶Ç²ÎAD
µ²½×: ¬Yx¤¤¤ß9(6+3)¤H 6/22=27%¡A©Û¶Ò¼f¬d¥¢»~(À³¥i±±)¡A¤j¤j¤zÂZITTªºÀ³¦³¤ô·Ç¡C
----«D¶Ç²Î6¦ìAD ¡«á EASI¥§¡°´T©M¹ï·Ó²Õ ¬Ûªñ50%, IL4/IL13§í¨îµL®Ä,Dupilumab¥çÀ³µL®Ä.
---Dupilumab ¤T´Á,©ñ¤j¨ì225:2225¤H , EASI¥§¡°´T 70% VS ¹ï·Ó²Õ34%.¦Û°Êµ}ÄÀ«D¶Ç²ÎADªº¼vÅT¤O.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/20 ¤U¤È 07:52:44
²Ä 152 ½g¦^À³
|
¼ÒÀÀ---ITTì´Á±æ22¦ì ASLAN004 600mg*8¶g 6¦ì«D¶Ç²ÎAD vs 13¦ì(RITT/EEPP) vs ITT22 ¦ì vs ¼ÒÀÀITTì´Á±æ22¦ì
°ò½u EASI 18 vs EASI30.5 vs EASI27.6 vs EASI27.6 -------------------------------------------------------------- ¡«á EASI°´T 50% vs 80%vs 61% vs 74%
EASI¥h°£ EASI1 9 vs EASI1 24.4 vs EASI 16.8 vs EASI 20.4 EASI´Ý¯d EASI1 9 vs EASI1 6.1 vs EASI 10.7 vs EASI 7.1
EASI 50, 67% vs 100% vs 77% vs 86% EASI 75, 0% vs 85% vs 50% vs 77% EASI 90, 0% vs 46% vs 27% vs 54% IGA 0,1, 0% vs 54% vs 32% vs 59%
¼ÒÀÀITTì´Á±æÈ22¦ì¡K¡K§ï«D¶Ç统6¦ì¡A¬°¶Ç统AD¡A°ò½uEASI18,¡«á¬°100%¹F¡AEASI90¡AIGA0,1¡A¥HASLAN004¤§¯à¤O预¦ô¬°°ò¦¡C¤¤Â_²v «O¯d3/22=13.6% . ----13¦ì(RITT/EEPP) : ITT 22¦ì-¤¤Â_3¦ì-6¦ì«D¶Ç²ÎAD
µ²½×: ¬Yx¤¤¤ß9(6+3)¤H 6/22=27%¡A©Û¶Ò¼f¬d¥¢»~(À³¥i±±)¡A¤j¤j¤zÂZITTªºÀ³¦³¤ô·Ç¡C
----«D¶Ç²Î6¦ìAD ¡«á EASI¥§¡°´T©M¹ï·Ó²Õ ¬Ûªñ50%, IL4/IL13§í¨îµL®Ä,Dupilumab¥çÀ³µL®Ä.
---Dupilumab ¤T´Á,©ñ¤j¨ì225:2225¤H , EASI¥§¡°´T 70% VS ¹ï·Ó²Õ34%.¦Û°Êµ}ÄÀ«D¶Ç²ÎADªº¼vÅT¤O. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/17 ¤U¤È 01:03:24
²Ä 151 ½g¦^À³
|
¼ÒÀÀ ASLAN004 6¦ì «D¶ÇAD vs ¶Ç统AD13¦ì(RITT/EEPP) vs ITTì´Á±æ22¦ì vs ITT22 ¦ì EASI 50, 67% vs 100% vs 86% vs 77% EASI 75, 0% vs 85% vs 77% vs 50% EASI 90, 0% vs 46% vs 54% vs 27% IGA 0,1, 0% vs 54% vs 59% vs32% ¥§¡EASI°´T 50% vs 80%vs 74% vs61%
Y§ï«D¶Ç统6¦ì¡A¬°¶Ç统AD¡A°ò½uEASI18,¡«á¬°100%¹F¡A¤@EASI90¡A¥HASLAN004¤§¯à¤O¡C
¬Yx¤¤¤ß9¤H¡A©Û¶Ò¼f¬d¥¢»~(À³¥i±±)¡A¤j¤j¤zÂZITTªºÀ³¦³¤ô·Ç¡C
§Æ±æÂǥѦh¦ì±M®a¥[¤J¡A³]p¥X2b,300¤Hªº¤§²z·Q©Û¶Ò±ø¥ó¡C ®i²{ASLAN004¤§¯à¤O¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/17 ¤U¤È 12:01:04
²Ä 150 ½g¦^À³
|
9/27 1b¤ÀªR
RITT-EEPP(ç°£¬Y¤¤¤ßTRAC<1115pg/ml,ç°£3¦ì¤¤断) ¹êÅç组13¤H¡A¥´§¹8°wx600mg/针-¶g
EASI75=85%(11/13) EASI90=46%(6/13) IGA 0,1=54%(7/13) ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¨ä¤¤3¦ì¬O3¤ë«e©Û¶Ò±wªÌ¡A·í¤¤¦³2¦ì¹FEASI75¡A67%(2/3),¦U¦³¤@¦ì(1/3)¡P33.3%¹FEASI90¤ÎIGA0,1¥t¤@¦ì¥ç¹FEASI50.
3¤ë1¤é«á©Û¶Ò18¤H¹êÅç组/ÂX¥R组¡AEEPP(¦©°£§CTRAC6¤H¡A¦©°£¤¤断2¤H)¡A10¤H¥´§¹8°w/8¶g¡A
EASI50,100%(10/10) EASI75,90%(9/10) EASI90,50%(5/10)¡K¡K¦ôÁÙ¦³15%-20%,¥¼¨Ó9-16¶g¡C IGA0,1,60%(6/10)¡K¡K ¦P¤W
«D±`°ªªºÀø®Ä¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/17 ¤W¤È 09:05:41
²Ä 149 ½g¦^À³
|
Dupilumab 2b VS Phase 3 vs ASLAN004 1b
(DUPILUMAB Q2w ¡Ñ16 ¶g/ASLAN004 Qw ¡Ñ8¶g)
1.ITT ¤ÀªR(¹êÅç组/¹ï·Ó组) EASI50 78%/30%vs67%/24%vs82%/38% EASI75 53%/12%%vs48%/14%vs50%/13% EASI90 30%/3%vs33%/8%vs23%/13% IGA0,1 30%/2%vs37%/9%vs27%/13%
clinicaltrials.gov/ct2/show/results/NCT01859988
www.nejm.org/doi/full/10.1056/nejmoa1610020
clinicaltrials.gov/ct2/show/results/NCT02277743
clinicaltrials.gov/ct2/show/results/NCT02277769
2.EEPP ¤ÀªR(ç°£¤¤断±wªÌ¤ñ²v)
EASI50 96%/43%vs72%/29% vs 95%/46% EASI75 66%/17%vs51%/17%% vs 58%/15% EASI90 37%/5%vs35%/9% vs 26%/15% IGA0.1 37%/2%%vs40%/11% vs 32%/15%
ASLAN004 «D¶Ç²ÎAD¼vÅT 6/22=27%, 9-16 ¶g¥ç¼vÅTEASI75/EASI90/IGA0,1¡A¦ô12%-20%
Dupilumab 2b/Phase3 ¥ç¨ü¤£¦P©Ó«×«D¶Ç²ÎAD¼vÅT¡C
¡K¡K ¤¤断²v Dupilumab 2b 19%(12/64)/31%(19/61) vs Dupilumab p3 6%(29/457)/19%(86/460) vs Aslan004 1b 14%(3/22)/19%(3/16) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/8 ¤W¤È 06:53:14
²Ä 148 ½g¦^À³
|
¤@.ASLAN004 8¶g, EASI °´TÁͶժí
1//2//3//4/5//6//7//8(¶g)== %
9/27 13¤H 21//30//55//60//67//68//72//80(EEPP :ç°£¤¤Â_3¤H,ç°£TRAC <1200pg/ml) vs 3/1 9¤H 18//45//56//61//65//68//71//76(400mg+600mg ,9¤H/EEPP : µL¤¤Â_)
¥H¤W2²Õ§e²{¥X¬Û¦üªºEASI °´TÁͶÕ.
2b, ¥¼¨Ó9-16¶g¦ôASLAN004 EASI¦³8~12%ªº¥§¡°´T,
Y°²³]¤¤Â_²v¬°7%,
¥¼¨Ó2b,16¶gªvÀø¦ô
¥i¹FEASI 81%~85% ¥§¡°´T-------°ò½uTRAC >1200, ¥§¡4000~6000pg/ml ,¦û2/3©Û¶Ò¤Hû
¥i¹FEASI ??? ¥§¡°´T-------°ò½uTRAC <1200 pg/ml ,¦û1/3©Û¶Ò¤Hû------«ÝÅçÃÒ
¤G.Dupilumab ¤T´Á1377¤H(919+460),16¶g °O¿ý. (¤º§t7%¤¤Â_²v)
»´ °ò½uTRAC< 1115pg/ml,¥§¡EASI25 ,IGA4=24% 16¶gªvÀø«á¥§¡°EASI77%
¤¤ °ò½uTRAC >1115 <4300pg/ml ,¥§¡EASI31,16¶gªvÀø«á¥§¡°EASI67%
« °ò½uTRAC >4300 pg/ml,¥§¡EASI41,IGA4=80% 16¶gªvÀø«á¥§¡°EASI65%
¦Xp ¥§¡ °ò½uTRAC >6100 pg/ml,16¶gªvÀø«á¥§¡°EASI70%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/7 ¤U¤È 03:21:07
²Ä 147 ½g¦^À³
|
ASLN004¤@´Á¸Ñª¼¥¿¦V,¦ý¤´¦³«Ý¥«³õ»{¦P,§Æ±æ§ë¸ê¤H³£¯à¥þ¨¦Ó°h µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07 2021.09-¤@´Á¼Æ¾Ú²³ø:ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/7 ¤U¤È 02:25:06²Ä 4690 ½g¦^À³ 9/27 ¸É¥R EASI °´TÁͶժí 1//2//3//4/5//6//7//8(¶g)== % ASLAN004 §CTRAC 6¤H 3//-4//19//31//29//30//41//50 (³Qç°£¬Y¤¤¤ß¹êÅç²Õ6¤H) ¹ï·Ó²Õ §CTRAC 3¤H -9//20//21//24/15//26//48//49 (³Qç°£¬Y¤¤¤ß¹ï·Ó²Õ3¤H)
¦ý»P¹ï·Ó²Õ¬Û¤ñASLAN004²Õ,²Ä8¶gÀ³µL®t²§. ------------------------------------------------------------------------------- ¹ï·Ó²Õ ITT 16¤H 10//25//30//28/32//30//35//32 RITT 13¤H 10//25//30//28/32//30//35//32 (³Qç°£¬Y¤¤¤ß¹ï·Ó²Õ3¤H) RRITT 10¤H 13//33//30//39/42//39//46//42 (ç°£¤¤Â_3¤H) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/7 ¤U¤È 01:39:04
²Ä 146 ½g¦^À³
|
¤@.ASLAN004 EASI °´TÁͶժí
9/27 RRITT 13¤H 21//30//55//60//67//68//72//80(¦©°£¤¤Â_3¤H) vs 3/1 9¤H 18//45//56//61//65//68//71//76(400mg+600mg 9¤H/µL¤¤Â_)
¥H¤W2²Õ§e²{¥X¬Û¦üªºEASI °´TÁͶÕ.
¤G. 9/27 §CTRAC 6¤H 3//-4//19//31//29//30//41//50 (³Qç°£¬Y¤¤¤ß¹êÅç²Õ6¤H)
6/7/8 ¶g¶}©l¥[³t¤ÏÀ³,2b Á{§É9-16¶g¦³¾÷·|,¥Ñ¥§¡50%©¹80% ¾aªñ.
«e2¶g¤ÏÀ³«Ü®t.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/7 ¤U¤È 01:09:47²Ä 4688 ½g¦^À³ 9/27 ¸Ñª¼³ø§i ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 p.23 ---Time course (mean change from baseline)
ASLAN004 EASI °´TÁͶժí 1//2//3//4/5//6//7//8(¶g)== % ITT 22¤H 14//17//38//44//48//49//54//61 RITT 16¤H 18//25//45//49//55//56//59//65(ç°£¬Y¤¤¤ß¹êÅç²Õ6¤H)
§CTRAC 6¤H 3//-4//19//31//29//30//41//50 (³Qç°£¬Y¤¤¤ß¹êÅç²Õ6¤H)
RRITT 13¤H 21//30//55//60//67//68//72//80(¦©°£¤¤Â_3¤H) ---------------------------------------------------------------- 3/1 ¸Ñª¼³ø§i ir.aslanpharma.com/static-files/0497e948-4fc0-44fc-bddd-0fdd7b88cd4b p.19
ASLAN004 EASI °´TÁͶժí RRITT 9¤H 18//45//56//61//65//68//71//76(400mg+600mg 9¤H) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤W¤È 11:21:50
²Ä 145 ½g¦^À³
|
Dupilumab ¤T´ÁCCL17/TRAC ³ø§i¡C
¦b¤T²Õ°ª¤¤§C16¶gªvÀø«á¥§¡°´T 63%-79% ¥NªíADªº±w¯f¾÷¨î¨Ã«D100%¡A¥Ñ¤uL4/IL13 ©ÒÁÍ°Ê¡C
REGN ´£¥XIL32¡A¦ý¥Ø«eµLÁ{§É资®Æ¥iµý©ú¡C ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/6 ¤W¤È 09:05:40²Ä 4664 ½g¦^À³ 9/27 1b ¸Ñª¼
RITT ASLAN004 16¤H¡A8¶gªvÀø¡C
°ò½uEASI 30.5 TRAC.>4000 pg/ml
§t3¦ì¤¤Â_¡A¤¤Â_²v3/16=19%
RITT ¥§¡°´T65% ¥Ñ©ódupilumab ¤T´Á¤¤断²v¶È7%.
RITT 16¡K¡K¤¤断°²³]¤U׬°1¤H¡A
16¡Ñ65%/14=74%
¥t¥~9-16¶gªvÀø¡A¦ô¥t¥~¼W¥[8%,74%+8%=82%ªº´Á±æÈ 16¶gªºRITT/REEPP¡C
Dupilumab 3´ÁÁ{§É¡A°ò½uCCL13/TRAC >1155pg/mlªº16¶gªvÀø«áEASI¥§¡°´T63%-67%.
¡«áEASI ¥§¡°´T ASLAN004 VS Dupilumab
82% vs 63%-67%
ASLAN004 22%-30% ¡AÀu©óDupilumab¡K¡K°ª¥Íª««ü¼Ð
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
www.morressier.com/article/biomarkers-ccl17tarc-total-ige-not-predict-clinical-response-dupilumab-atopic-dermatitis-ad-post-hoc-analysis-pooled-phase-3-data-solo-1--2/5d4980cb8fb7e44098e72cd2?
Biomarkers CCL17/TARC and Total IgE Do Not Predict Clinical Response to Dupilumab in Atopic Dermatitis (AD): a Post hoc Analysis of Pooled Phase 3 Data (SOLO 1 & 2) Submitted Sep 2, 2019
Jennifer D. Hamilton
Zhen ¡K¡K
结½×1..CCL17/TRAC ªº¥Íª«¼Ð»xª«®Ä»ù§C¡A°ò½uEASI´N§C¡C
¤Ï¤§°ª«h°ª¡C
CCL17/TRAC// ¤H¼Æ// °ò½u¥§¡EASI//ªvÀø«áEASI¥§¡°´T(¤ñ²v)//¥§¡°ªº¤À¼Æ¡C
Dupilumab 组 solo1 ¤pp 457. //32.4//70//22.6 <1115 154//24.1// 77.9// 19.5 1115~4300//153//32.4//67.4%//21.9 >4300//149//41.1/63.1%//26.2
Solo2 ¤pp 462 //32.5//70.7%//23,1 <1115 160//25.8//75.4%/19.1 1115~4300//147//31.2//66.4%//21.9 >4300//152//40.9//67.5%/27.5 ¡K¡K¡K¡K ¡K¡K¡K¡K ¹ï·Ó组 ¤pp460 //34.1//34.3%//11.5
143 //25.3//43.7%//11.5 157//32.4//23.3%//8.7 156//43.9//27.1%//11.5
结½×2 Dupilumab ªvÀø«áªºEASI¥§¡°´TÀø®Ä»P°ò½uCCL17/TRAC¥Íª««ü¼Ð®Ä»ù°ª§CµL¥¿¬ÛÃö¡C
¤T组CCL17/TRAC¤£¦P®Ä»ù¡A ¦P¼Ë¦³Àø®Ä¡C
¡K¡K¡K¡K 9/27 ASLAN004 1b 8¶g¡A¸Ñª¼¡C
6+3 ¤Hªº«D¶Ç²Î¤¤-««×±wªÌTRAC<1200pg/ml
¦ýªvÀø«á©M¹ï·ÓEAS¤u¥§¡°´T®t²§¤£¤j¡A¦b50%¥ª¥k¡C
²zÀ³°65%-70%.
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
¥H¤UÓ¤H¬Ýªk ¦³«Ý2bÁ{§É ¤H¼Æ©Ô°ª¨ì60:60(§CCLL17/TRAC <1115¡A20:20¤H¡A¨Ó¦A¦¸ÅçÃÒ¡C
Y2b 16¶gªvÀø¡A©ñ¤j¨ì20:20¡A¤´µL®t²§¡A
则³Ìp3¡An¨Æ¥ý¥Î¥Íª««ü¼ÐCCL17/TRAC ¤À2组<1115 ¤À¤@组¡A¥t¤@组>1115®Ä»ù¡C
<1115 ©Û¶Ò¤H¼Æ¦û1/3, >1115 ©Û¶Ò¤H¼Æ¦û2/3
Y<1115,§C¥Íª««ü¼Ð®ÄªºªvÀø«áEASI«ü¼Ð©M¹ï·Ó组¤´µL®t²§¡A 则¥Ó½ÐÃÄ证¡A ¶È¥i½Ð>1115°ª®Ä»ù¥Íª««ü¼ÐªºÃÄ证¡A¦ûAD¥Ø¼Ð¥«³õ约2/3.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/4 ¤W¤È 08:47:48
²Ä 144 ½g¦^À³
|
¼ÒÀÀ Lebrikizumab 2b¼Æ¾Ú, ¦b²Ä8 ¶g,N=22:16®É, ¥þxÂШS!没¦³¤@¶µ«ü¼Ð¹LÃö.
¦ý¤H¼Æ¥[¤j¨ì75:52, 16 ¶gªºªvÀø«á, PȬÒ<0.001
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
p.25
Lebrikizumab 2b ,°²³] Á{§É¤H¼Æ N= 38, ¹ï·Ó²Õ16 VS Lebrikizumab 22
¹ï·Ó²Õ VS Lebrikizumab
----------P<0.05¹LÃö------
EASI 75 17% vs 46% , p=0.129 (¨S¹LÃö) IGA 0,1 5% vs 31% , p=0.117(¨S¹LÃö) EASI¥§¡°´T 31% VS 64% ,P=0.093(¨S¹LÃö)
Pruritus 22% vs 46%, p=.238 (¨S¹LÃö)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466 ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/3 ¤U¤È 07:25:28²Ä 4643 ½g¦^À³ Dupilumab 1b ¥Dn«ü¼Ð¬Ò没¹LÃö, 没¤H´±»¡¥¦®t!
EASI 75 6% vs 29% , p=0.118 (¨S¹LÃö) IGA 0,1 6% vs 12% , p=0.245(¨S¹LÃö) Pruritus 18.6% vs 41.3%, p=.582 (¨S¹LÃö)
www.nejm.org/doi/10.1056/NEJMoa1314768
Dupilumab ,1b*4¶gªvÀø*300mg,N=67 ¥Íª««ü¼ÐSerum = 6000 pg/ml(´X¥G¬°¶Ç²Î-««×AD±wªÌ) °ò½u:¹ï·Ó²Õ22.8 VS Dupilumab 30
¹ï·Ó²Õ VS. Dupilumab N=16 VS 51
-----------P<0.05¹LÃö------
EASI 50 19% vs 59% , p=0.012 EASI 75 6% vs 29% , p=0.118 (¨S¹LÃö) IGA 0,1 6% vs 12% , p=0.245(¨S¹LÃö) EASI¥§¡°´T 25.7% VS 57.7% ,P=0.049
Pruritus 18.6% vs 41.3%, p=.582 (¨S¹LÃö)
dupilumab ¶È¥|¶gªvÀø,没¹LÃöªº亖´Á16¶g¥Dn«ü¼Ð EASI75/IGA 0,`1 «Ü¥¿±`. ¤T´Á¤H¼Æ N=230:230
5-16¶gªºEASI75·|¤W¤É¨ì50%±q¥|¶g29% 5-16¶gªºIGA0,1·|¤W¤É¨ì38%±q¥|¶g12% 5-16¶gªºPruritus·|¤W¤É¨ì51%±q¥|¶g41.3% ------------------------------------------------------------
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/2 ¤U¤È 08:32:09
²Ä 143 ½g¦^À³
|
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 P.14 ¸É¥R:
ASLAN004+Placebo site x <1200 pg/ml(8¤H)
ASLAN004+Placebo other site ¬ù4600 pg/ml(21¤H)--- B
Dupilumab p3 ¬ù6100 pg/ml(1379¤H)-----C
B/C=75% , ¥Nªí Dupilumab p3 ,1379¤H ªº¦¬®×¬Û¹ï©óASLAN004+Placebo other site ¬ù4600 pg/ml(21¤H)--- B
¬O§ó¯Â/§ó°ª¤ñ²vªº¶Ç²Îªº¤¤-««×AD±wªÌ.
------------------------------------------------------------------- ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,°ò½u¥§¡EASI 19.9 vs 18.2 ,IGA3
³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.¤]¤£¬Odupilumab/lebrikizumab/tralo ¥Ø¼Ð±wªÌ,
¥L̥ΤWzÃÄ=¤£¥ÎÃÄ. 66% ·|¦Û¤v´î¨ìEASI50, ¥u¦³³æ¤@AD¯gª¬, «Ü¤jªº¥i¯à¶°¤¤¦b°ò½uEASI 20 ¥ª¥k.IGA3
¤£¬OII ª¢¯gªº¾÷Âà,
-------------------------------- µ²½×: 1.ASLAN004ªº³Ì¤jÄvª§¤O, ¦ô¦bAD°ò½u29~41 ¦³100%¥D®_¤O,¬° NO.1 Àø®Ä,µL¥LÃįà¤Î.
2.¤é«áP3 AD¦¬®×,¥§¡°ò½u¦bEASI31~32, ¦ôp°ò½uEASI 20¥ª¥k¤ñ²vÀ³«D±`¤Ö, ¼vÅT¥Dn«ü¼ÐEASI75/IGA0.1 ¥ç«Ü¤Ö. ¤j®a³£¤@¼Ë.
-------------------------------------------- 9/27,°ò½uEASI :
600mg vs ¹ï·Ó²Õ ITT 27.6 vs 29 RITT 30.5 vs 31.5 ç°£9¤H 19.9 vs 18.2
°ò½uIGA3/IGA4
ITT 68%/32% vs 67%/33% RITT 56%/44% vs 54%/46% ç°£9¤H 100%/0% vs 100%/0%
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/1 ¤U¤È 02:46:57²Ä 4628 ½g¦^À³ ¸¤H¤j¡A
Dupilumab¤ÎLebrikizumab 2/3´ÁÁ{§É¬Ò¥¼ç°£«D¶Ç²Î¤¤-««×AD±w¡A Ó¤H²qASLAN004 2b¡A¤£·|¥Î¥Íª«¼Ð»x¨Ó±Æ°£¡C
©ñ¤j¨ì3´ÁN=200:200¡A§ó¤£·|±Æ°£¡C
¤]³\16¶g·|¹FEASI75¡A©M¹ï·Ó¤@¼Ë¡A ¦b8¶gEASI50=66%¡P
II«¬ Recepter M0AªºªvÀø¦P¹ï·Ó组¡Adupilumab¤]¹J¦P¼Ë°ÝÃD¡CLebrikizumab,Tralo ¬Ò¤@¼Ë¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 11:31:13
²Ä 142 ½g¦^À³
|
¿Ë·Rª©¥D:
½Ð§ó§ï¥»ª©ª©ÀY¤º¤å,¦p¤U:
¤@.¤¤-««×AD¥«³õ : 2029¦~¥þ²y¦ô240»õ¬ü¤¸(¬ü°ê72%/¼Ú¬w25%/¤é¥»3%)
Dupilumab ¾P°â°ªÂI;±N¹F120»õ¬ü¤¸.(2021¦~¤w¾P30¸U¤H,60¦hÓ°ê®a,¤µ¦~¦ô¾P56»õ¬ü¤¸)
¬ü°ê«D¨ü±±AD,¦¨¤H170¸U,¨ä¥L50¸U¤H.
¤G.2021/09/27 1b ¸Ñª¼
1. ¤½§G1b·§©À©ÊÁ{§É¦¨¥\.½T»{MOA. ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
³oºØ¼Æ¾Ú¦b¤H¼Æ©ñ¤j¨ì¤T´ÁÁ{§É 400¤H(200:200) , P¡Õ0.000001 ,¤T´ÁÁ{§É¹êÅç²Õ°ª¹ï·Ó²Õ66%¡Ap<0.05´N¹LÃö¡C
---¬Ý§¹MOA¼v¤ù,¤@³q¥|Ãĺɳq! ªø§ë°ò¥»¥\.
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
Dupilumab MOA -¼v¤ù www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
2b Á{§É³]p¥XÄl:
Á{§É¤À¤²Õ¦@¦¬300¤H*16¶gªvÀø,2021Q4¶}©l©Û¶Ò
(1).300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg),9¦¸, ¦Xp3300mg (2).400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg),9¦¸, ¦Xp4000mg (3).400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg),6¦¸, ¦Xp3000mg (4).600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg),6¦¸ ¦Xp3600mg (5).¹ï·Ó²Õ
2¡B¥i±æ¦P¯Å³Ì¨ÎÀø®Ä¤Î³Ì¨Î¦w¥þ©Ê
Dupilumab»PASLAN004 ¯à¦P®ÉªýÂ_IL-4©MIL-13ªº°T¸¹¶Ç¾É ----------------------------------------------------------- ¨ä¥LÃĪ«¨Ò¦plebrikizumab©Mtralokinumabµ¥¥u¯àªýÂ_IL-13¤Î³¡¥÷IL4°T¸¹¶Ç¾É
³Ì¨Î: Àø®ÄIGA 0/1/EASI 75/EASI50 ,¥ÎÃÄÀW²v¥i±æ4¶g¤@°w,³Ì¦w¥þ(Dupilumab ªñ40%µ²½¤ª¢³ø§i)
Àø®Ä¹w¦ô
(1b ,n=16-RITT/REEPP,¤¤Â_²v6.3%, IGA4=48%,ITT¼ÒÀÀ)
ASLAN004 ¦ô2b/P3 VS Dupilumab ¤T´Á
EASI50 94% VS 65% EASI75 75% VS 50% EASI90 62% VS 36% IGA 0,1 64% VS 38%
¤T¡BÁ`Ävª§¤O:
¦³¼ç¤O°ª¤@Ó¶q¯ÅªºÀø®Ä, ¥Dn¡«á«ü¼Ð,¬Û¹ï©óDupilumab EASI75, 150%(75%/50%) IGA0,1 , 168%(64%/38%) ,
°ò½uEASI 29~41 ªºAD¥«³õ¥D®_.
¥B°Æ§@¥Î§C.¥|¶g¤@°wªº¼ç¤O
¥|¡B¹w¦ô·m¤U Dupilumab ¤@¥b,p60»õ¬ü¤¸II«¬ª¢¯g¥«³õ
www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/investors/20200611_Dupixent_call_FINAL.pdf?la=en&hash=D80AF8E4B5DA6A9A9ED74F9E34B03251
ÁÉ¿Õµá 2020/06/11 Dupilumab 100»õ¼Ú¤¸(120»õ¬ü¤¸) ¶}µop¹º
¬ü°êDupilumap ¥Ø¼Ð«È¤á---II«¬ª¢¯g(µLªk±±¨î)¥«³õ, ¬ù400¸U¤H¡C
¤¡B°ê»Ú¼Ð¹vªvÀø ¤¤-««×²§¦ì©Ê¥Öª¢AD¤§±ÂÅv¤Î¨ÖÁÊ:
1.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë) ²Ä¤@ÓÂê©wIL13 °tÅé¤À§OªýÂ_»PIL13¨üÅé¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤ÎªýÂ_¨üÅé£\2¦¸³æ¦ì (¥çºÙ¬°IL-13R£\2) µ²¦X¡A ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.1 , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
3.2019/05/31 , CSL»P¨È·à2014¦~°_¦@¦P¶}µo,§Q¼í¦U¥b. 1a °µ§¹ CSL ¨È·à¦@¦P±ÂÅvASLAN004 ¥þ²yµo®i/¥Í²£/°Ó·~¤Æµ¹ ¨È·à±d, (±ÂÅvª÷=(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)*2=7.8*2»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)*2 ¦U±o¤@¥b.
¨È·à¶RÂ_»ù =±ÂÅvª÷(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)=7.8»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)
4.2020/¤¸¤ë ,§¨Ó¨ÖÁÊDermira ¤½¥q/Lebrikizumab
§é²{»ùÈ 29»õ¬ü¤¸.
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 29»õ¬ü¤¸,
----------------
¤».资°T¤£¹ïºÙ»ùÈ
¬üªÑ¥«©|¥¼¤ÏÀ³ 1.¨È狮»PCSL¦@¦P¶}µoASLAN004¨ì1aÁ{§É§¹¦¨ªº§Q¯q¡C 2019/05/31¤w¸g°ê»Ú±ÂÅv¡A¨È·à©Ò±o§Q¯q¦ô§é现È10»õ¬ü¤¸¡C¥tCSL¥ç±o10»õ¬ü¤¸ªº¼ç¦b§Q¯q¡A¦@20»õ¬ü¤¸¡C ñ约°ò¦¡A°Ñ¦Ò°ê»Ú¦P级¦X¬ù¡A¦ô³Ì°ª销°â30»õ¬ü¤¸¡C (·í®ÉDupilumab ¥«³õ»{¦P¥¼¨Ó³Ì°ª¥i销50»õ¬ü¤¸)
2.2020¦~¤¸¤ë ¦PMOAªºLebrikizumab¨ÖÁʧé²{»ùÈ 29»õ¬ü¤¸. 2020/01 §¨Ó¨ÖÁÊDermira ¤½¥q
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 11»õ¬ü¤¸+18»õ¬ü¤¸=29»õ¬ü¤¸,
3.2020/7/13
a.¦]Dupilumab ¥«³õ»{¦P°ª¾P°âÃB´£¤É¨ì120»õ¬ü¤¸¡C ASLAN004ÀH¥«³õÂX¤j¡A¥¼¨Ó·s°ê»Ú±ÂÅvÈ¨Ì¾Ú ³Ì°ª¾P°â¦ô¥i¹F60»õ¬ü¤¸
b¡D2020¦~¤¸¤ë§¨Ó¨ÖDermiraªº§é现»ù¡A¤w¹F29»õ¬ü¤¸¡C
LebriKiulmabªº¤T´Áý³Ý¡A2017¦~¸Ñª¼¥¢±Ñ¡CªÍ³¡C0PD¥ç¥¢±Ñ¡C
C¡D¨È·à«O¦³¦Pdupilumab ¸ô®|, ý³Ý/ªÍ³¡COPD/EOE.... ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X -------------------------------------------------- ¤C.¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù:
11/50*120*2=52.8»õ¬ü¤¸(¨È·à¿W±o)
Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*2021¦~dupilumab 120»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2022¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 09:45:15
²Ä 141 ½g¦^À³
|
CAN PEOPLE HAVE MORE THAN ONE TYPE 2 INFLAMMATORY DISEASE? It is not uncommon for people to have two or more type 2 inflammatory diseases, with different levels of severity. When a person has multiple coexisting type 2 inflammatory diseases, management is even more challenging. ¤H¥i¥H¶W¹L¤@Ó 2«¬ª¢¯g©Ê¯e¯f¡H ¤H֦̾³¨âºØ¥H¤WªºÃþ«¬¨Ã¤£¤Ö¨£ 2ºØª¢¯g©Ê¯e¯f¡AÄY«µ{«×¤£¦P¡C ¤@Ó¤H±w¦³¦hºØ¨Ã¦sªº2«¬ª¢¯g ¯e¯f¡AºÞ²z´N§ó¨ã¬D¾Ô©Ê¡C Up to 35% of people with asthma also have AD and up to 50% of those with AD have asthma
¦h¹F35¢Hªº¤H ÁÙ¦³ý³Ý ¦³AD¡Aª½¨ì ¦³50¢Hªº¤H AD¦³ ý³Ý
About 17% of people with CRSwNP also have AD and around 13% of those with AD have CRSwNP14,15
¬ù17¢H »P CRSwNP¤]¦³ AD©M ¤j¬ù13¢H ¨º¨Ç±w¦³ADªº¤H ¦³CRSwNP14,15
Around 50% of people with CRSwNP also have as thma and up to 45% of those with severe as thma have CRSwNP13,16
¤j¬ù50¢H ªº¤H CRSwNP¤]¦³ ý³Ý¤Î ¦³45¢Hªº¤H ÄY«ý³Ý¦³ CRSwNP
www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/about-us/5-TYNTK-TYPE-2-INFLAMMATION-EN_APPROVED.pdf ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/1 ¤W¤È 09:15:44²Ä 4619 ½g¦^À³ www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf
Dupilumab ¼ÐÅÒÀÉ,
nªø§ëªÌ½Ð¦n¦n¬ã¨s©Ò.
p.20 ¦³ ¤T´Á¤¤-««×Á{ADªºIGA0,1 ®É¶¡ÁͶչÏ
DUPILUMAB 300mg q2w*16¶g SOLO1 ²Ä8¶g25%,²Ä16¶g40% SOLO2 ²Ä8¶g25%,²Ä16¶g36%
(©MLebrikizumab 2b ®t¤£¦h)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
¦³x®É¶¡§Ç¦C,ªº¦U«ü¼ÐyÁÍ¶Õ ¹Ï,
0/4/8/12/16 ¶g. ¥idownload ÀÉ®×¥h¬Ý
Lebrikizumab 2b , Q2W*250MG ,
IGA 0,1 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.6%
EASI50 ²Ä8¶g¦b¬ù70%,²Ä16¶g81.0%
EASI75 ²Ä8¶g¦b¬ù44%,²Ä16¶g60.6%
EASI90 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.0%
-------------------------
2¶g¤@°wvs ¤@¶g°wªºEASIÁͶչÏ(Dupilumab 2Ó¤T´ÁÁ{§É)
3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020
--------------------------------------
·sÃħë¸ê«e´Á³Ì«nªºMOA!
·sÃħë¸ê«e´Á³Ì«nªºMOA!
·sÃħë¸ê«e´Á³Ì«nªºMOA!
ASLAN004ªºMOA ¦¦b2013 DUPILUMAB MOA ½T»{®É¤w³Q½T»{.
Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
¤Wz°Êµe¤w¥æ¥NASLAN004 IL13R ªº¥\¥Î¦PIL4R. ¥Î§ÜÅé«Ê¦í¨ä¤¤¥ô¤@Ó¬Ò¦P®É¥iªýÂ_IL4/IL13°T®§¶Ç»¼.
9/27 ¹êÅç²Õ¶È22Ó±wªÌ¸ê®Æ
¤¤Â_ 3¤H,«D¶Ç²ÎAD 6¤H, ¦Xp9¤H, ¼vÅT9/22=41%ªºÂ¡«áÀø®ÄEASI75/EASI90/IGA0,1 ¬Ò³Q¼vÅT.
¦A¨Ó¬Ý2b/p3
¤jÃļtnªº¸ê®Æ¤w¨¬°÷,¤U¨Mµ¦¨ÖÁʤF, ¦]¬°§Ú̦³¦ì¦n¦Ñ®vDupilumab/Lebrikizumab/Tralokinumab ¦b«e¤Þ¸ô.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/1 ¤W¤È 08:45:09²Ä 4618 ½g¦^À³ 1.CNTB ¬O¥t¤@ÓDupilumab ,¦b¬ü°ên¤W¥««Ü§xÃø,¥²±Á{±M§QÅv©x¥q,REGN ©x¥q¥²¥´. ª½¨ì2030¦~dupiiumab ¬ü°ê·sÃĤW¥«±M§Q12¦~¨ì´Á.
2.CNTB ¤ÎRAPT 1b ¬Ò¥Î°ò½u¥§¡EASI21~23,¦bÅã¥Ü¦nÀø®Ä.¬°¶Ò¸ê¤è«K.
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/9/16 ¤W¤È 10:06:22²Ä 4461 ½g¦^À³
RPT193 ªÑ»ùVS 1bÁ{§É³ø俈
www.marketwatch.com/investing/stock/rapt?mod=mw_quote_recentlyviewed 2021/06/14 µo§GRPT193 ¤fªAÃÄ 1b ADÁ{§É³ø§i»|(N=31 21/10), ªÑ»ù¤@¤Ñº¦120%(18~40),¥«È¥Ø«e11»õ¬ü¤¸. 37.5¬ü¤¸/ªÑ,¬ü°ê¤ÀªR®v¥Ø¼Ð»ù56¬ü¤¸(¥«È16.5»õ¬ü¤¸).
investors.rapt.com/static-files/32402320-09d1-43d2-9ef1-0dbd73d260b3
°ò½uBaseline Characteristics
PLACED//RPT193
EASI, Mean (Range) 21.07 (13.6-45.5) //18.49 (12-30) BSA, Mean (Range) 24.5 (10-61)// 23.3 (11-55) vIGA 3, n (%) 8 (80.0%)// 18 (85.7%) Peak NRS, Mean (Range)7.3 (3-10)// 6.9 (3-10) Peak NRS ≥4, n (%) 9 (90.0%)// 20 (95.2%)
Topline data from a placebo-controlled double-blinded Phase 1b trial examining 400 mg oral RPT193 as monotherapy for 4 weeks in 31 patients with moderate-to-severe atopic dermatitis* ¡V Efficacy: RPT193 demonstrates clear improvement over placebo on all key exploratory endpoints o At Day 29: EASI [36.3% vs. 17.0%], EASI-50 [42.9% vs. 10.0%], vIGA 0/1 [4.8% vs. 0.0%], and pruritis NRS-4 [45.0% vs. 22.2%] o Further improvement observed during the 2-week follow up period to Day 43: EASI [53.2% vs. 9.6%]†, EASI-50 [61.9% vs. 20.0%]†, and vIGA 0/1 [14.3% vs. 0.0%] ¡V Safety: Overall safety profile to date suggests a well-tolerated oral drug that would not require laboratory safety monitoring o No SAEs reported; all AEs reported were mild or moderate in intensity The clear clinical benefit combined with the favorable safety profile and oral convenience would support positioning ahead of approved and late-stage therapies A 16-week Phase 2b dose-ranging study in patients with moderate-to-severe AD will be initiated ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/1 ¤W¤È 08:34:21²Ä 4617 ½g¦^À³ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/4/7 ¤U¤È 08:02:41²Ä 4060 ½g¦^À³ www.connectbiopharm.com.cn/Templates/default/Common/images/EADV-2020-e-Poster-P0269-CBP201-AU002-FINAL-19-10-2020.pdf
CBP-201 1b 31¤HªºÁ{§É¸Ô²Ó¸ê®ÆÀÉ
baseline °ò缐¸ê®Æ¦p¤U
150mg//300mg///¹ï·Ó²Õ
1.EASI ¥§¡ 20.68//23.21///33.36( ¹êÅç²Õ¬O¹ï·Ó²Õªº69%,ASLAN004 1b¤Î Dupilumab ±µªñ33¥ª¥k)
2.IGA 0.1=4¤§¤ñ²v 0%//28.6%///25% (Dupilumab =50%¥ª¥k
µ²½× : ¨Ì°ò缐¦Ó¨¥¡ACBP-201 ¬O¤j¦hIGA0.1 =3ªº¤¤«×¤§¯gª¬¬°¥D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 07:06:04
²Ä 140 ½g¦^À³
|
Beck et al (2014) N Engl J Med 2014;371:130-9
3 Hamilton et al (2019), 49th Annual ESDR Meeting Sep 18-21, 2019 P.14//9/27
Dupilumab 2Ó°O¿ý Serum ¥Íª««ü¼Ð¡A½×¤å¡A¨Ó¥Õ1b/2a/p3Á{§É¡C
³Ì°ª6000¦hpg/ml
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 06:54:46
²Ä 139 ½g¦^À³
|
P.14 ,9/27¸Ñª¼³ø§i Patient history and biomarkers not consistent with typical moderate-to- severe AD patient population: • All patients1 at Site X had TARC levels below 1,200 pg/ml • 89% of patients at Site X had no allergic co-morbidities (compared to 13% at other sites) • Baseline eosinophil levels at Site X around an order of magnitude lower than other sites and other comparable AD studies ªÌ¯f¥v©M¥Íª«¼Ð»xª«¤£»P¨å«¬ªº¤¤¦Ü ««× AD ±wªÌ¤H¸s¬Û¦P¡G
• ¯¸ÂI X ªº©Ò¦³±wªÌ 1 ³£¦³ TARC(¥Íª«¼Ð»x) ¤ô¥ §C©ó 1,200 pg/ml(Dupiluman °ª4000-5000pg/ml) ¦³2ӽפå¨Ó·½¦bp.14 • ¯¸ÂI X 89% ªº±wªÌ¨S¦³ ¹L±Ó©Ê¦X¨Ö¯g¡]»P13% ¦b¨ä¥L¦¬®×¤¤¤ß¡^ • ¯¸ÂI X ªº°ò½u¶Ý»Ä©Ê²É²ÓM¤ô¥ ¤j¬ù§C¤@Ӽƶq¯Å ¤ñ¨ä¥L¦¬®×¤¤¤ß©M¨ä¥L¥i¤ñAD¬ã¨s ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/1 ¤W¤È 06:25:19²Ä 4610 ½g¦^À³ ¦³¥Íª«¼Ð»x¤@¤Á¦n¿ì¨Æ¡I ³o¤~¬O¬ì¾Ç¡I
¦X¤@ªºFB825¾Ú¤½¥qºÙ¡A¤w§ä¥X¥Íª«¼Ð»x(¤£¬O²Ä¤@¥NªºIGg)¡A ¥i´£¤ÉÀø®Ä¡A¥u¬OnÄ묹¤@¨Ç«D¥Íª«¼Ð»xªº¥«³õ¡C
ç°£9¤Hx¦¬®×¤¤¤ß¡A«D¶Ç²Î¤¤-««×AD±wªÌ
89% (8/9)µLADªº¨ä¥L¨Öµo¯g¡A¦pµLýºÝ¡BEOE¡K¡K¡K¡K ¦ý¨ä¥L¦¬®×¤¤¤ß¦¹Ãþ¤ñ²v¶È13%¡C¡A¤@¯ëII«¬ª¢¯g¤¤-««×±w¯f20¦h¦~¡A¤@¯ë¦³AD´N·|¦³°ª¤ñ²vªº¦pý³Ý¡BEOE¡B¡K¡Kµ¥¨Öµo¯g¡ADupilumab ¤x¥X¹L³ø§i¡C
¥Íª«¼Ð»xª«¥ç¿@«×«D±`§C1200³æ¦ì¡A ASLAN004¨ä¥L¦¬®×¤¤¤ß¤ÎDupilumab¦b4000-5000³æ¦ì
¥H¤W¨Ó¦Û9/27¸Ñª¼³ø§i¡A ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K 1.¤w¸g¦³Dupiluman/Lebrikizum/Taol¤T¤jÃÄ©MASLAN004 ¦P¾÷Âà(M0A)¡A¥L̤]¹J¦¹°ÝÃD¡ADupilumab¯d¤U¦U¶¥Á{§Éªº测ÅçÈ¡C 2.¬Ý°_¨Ó«D¶Ç²ÎAD¯f±w¤ñ²v¡A¤j约13%-15%¥ª¥k¡A¦³2/3¡«á¥i¹FEASI 50,¹ï·ÓEASI901/3, ¦]¦¹¬ì¾Ç©eû·|¨Sç°£¨ä¥L13%«D¶Ç统AD±wªÌ¡C
结½×¡Adupilumab¦¨¥\ªº¸ô径´N¬OASLAN004ªº¸ô¡C
¤j®a¹J¨ìªº°ÝÃD³£¤@¼Ë¡A§O¤HY¤£ºÞ¥L¡A©ñ¤j¦¬®×¤H¼Æ¡A¦ÛµM¸Ñ¨M¡C
¤]³\«D¶Ç²Î¤¤-««×ADªº¤ñ²vªñ15%¡A ³o¬O¡«á«ü¼ÐEASI50©MEASI75ªº®t²§«¤j¦]¯À Dupilumab ¤T´Á EASI50=65% EASI75=50%¡P
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/30 ¤U¤È 09:53:40
²Ä 138 ½g¦^À³
|
ÁÙ¦n¡A¸êª÷¥ý®³¨ì¤â¤F ¤£µM³oªÑ»ù...ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 09:45:18
²Ä 137 ½g¦^À³
|
¥»¨Ó¥Î¨Ó¥[¤Àªº»´¤¤¯gAD(°ò½uEASI19),Åܦ¨ITT t¤À-----¹B®ð¯uªº¤£¦n.
¼ÒÀÀITT ----¦pªG¬O6¤HÅܬ°¶Ç²ÎAD-»´¤¤¯g(°ò½uEASI 19 ¥H¤U ) ,ASLAN004 600mg ²Õ,
¦pªG¬O¶Ç²ÎAD-»´¤¤¯g EASI 19 ¥H¤UASLAN004¯à¤O
600mg²Õ 22¤H(¥]§t3¤H¤¤Â_)---¼ÒÀÀITT EASI50 86%(2+17/22) EASI75 77%(6+11/22) EASI90 54%(6+6/22) IGA 0,1 59%(6¡Ï7/22)
¥§¡EASI°´T72%
-----------------------------------
¦pªG¬O¶Ç²ÎAD-»´¤¤¯g EASI 19 ¥H¤U
ASLAN004¯à¤O
600mg²Õ 6¤H IGA 0,1 100%(6/6) EASI50 100%(6/6) EASI75 100%(6/6) EASI90 100%(6/6) ¥§¡EASI°´T90%
¥»¨Ó¥Î¨Ó¥[¤Àªº»´¤¤¯g,Åܦ¨ITTt¤À-----¹B®ð¯uªº¤£¦n.
---------------------------- ³Qç°£«D¶Ç²ÎAD 9¤H¡«á«ü¼Ð
(°ò½u¥§¡EASI 19.9 vs 18.2 ,IGA3)
600mg²Õ 6¤H IGA 0,1 0%(0/6) EASI50 67%(4/6) EASI75 0%(0/6) EASI90 0%(0/6) ¥§¡EASI°´T50%
¹ï·Ó²Õ 3¤H IGA 0,1 0%(0/3) EASI50 67%(2/3) EASI75 0%(0/3) EASI90 33%(1/3) ¥§¡EASI°´T54%
---------------------------------------------------------- ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ (°ò½u¥§¡EASI 19.9 vs 18.2 ,IGA3)
³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
°ò½uEASI:
600mg vs ¹ï·Ó²Õ ITT 27.6 vs 29 RITT 30.5 vs 31.5 ç°£9¤H 19.9 vs 18.2
°ò½uIGA3/IGA4
ITT 68%/32% vs 67%/33% RITT 56%/44% vs 54%/46% ç°£9¤H 100%/0% vs 100%/0%
µ²½×: ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
³Qç°£9¤H.
°ò½u¥§¡EASI 19.9 vs 18.2
°ò½u100%¬Ò¬OIGA 3
P.15
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 05:23:07
²Ä 136 ½g¦^À³
|
BTD (¬ð¯}©ÊÀøªk): FDA °w¹ï°µ§¹¤G´ÁÁ{§É«á¼Æ¾Ú¼f¬d«á©Òµo¤§µý©ú, ¥iÁY´î¨ú±oÃĵý¤§®É¶¡¬°¥b¦~¤º.(¤@¯ë¬°12Ó¤ë)¤Îºu°Ê¦¡¼f¬d,¥Ó½ÐÃĵý¶O¥Î¤§´î§K.
«D±`¤£®e©ö¨ú±o.(¨ãÆ[¹î¤@¯ënÀu©ó²{¦³Àøªk3¿¥H¤W¤§Àø®Ä)
ASLAN004 600mg, ¤ñ¨ú±o¤G±iBTD(AD+EOE) ªºDupilumab §ó°ª¤@µ¥¯Åªº¤¤-««×AD¹w¦ôÀø®Ä, ¬Û¦P¯àªýIL4/IL13°T®§¶Ç»¼ ªºMOA,°Æ§@¥Î§ó§C(Dupilumab 40%µ²½¤ª¢),§ó¦w¥þ,¥|¶g¤@¦¸µ¹ÃĪº¥i¯à.
------------------------------------- ¼ÒÀÀASLAN004 2b,P3, ITT¡A¡«á«ü¼Ð¦p¤U
ASLAN004 EASI75= 75% vs dupilumab(¤T´Á) 50% ASLAN004 EASI90= 62% vs dupilumab(¤T´Á) 36% ASLAN004 IGA0,1= 64% vs dupilumab(¤T´Á) 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô
----------------------------------------------- ¥«³õ : Dupilumab ¤w¬ã¨s²M·¡II«¬ª¢¯g,¬ü°ê«D¨ü±±420¸U¤Hªº¦hºØ¾AÀ³¯g(AD 220¸U//ý³Ý95¸U//¨ä¥L) Dupilumab ¥Ø¼Ð:120»õ¬ü¤¸³Ì°ª¾P°â.
ASLAN004 ¦ô»´©ö¨ú±o¤@¥bªº¥Ø¼Ð¥«³õ----60»õ¬ü¤¸
2¦~¤º³Q¨ÖÁÊ»ùȦô60»õ¬ü¤¸.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 04:47:25
²Ä 135 ½g¦^À³
|
³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ (°ò½u¥§¡EASI 19.9 vs 18.2IGA3)
³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
°ò½uEASI:
600mg vs ¹ï·Ó²Õ ITT 27.6 vs 29 RITT 30.5 vs 31.5 ç°£9¤H 19.9 vs 18.2
°ò½uIGA3/IGA4
ITT 68%/32% vs 67%/33% RITT 56%/44% vs 54%/46% ç°£9¤H 100%/0% vs 100%/0%
µ²½×: ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
³Qç°£9¤H.
°ò½u¥§¡EASI 19.9 vs 18.2
°ò½u100%¬Ò¬OIGA 3
P.15
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
---------------------------
¼vÅTIGA0.1/EASI90, PÈ¥¼¹LÃö 4ì¦]
. ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/9/30 ¤W¤È 09:27:29²Ä 4584 ½g¦^À³ Yang ¤j¡A
1.EASI 90 ¡Aªí¥Ü±q°ò½uªvÀø¶}©l´î¤Ö90%ªºªí±¬õ¸~¡K¡KAD¯g¡Aª¬¡A³o»Ý®É¶¡¡A¨Ì¾ÚLebrikizumab 8¶g¥i¤ÏÀ³¤j约30%, 9-16¶g¡A¥t¥~¤W¤É15%¨ì45%¥ª¥k¡C(¦pªþ¥ó)
IGA0.1¦P¼Ë¡C
2.¨ü¤¤Â_²v19%.¼vÅT¡ADupilunab 3´Á220¤H¤¤断²v¶È7%.
3.ç°£9¤H¡A·íµM¦³¼vÅT¡A ITT22¤H 600mg¹êÅç组¡A§t6¦ì »´¤¤«×«D¶Ç²ÎAD±wªÌ¡AEASI90/IGA0/1¬Ò¥¼¹F¼Ð¡B ç°£«á6¦ì¹êÅç组«D¶Ç²ÎAD¡AIGA0/1±q27%¤É44%.
4.PÈ ,·í¦P¤ñ²v®É,·|ÀH¤H¼Æ¼W¥[¦Ó´î¤Ö.
¦pRITT
N=16:13 IGA0.1 ASLAN004 44%(N=16) VS ¹ï·Ó²Õ15%(N=13),P=0.107(¤£¹LÃö)
·íN=60:60---(2b ¤H¼Æ) IGA0.1 ASLAN004 44%(N=60) VS ¹ï·Ó²Õ15%(N=60),P=0.0005(¹LÃö)
¹êÅç¤H¼Æ¼vÅT¥ç«Ü¤j
©ñ¤j¨ì¤T´Á, N=200 : 200 ,p§ó¤p,
PÈ·U¤p,ªí¥Ü¨â²Õ¸ê®Æ©úÅã®t²§¾÷²v·U°ª
--------------------------- ªþ¥ó
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
¦³x®É¶¡§Ç¦C,ªº¦U«ü¼ÐyÁÍ¶Õ ¹Ï,
0/4/8/12/16 ¶g. ¥idownload ÀÉ®×¥h¬Ý
Lebrikizumab 2b , Q2W*250MG ,
IGA 0,1 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.6%
EASI50 ²Ä8¶g¦b¬ù70%,²Ä16¶g81.0%
EASI75 ²Ä8¶g¦b¬ù44%,²Ä16¶g60.6%
EASI90 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.0%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 04:36:32
²Ä 134 ½g¦^À³
|
´Á¥¼PK ´Á¤¤ (¦P¬°EEPP:ç°£¤¤Â_¤H¼Æ, 9/27ç°£«D¶Ç²ÎAD ±wªÌ¤§¤ñ¸û)
9/27 ASLAN004 600mg²Õ ,¨Ï¥ÎRITT+EEPP«á ,N=13¤H EASI 50= 100%(RITT-EEPP)(¤À¥À¦©°£3¦W--(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)¤Îç°£«D¶Ç²ÎAD 6¤H) EASI 75= 85%(RITT-EEPP) EASI 90= 46%(RITT-EEPP) IGA 0,1= 54%(RITT-EEPP)
°ò½u:IGA3/IGA4=56%/44% --------------------------- 3/1, ´Á¤¤600mg+400mg (N=3+6=9¤H)¼Æ¦r ,EEPP
EASI 50= 89%(EEPP)(¤£¥]§t¥¼§¹¦¨29¤ÑªvÀø/µû¦ô//¤£§t¤¤Â_±wªÌ) EASI 75=67%(EEPP) EASI 90=56%(EEPP) IGA 0,1=22%(EEPP)
°ò½u:IGA3/IGA4=67%/33%
ir.aslanpharma.com/static-files/327571f4-2df1-48b6-b922-f7cc2633882f |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤U¤È 12:36:36
²Ä 133 ½g¦^À³
|
×¥¿¤@.³Ì·s±À¦ô
1¡BLebrikizumab AD2b Á{§É¡A60.6%/71%=85.3%(2b¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F85.3%¡A °ò½uIGA4ªÌ¡A¡«á¹FEASI75=¦ô0%
2.dupilumab 3´ÁÁ{§É 50%/52%=96%(p3¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F96%¡A °ò½uIGA4ªÌ¡A¡«á¹FEASI75=¦ô0% (ªvÀø«á没¤H¥i¹FEASI75)
------- 3.ASLAN004 2b/P3 300mg *Q2W*16¶g(ITT)
IGA4 =48%, IGA3=52%,(°ò½u)
¡«áEASI75=75%
¡«á(EASI75 75%/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¥i¨Ï°ò½uIGA3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F100%¡A
°ò½uIGA¡A0/1=4ªÌ¡A¡«á¹FEASI75=23%/48%=48%, ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½uIGA4««×AD±wªÌ¡A¡«áEASI75 ¥i¹F48%¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/29 ¤U¤È 12:03:27
²Ä 132 ½g¦^À³
|
¼ÒÀÀASLAN004 2b,P3, ITT¡A¡«á«ü¼Ð¦p¤U
ASLAN004 EASI75= 75% vs dupilumab(¤T´Á) 50% ASLAN004 EASI90= 62% vs dupilumab 36% ASLAN004 IGA0,1= 64% vs dupilumab 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô
1.¨ÌRITT¬°°ò¦,¤¤断²v¥»¬°3/16=19%,׬°1/16=6.3%,±µªñDupilumab 3´Áq2w¤¤断²v7%. 2.´£°ª°ò½uIGA 4 ¦Ü48%,쬰44%. ¦PDUPILUMAB ¤T´Á¤ñ²v
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/8/19 ¤W¤È 09:58:38
²Ä 131 ½g¦^À³
|
1¡BLebrikizumab AD2b Á{§É¡A60.6%/71%=85.3%(2b¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F85.3%¡A °ò½uIGA¡A0/1=4ªÌ¡A¡«á¹FEASI75=¦ô0%
2.dupilumab 3´ÁÁ{§É 50%/52%=96%(p3¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F96%¡A °ò½uIGA¡A0/1=4ªÌ¡A¡«á¹FEASI75=¦ô0%
3.ASLAN004 1b 600mg ,67%/33%=200%(1b¡«áEASI75¤ñ/°ò½uIGA3¤ñ) ¡K¡K¯à¤O±À¦ô¶È¥i¨Ï°ò½u¤uGA,0/1=3¸û»´¯gªº±wªÌ¡A¡«áEASI75 ¥i¹F100%¡A °ò½uIGA¡A0/1=4ªÌ¡A¡«á¹FEASI75=50%(1/2)(¼Æ¾Ú¤Ö¡A«Ý©¹«áÁ{§É¦LÃÒ) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/8/19 ¤W¤È 07:04:06
²Ä 130 ½g¦^À³
|
¨Ì¾ÚLebrikizumab ¤T´Á¹êÅç组EASI75=50% ±À¦ô¨ä°ò½uIGA¡A0/1 =4¤Î3¡A¦¬®×¤ñ²v¤À§O¬° 41%/59%.
Lebrikizumab 2b °ò½u IGA¡A0/1=3¦³71%, ¡«áEASI75=60.6%
60.6%/71%=85.3%(2b¡«á¤ñ/°ò½uIGA3¤ñ)
50%/85.3%=59%(±À¦ô¤T´Á°ò½uIGA¡A0/1=3©Û¶Ò¤ñ²v¬°59%)
¡K¡K¡K¡K¡K¡K¡K¡K Lebrikizumab ,2bÁ{§É ¡«áEASI75¹F60.6%¡A °ò½u IGA¡A0/1=4¸ûÄY«ªº¯f¤H¤ñ²v29%. IGA0/1=3,¤ñ²v71%(dupilumab IGA¡A0/1=4/3 ¡G49%/51%) EASI¥§¡25.5(Dupilumap 32) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/8/19 ¤W¤È 06:51:41
²Ä 129 ½g¦^À³
|
¨Ì¾ÚLebrikizumab ¤T´Á¹êÅç组EASI75=50% ±À¦ô¨ä°ò½uIGA¡A0/1 =4¤Î3¡A¦¬®×¤ñ²v¤À§O¬° 41%/59%.
Lebrikizumab 2b °ò½u IGA¡A0/1=3¦³71%, ¡«áEASI75=60.6%
60.6%/71%=85.3%(2b¡«á¤ñ/°ò½uIGA3¤ñ)
50%/85.3%=59%(±À¦ô¤T´Á°ò½uIGA¡A0/1=3©Û¶Ò¤ñ²v¬°59%)
¡K¡K¡K¡K¡K¡K¡K¡K Lebrikizumab ,2bÁ{§É ¡«áEASI75¹F60.6%¡A °ò½u IGA¡A0/1=4¸ûÄY«ªº¯f¤H¤ñ²v29%. IGA0/1=3,¤ñ²v71%(dupilumab IGA¡A0/1=4/3 ¡G49%/51%) EASI¥§¡25.5(Dupilumap 32) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/8/18 ¤U¤È 10:45:23
²Ä 128 ½g¦^À³
|
Lebrikizumab ,2bÁ{§É ¡«áEASI75¹F60.6%¡A °ò½u IGA¡A0/1=4¸ûÄY«ªº¯f¤H¤ñ²v29%. IGA0/1=3,¤ñ²v71%(dupilumab IGA¡A0/1=4/3 ¡G49%/51%) EASI¥§¡25.5(Dupilumap 32) ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K §¨Ó¤½§GLebrikizumab ¡B¤¤-««×AD¡A 16 ¶g¡A2Ó¤T´ÁÁ{§É(¦U400¤H¡A¦Xp800¤H)¡A¼Æ¾Ú¥¿¦V结ªG¡C
¥Dn«ü¼Ð ¡G (1)IGA¡A0/1¡A¼Æ¾Ú¥¼¤½§G¡C (2)EASI 75¡A¹êÅç组 >50%¡A¹ï·Ó组¡APÈ¥¼¤½§G °ò½u¼Æ¾Ú¥¼¤½§G ©Û¶Ò¹ï¶H12·³-18·³¤Î¦¨¤H¡C
Lilly¡¦s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials August 16, 2021 Download PDF - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company¡¦s (NYSE: LLY) ADvocate 1 and ADvocate 2 Phase 3 clinical trials. In the top-line results from these two studies of lebrikizumab as a monotherapy in AD, primary and all key secondary endpoints, including skin clearance and itch improvement, were met at Week 16. Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. 1-4 The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lebrikizumab for moderate-to-severe AD in adult and adolescent patients (aged 12 to less than 18 years of age and weighing at least 40 kg). Fast Track designation is granted for a medicine that is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.
AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response. People living with AD often report symptoms of intense, persistent itch which can be so uncomfortable that it can affect sleep, daily activities and social relationships. In people with AD, the IL-13 protein¡Xa central pathogenic mediator in the disease¡Xis overexpressed, driving multiple aspects of AD pathophysiology by promoting T-helper type 2 (Th2) cell inflammation and resulting in skin barrier dysfunction, itch, infection and hard, thickened areas of skin.5,6
AD is a heterogenous disease with signs and symptoms varying greatly between patients, underscoring the need for additional treatment options with different mechanisms of action, said Jonathan Silverberg, M.D., Ph.D., M.P.H., associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial. Data from the studies showed lebrikizumab¡¦s effect on skin clearance and its potential to address a key driver for this disease as well as provide improvements in itch, sleep disturbance and quality of life.
ADvocate 1 and ADvocate 2 are ongoing 52-week randomized, double-blind, placebo-controlled, parallel-group, Phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients (aged 12 to less than 18 years of age and weighing at least 40 kg) with moderate-to-severe AD. The primary efficacy endpoints were assessed at 16 weeks in the two studies and were measured by an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline at Week 16 and at least a 75 percent or greater change from baseline in their Eczema Area and Severity Index (EASI) score at Week 16.
Lebrikizumab also achieved key secondary endpoints versus placebo in patients with AD, including early onset in skin clearance and itch relief, improvement in interference of itch on sleep and quality of life. Key secondary endpoints were measured by the IGA, EASI, the Pruritus Numeric Rating Scale, Sleep-Loss due to Pruritus and the Dermatology Life Quality Index.
In the initial 16-week placebo-controlled period of ADvocate 1 and ADvocate 2, the incidence of treatment-emergent adverse events (AEs) and serious AEs among patients treated with lebrikizumab was consistent with that of the previous Phase 2 lebrikizumab study in AD. The most common AEs included conjunctivitis, nasopharyngitis and headache for lebrikizumab-treated patients. Discontinuations due to AEs were similar in the lebrikizumab group (1.4%) compared to placebo (1.7%).
We understand the needs of people in the AD community worldwide and are aware that many are still in need of new treatment options despite available medicines, said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability. Today¡¦s results show that the inhibition of IL-13 cytokine plays a main role in AD treatment, as demonstrated by more than half of the patients achieving at least 75% clearance to total clearance on lebrikizumab monotherapy.
The full study results from ADvocate 1 and ADvocate 2 will be disclosed at future congresses in 2022. Data from a Phase 3 combination study (ADhere) of lebrikizumab with topical corticosteroids in patients with AD will be available later this year. These studies are part of the lebrikizumab Phase 3 program, which consists of five key ongoing, global studies including two monotherapy studies and a combination study as well as long-term extension (ADjoin) and adolescent open label (ADore) trials.
We are excited about the data received from the studies that support lebrikizumab¡¦s potential efficacy in AD and by the prospect of delivering this promising therapy to people living with moderate-to-severe AD in Europe, stated Karl Ziegelbauer, Ph.D., Almirall S.A.¡¦s Chief Scientific Officer.
Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and rest of world outside Europe. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/7/24 ¤U¤È 12:24:21
²Ä 127 ½g¦^À³
|
ASLAN004ªº»ùȳгy¡K¡K
¤½¥q²¤¶¡AP7 ir.aslanpharma.com/static-files/327571f4-2df1-48b6-b922-f7cc2633882f
However, there remains a significant unmet need (¤TÓAD¥«³õ¥¼³Qº¡¨¬ªº»Ý¨D)
1¡V Only 35% of patients treated with dupilumab achieved an optimal response Dupilumab ªvÀø«á¶È35%±o¨ì³Ì¨Î¤ÏÀ³(EASI90%)¡C ¡K¡KASLAN004 ¦ô52%-57%¥i³Ì¨Î¤ÏÀ³¡C ¡K¡KLebrrkiumab ¦ô22%-25%¥i±o³Ì¨Î¤ÏÀ³¡C ¥H¤W°²³]¦PDupilumab¤T´ÁÁ{§É°ò½u¡A¤uGA¡A0/1=4,¤ñ²v48%
2¡V Conjunctivitis common and can lead to treatment discontinuations Dupilumab 结½¤ª¢¤ñ¨Ò30-40% ¤¤Â_ªvÀø:¥Ø«eªvÀø16¶g«á¡AEASI¥¼¹F50ªÌ¡A«OÀI¤½¥q¤£¦A¤ä¥I«áÄò16-52¶gªvÀø费¥Î¡C Dupilumab ¤T´ÁÁ{§É¬ù35%,ªvÀø16¶g«á¥¼¹FEASI 50¡A©M¹ê»Ú¤¤Â_ªvÀøª¬ªp¤ñ²v¬Û²Å¡C
ASLAN004 ²Ä¤@´Á´Á¤¤¤ÀªR¡A600mg, ¡«áEASI50,¹F100%¡B(3/3)¡A
¥¼¨Ó¥i预´ÁASLAN004¡«á«D±`°ª¤ñ²v¥i¹FEASI50. ¦ô85%¥H¤W.
Lebrikibumab ¦ô¡«áEASI50¤ñ²v约55%¡C
3¡V Opportunity to improve on biweekly dosing regimen ¦³§ïµ½DupilumsbÂù¶g¥´¤@针Åܦ¨ASLAN004¥|¶g¤@°wªº¾÷·| |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/6/2 ¤U¤È 06:23:39
²Ä 126 ½g¦^À³
|
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis clinicaltrials.gov/ct2/show/NCT03703102?term=KHK4083+ad&draw=2&rank=1
2b 274¦ì ¤¤-««×ADÁ{§É2020¦~2¤ë¤w°µ§¹¡C
¤T´ÁÁ{§É©|¥¼¶}©l¡C±ÂÅv¨ú±o¥|»õ¬üª÷ªº«eª÷¡A·Ç³Æ°µ¤T´ÁÁ{§É¡C
¥»¦¸±ÂÅv Under the deal, Kyowa Kirin will receive $400 million upfront and potentially as much as $850 million more if certain goals are met. Amgen plans to take charge of development, manufacturing and commercialization activities, except in Japan. Kyowa Kirin will hold co-promotion rights in the U.S. and can opt in to co-promote the product in certain other markets.
®Ú¾Ú¨óij¡A¨ó©MÄQÅï(Kyowa Kinin)±NÀò±o 4 »õ¬ü¤¸ªº¹w¥I´Ú¡A¦pªG¹ê²{¬Y¨Ç¥Ø¼Ð¡A«h¥i¯à¦hÀò±o 8.5 »õ¬ü¤¸¡C ¦w¶ip¹ºt³d°£¤é¥»¥H¥~ªº¶}µo¡B»s³y©M°Ó·~¤Æ¬¡°Ê¡C Kyowa Kirin ±N¦b¬ü°ê¾Ö¦³¦@¦P±À¼sÅv¡A¨Ã¥B¥i¥H¿ï¾Ü¦b¬Y¨Ç¨ä¥L¥«³õ¦@¦P±À¼s¸Ó²£«~¡C
2021¦~2¤ë18«Å§G2´ÁÁ{§É¥¿¦V结ªG µL¸Ô²Ó¸ê®ÆÅã¥Ü¡C
www.businesswire.com/news/home/20210218005535/en/Kyowa-Kirin-Announces-Positive-Phase-2-Results-for-KHK4083-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis Atopic dermatitis is a chronic, pruritic, inflammatory dermatosis that is believed to affect an estimated number of 26M patients in North America, EU, and Japan1 KHK4083, an anti-OX40 fully human monoclonal antibody discovered by Kyowa Kirin, shows a combination of antibody dependent cellular cytotoxicity (ADCC) and antagonist activity against OX40 Kyowa Kirin plans to present the detailed results of the Phase 2 study through future academic conferences or publications February 18, 2021 06:43 AM Eastern Standard Time ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡GROGER588910148151 µoªí®É¶¡:2021/6/2 ¤U¤È 01:29:47²Ä 4224 ½g¦^À³ 2021.6.1 Amgenªá12.5»õ¬ü¤¸±ÂÅvKyowa KirinªºÀã¯lÃĪ«¡Aº¥I4»õ¬ü¤¸²{ª÷¡Cwww.biopharmadive.com/news/amgen-kyowa-autoimmune-drug-deal-ox40/601062 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/15 ¤W¤È 08:00:14
²Ä 125 ½g¦^À³
|
ASLAN004 600mg ²Õ´Á¤¤3¤H¼ÒÀÀ
°ò缐 EASI °²³]//ªv8¶g«áÀø®Ä///¦ô°EASI¤À¼Æ EASI27.5// EASI90 ///27.5x90%=24.8(°ò½uIGA0,1=3)
EASI33//EASI 75///33x75%=24.8(°ò缐IGA 0,1=4) EASI37//EASI 50///37x66%=24.2(°ò½uIGA 0,1=4)
¦Xp°ò½uEASI 97.5// ¥§¡EASI 32.5,///ªvÀø«á ¥§¡° 76% ªºEASI
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 600mg*18¤H ©µ¦ù½ÐÁ{§É, 5¤ë©³¸Ñª¼²q´ú
°²³]°ò½u// ªvÀø8¶g«á¤§EASI°´T
1. EASI24//EASI90 2. EASI25//EASI90 3. EASI26//EASI90 4. EASI27//EASI90 5. EASI28//EASI90 6. EASI29//EASI90 7. EASI30//EASI90 8. EASI31//EASI90 9. EASI32//EASI90
10. EASI33//EASI75 11. EASI34//EASI75 12. EASI35//EASI75 13. EASI36//EASI75
14. EASI37//EASI50 15. EASI38//EASI50 16. EASI39//EASI50 17. EASI40//EASI50
18. EASI41//EASI40(¥¼¹FEASI50) ================================== °ò½u¨ÌDupilumab ¤T´Á¬°¼ÒÀÀ°ò¦, ¤¤¦ì¼Æ/¥§¡ EASI 32.5
EASI 50 =17/18(94.4%)
EASI 75 =13/18(72.2%) ,
EASI 90 =9/18(50.0%)
---°ò½uEASI32 /IGA 0,1=3)¥H¤U¬Ò¥i¹FEASI90= 50% ,Àu©óDupilumab ¤T´ÁEASI90 =36%, Àu¤ñ50%/36%=138% ---EASI75 ASLAN004 72.2% VS Dupilumab¤T´Á 50%, 72.2%/50%=144% ___EASI50 ASLAN004 94.4% VS Dupilumab¤T´Á 69%, 94.4%/69%=137% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/14 ¤U¤È 03:59:40
²Ä 124 ½g¦^À³
|
¦U·sÃĦb¤¤-««×AD³Ì¨ÎªvÀø=IGA0,1=0 or 1¤§¯à¤O¦ôp
Lebrikizumab --×¥¿2
¤T¡BLebrikizumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 2b´ÁÁ{§É
1. IGA 0,1= 0 or 1 = 33/75(44.6%) , ¦ô°ò½u EASI =24.9¤À¥H¤U//«e40.8%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
1.1 20+((25.5-20)*44.6%x2)=24.9¤À
1.2 24.9-20=4.9
4.9/(32-20)=40.8% ,ªí¥Ü«e40.8%ªºIGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¡A¹FIGA 0,10= 0 or 1
¡X¡X¡X¡X¡X¡X¡X¡X °ò½u ¹êÅç²Õ Lebrikizumab 1.1 EASI, median¤¤¦ì¼Æ ¥§¡25.5(°²³] 25.5 ¬°¤¤¦ì¼Æ¡A°_©l20¤À¶}©l)
1.2 IGA 0,1 =4 29.3%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¥|ºØ·sÃĦb¤¤-««×AD³Ì¨ÎªvÀø(IGA0,1=0 or 1)¤§¯à¤O¦ôp
¥|¡BASLAN004 IGA o,1 (400mg ²Õ,²Ä8¶g /QW¨C¶g¤@°w), 1b´Á´Á¤¤Á{§É
¦ô°ò½u EASI =31¤À¥H¤U//«e92%ªºIGA0,1=3ªÌ¦bASLAN004 ªvÀø8¶g«á¥i¹FIGA 0.1,=0 or 1
¤T¡BLebrikizumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 2b´ÁÁ{§É
¦ô°ò½u EASI =24.9¤À¥H¤U//«e40.8%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
¤G¡B Dupilumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 3´ÁÁ{§É
SOLO 1 , ¦ô°ò½u EASI =28.3¤À¥H¤U//«e69%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
¤@¡B Tralokinumab IGA o,1 (²Ä16¶g ), 3´ÁÁ{§É
¦ô°ò½u EASI =23.5¤À¥H¤U//«e29%ªºIGA0,1(EASI20~32)=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1 -----------------------------------------------
Lebrikizumab VS Tralokinumab ¨âªÌMOA¦PªýÂ_IL-13°T¸¹¶Ç»¼,
¸gµý©ú¯à¤OLebrikizumab 40.8% Àu©ó Tralokinumab 29%
¤T¡BLebrikizumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 2b´ÁÁ{§É
¦ô°ò½u EASI =24.9¤À¥H¤U//«e40.8%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
¤@¡B Tralokinumab IGA o,1 (²Ä16¶g ), 3´ÁÁ{§É
¦ô°ò½u EASI =23.5¤À¥H¤U//«e29%ªºIGA0,1(EASI20~32)=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/14 ¤U¤È 02:11:45
²Ä 123 ½g¦^À³
|
¥|ºØ·sÃĦb¤¤-««×AD³Ì¨ÎªvÀø(IGA0,1=0 or 1)¤§¯à¤O¦ôp
¥|¡BASLAN004 IGA o,1 (400mg ²Õ,²Ä8¶g /QW¨C¶g¤@°w), 1b´Á´Á¤¤Á{§É
¦ô°ò½u EASI =31¤À¥H¤U//«e92%ªºIGA0,1=3ªÌ¦bASLAN004 ªvÀø8¶g«á¥i¹FIGA 0.1,=0 or 1
¤T¡BLebrikizumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 2b´ÁÁ{§É
¦ô°ò½u EASI =24¤À¥H¤U//«e33%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
¤G¡B Dupilumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 3´ÁÁ{§É
SOLO 1 , ¦ô°ò½u EASI =28.3¤À¥H¤U//«e69%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
¤@¡B Tralokinumab IGA o,1 (²Ä16¶g ), 3´ÁÁ{§É
¦ô°ò½u EASI =23.5¤À¥H¤U//«e29%ªºIGA0,1(EASI20~32)=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
--------------------------------------------------------------------------- ¦U·sÃĦb¤¤-««×AD³Ì¨ÎªvÀø=IGA0,1=0 or 1¤§¯à¤O¦ôp
¥|¡BASLAN004 IGA o,1 (400mg ²Õ,²Ä8¶g /QW¨C¶g¤@°w), 1b´Á´Á¤¤Á{§É
EASI90=4/6(67%), ¦ôIGA 0,1= 0 or 1 = 4/6(67%) ¦U·sÃÄ16¶gªvÀø«áªºIGA0.1=0 or 1 ªº¤ñ²v¤ñEASI90 °ª¡A¬ùEASI85´N¥i¹FIGA 0,1
1. ¦ô°ò½u EASI =31¤À¥H¤U//«e92%ªºIGA0,1=3ªÌ¦bASLAN004 ªvÀø8¶g«á¥i¹FIGA 0.1,=0 or 1
1.1 400mg °ò缐 N= 6¤H EASI ¥§¡30.9 IGA 0,1=4 ,N=1¤H , IGA0,1=3 ,N=5¤H ¥§¡6¤HEASI=30.9
°²³]IGA 0,1=4 , 1¤H¤§ EASI=35.4 , ¨ä¥LIGA0,1=3 , 5¤H¥§¡EASI=30, ¤À§O°²³]¬°¡]28/29/30/31/32)
1.2ªvÀø8¶gEASI¥§¡°74%,¦³4¤H¹FEASI90,¥t¤@¤H¹FEASI50~74,¥t¤@¤H¥¼¹FEASI50
µ²½× °ò缐 EASI 28~31¤À,¦@4¤H¡A ªvÀø«á¬Ò¥i¹FEASI 90, ¡§ EASI 32 ªvÀø«á EASI 50~74 ¡¨¡C EASI 35.4 ªvÀø«á ¥¼¹FEASI50
1.2 31-20=11
11/(32-20)=92% , ªí¥Ü«eASLAN004 400mg ²Õ¡AªvÀø8¶g, «e92%ªºIGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¡A¹FIGA 0,10= 0 or 1
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
***600mg ²Õ¥¼¨Ó·|§¹³Ó 400mg ²Õ¡A¤×¨ä¦b°ò½uEASI32~EASI40
¤T¡BLebrikizumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 2b´ÁÁ{§É
1. IGA 0,1= 0 or 1 = 33/75(44.6%) , ¦ô°ò½u EASI =24¤À¥H¤U//«e33%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
1.1 20+((25.5-21)*44.6%x2)=24.0¤À
1.2 24-20=4
4/(32-20)=33.3% ,ªí¥Ü«e33%ªºIGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¡A¹FIGA 0,10= 0 or 1
¡X¡X¡X¡X¡X¡X¡X¡X °ò½u ¹êÅç²Õ Lebrikizumab 1.1 EASI, median¤¤¦ì¼Æ ¥§¡25.5(°²³] 25.5 ¬°¤¤¦ì¼Æ¡A°_©l20¤À¶}©l)
1.2 IGA 0,1 =4 29.3%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7142380/
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¤G¡B Dupilumab IGA o,1 (²Ä16¶g /Q2W¤G¶g¤@°w), 3´ÁÁ{§É
1.SOLO 1 ,
IGA 0,1= 0 or 1 =85/224 (38%) , ¦ô°ò½u EASI =28.3¤À¥H¤U//«e69%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
2.SOLO 2, IGA0,1=0 or 1= 84/233 (36%) ,¦ô°ò½u EASI =26.5¤À¥H¤U//«e57%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
1.SOLO 1 , IGA 0,1= 0 or 1 =85/224 (38%) , ¦ô°ò½u EASI =28.3¤À¥H¤U//«e69%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
1.1 21.5+((30.4-21.5)*38%x2)=28.3¤À
1.2 28.3-20=8.3,
8.3/(32-20)=69% ,ªí¥Ü«e69%IGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¹FIGA 0,10= 0 or 1
2.SOLO 2, IGA0,1=0 or 1= 84/233 (36%) ,¦ô°ò½u EASI =26.5¤À¥H¤U//«e57%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
2.1 21.0+((28.6-21)*36%x2)=26.5¤À
1.2 26.5-20=6.5,
6.5/(32-20)=% , ªí¥Ü«e57% ªºIGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¹FIGA 0,10= 0 or 1
¡X¡X¡X¡X¡X¡X¡X¡X °ò½u ¹êÅç²Õ dupilumab 1.1 EASI, median¤¤¦ì¼Æ SOLO 1 30.4(21¡P5¡V40¡P8) SOLO 2 28.6(21.0¡V40¡P1)
1.2 IGA 0,1 =4 SOLO 1 48% SOLO 2 49%
www.nejm.org/doi/full/10.1056/nejmoa1610020
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¤@¡B Tralokinumab IGA o,1 (²Ä16¶g ), 3´ÁÁ{§É
1.ECZTRA 1 , IGA 0,1= 0 or 1 =95/601 (15.8%) , ¦ô°ò½u EASI =23.5¤À¥H¤U//«e29%ªºIGA0,1(EASI20~32)=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
2.ECZTRA 2, IGA0,1=0 or 1= 131/591 (22.2%) , ¦ô°ò½u EASI =23.5¤À¥H¤U//«e29%ªºIGA0,1=3(EASI20~32)ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
1.ECZTRA 1 ,
IGA 0,1= 0 or 1 =95/601 (15.8%) , ¦ô°ò½u EASI =23.5¤À¥H¤U//«e29.2%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
1.1 21.3+((28.2-21.3)*15.8%x2)=23.5¤À
1.2 23.5-20=3.5,
3.5/(32-20)=29% ,ªí¥Ü29%«eIGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¹FIGA 0,10= 0 or 1
2.ECZTRA 2, IGA0,1=0 or 1= 131/591 (22.2%) ,¦ô°ò½u EASI =23.5¤À¥H¤U//«e29%ªºIGA0,1=3ªÌ,ªvÀø16¶g«á¥i¹FIGA 0.1,=0 or 1
2.1 19.8+((28.2-19.8)*22.2%x2)=23.5¤À
1.2 23.5-20=3.5,
3.5/(32-20)=29% , ªí¥Ü«e29% ªºIGA 0,1=3 ¥iÀò³Ì¨ÎªvÀø¹FIGA 0,10= 0 or 1
¡X¡X¡X¡X¡X¡X¡X¡X °ò½u ¹êÅç²Õ 1.1 EASI, median¤¤¦ì¼Æ ECZTRA 1 28¡P2 (21¡P3¡V40¡P0) ECZTRA 2 28¡P2 (19¡P8¡V40¡P8)
1.2 IGA 0,1 =4 ECZTRA 1 50.6% ECZTRA 2 48.2%
www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/13 ¤W¤È 11:23:28
²Ä 122 ½g¦^À³
|
¹ï·Ó²Õ VS ¹êÅç²Õ Tralokinumab EASI 90 at week 16, n/N (%)
ECZTRA 1 8/197 (4¡P1%) VS 87/601 (14¡P5%) P < 0¡P001 ,(¦ô°ò½u EASI =22.9¤À¥H¤U,ªvÀø16¶g«á¥i¹FEASI 90) ECZTRA 2 11/201 (5¡P5%) VS 108/591 (18¡P3%) P < 0¡P001,(¦ô°ò½u EASI =21.8¤À¥H¤U,ªvÀø16¶g«á¥i¹FEASI 90)
°ò½u ¹ï·Ó²Õ VS ¹êÅç²Õ EASI, median¤¤¦ì¼Æ (IQR) ECZTRA 1 30¡P3 (22¡P0¡V41¡P5) VS 28¡P2 (21¡P3¡V40¡P0) ECZTRA 2 29¡P6 (20¡P6¡V41¡P4) VS 28¡P2 (19¡P8¡V40¡P8)
www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/13 ¤W¤È 08:23:33
²Ä 121 ½g¦^À³
|
www.ncbi.nlm.nih.gov/pmc/articles/PMC7986411/
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
¤T´Á³ø§i---¥þ¤å |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/12 ¤U¤È 07:18:21
²Ä 120 ½g¦^À³
|
±À¦ô结½×-1 ASLAN004 ¥i¯à¦¨¬°
°ò½uEASI27¥H¤W¡A IGA 0,1=4 100%¥«³õ¤Î IGA 0,1=3 30%-40%¥«³õ ªº³Ì¨ÎAD¯e¯fªvÀøÃĪ«¡C
¦Xp ¦³¼ç¤O¥D®_60%~70% ¤¤-««×AD(EASI >=27 )¥«³õ.
---------------------------------------------------------------- EASI27¤À¥H¤U¬O¾Ô°ê¥«³õ¡ADupilumab ¥D®_ªº¤Ñ¤U¡C
ASLAN004 600mg²Õ¡A¬D¾Ô°ò½uEASI41¡A¹FEASI50
ASLAN004 600mg²Õ³Ì°ª¬D¾Ô°ò½uEASI35¡A¹FEASI90©Î IGA 0/1=0/1 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/7 ¤U¤È 10:28:08
²Ä 119 ½g¦^À³
|
www.connectbiopharm.com.cn/Templates/default/Common/images/EADV-2020-e-Poster-P0269-CBP201-AU002-FINAL-19-10-2020.pdf
CBP-201 1b 31¤HªºÁ{§É¸Ô²Ó¸ê®ÆÀÉ
baseline °ò缐¸ê®Æ¦p¤U
150mg//300mg///¹ï·Ó²Õ
1.EASI ¥§¡ 20.68//23.21///33.36( ¹êÅç²Õ¬O¹ï·Ó²Õªº69%,ASLAN004 1b¤Î Dupilumab ±µªñ33¥ª¥k)
2.IGA 0.1=4¤§¤ñ²v 0%//28.6%///25% (Dupilumab =50%¥ª¥k
µ²½× : ¨Ì°ò缐¦Ó¨¥¡ACBP-201 ¬O¤j¦hIGA0.1 =3ªº¤¤«×¤§¯gª¬¬°¥D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/7 ¤U¤È 07:06:00
²Ä 118 ½g¦^À³
|
CBP-201 MOA ¾÷¥G©MDupilumab ¬Û¦P¡AYµL©MDupilumab ¥´±M§Q©x¥q¡A¤é«áÀø®Ä±N©MDupilumab ¬Ûªñªº¥i¯à©Ê°ª¡C
clinicaltrials.gov/ct2/show/NCT04444752
2b AD 220¤H Á{§É, ¤µ¦~9¤ë30¤é§¹¦¨
A Study Assessing the Efficacy and Safety of CBP-201
Study Type ƒÊ : Interventional (Clinical Trial) Estimated Enrollment ƒÊ : 220 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis Actual Study Start Date ƒÊ : July 17, 2020 Estimated Primary Completion Date ƒÊ : September 30, 2021 Estimated Study Completion Date ƒÊ : March 31, 2022 -----------------------------------------------------
1b 31 ¤H Á{§É µ²ªG2020.Jan.08¤½¥¬
www.prnewswire.com/news-releases/connect-biopharma-reports-positive-topline-data-from-moderate-to-severe-atopic-dermatitis-ad-phase-1b-study-of-cbp-201-300983333.html
Ten patients in each cohort were randomized 4:1 to CBP-201 (75 mg, 150 mg or 300 mg) or placebo,
Key Trial Results ¡ECBP-201 treatment resulted in rapid improvement in skin lesion as measured by change from baseline in EASI on Day 29. ◦42.9% and 50.0% of patients receiving 300 mg or 150 mg, respectively, achieved clear/almost clear skin, defined as a score of 0 or 1 in the Investigator¡¦s Global Assessment (IGA) scores, the primary efficacy endpoint required for FDA approval, compared with 12.5% in the placebo group. ◦100% and 87.5% of patients receiving 300 mg and 150 mg, respectively, achieved at least 50% decrease in Eczema Area and Severity Index (EASI) score (EASI50), compared with 37.5% in the placebo group. ◦Mean reductions from baseline in EASI score were 74.4% and 74.0% in the CBP-201 300 mg and 150 mg groups, respectively, compared with 32.9% in the placebo group. ◦Mean affected body surface area (BSA) reductions from baseline were 58.7% and 62.7% in the CBP-201 300 mg and 150 mg groups, respectively, compared with 28.7% in the placebo group. ¡ESkin lesion improvements were evidenced as early as one week after dosing and were correlated with a rapid reduction in pruritus intensity and frequency. ◦On Day 15, the average weekly Pruritus Numeric Rating Scale (PNRS) reductions from baseline were 40.4% and 26.4%, for the 300 mg and 150 mg groups, respectively, compared with 3.5% in the placebo group. ◦On Day 29, the average weekly PNRS reductions from baseline were 56.4% and 43.6% for the CBP-201 300 mg and 150 mg groups, respectively, compared with 20.6% in the placebo group. ◦On Day 29, the weekly average pruritus frequency reductions were 57.1% and 43.0% for the CBP-201 300 mg and 150 mg groups, respectively, compared with 19.9% in the placebo group. ¡ECBP-201 was well tolerated in this study. ◦There were no serious adverse events (SAEs) and no AEs of injection site reaction or conjunctivitis/keratitis in the study. ◦The proportion of subjects with at least one treatment emergent adverse event (TEAE) ranged from 62.5% for placebo to 85.7% for the CBP-201 300 mg group. There was no dose-proportional effect on TEAEs either by frequency or severity. ◦Most TEAEs were mild in severity, with the majority deemed unrelated to CBP-201. ◦There was a single TEAE (atopic dermatitis flare) leading to study treatment discontinuation in one subject in each of the CBP-201 75 mg and placebo groups.
About the Trial
The randomized, double-blind, placebo-controlled, multiple dose escalation study conducted in ten sites in Australia and New Zealand, evaluated the safety and efficacy of CBP-201 after four weeks of treatment in 31 patients with moderate-to-severe AD who have had inadequate response to topical corticosteroids and immunosuppressants. Ten patients in each cohort were randomized 4:1 to CBP-201 (75 mg, 150 mg or 300 mg) or placebo, respectively and were administered study treatment once weekly by subcutaneous injection for four consecutive weeks and followed for an additional seven weeks. The primary endpoints of the study were safety and tolerability of CBP-201, and other endpoints included multiple efficacy assessments (IGA scores, EASI scores, affected BSA and PNRS). |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/4/7 ¤W¤È 10:50:41
²Ä 117 ½g¦^À³
|
¤@.2022¦~(9~12¤ë)ASLAN004 «D¬ü,¾P°âÅv±ÂÅv¹w¦ô¡X-×¥¿1
°²³]³Ì°ª60»õ¬ü¤¸¾P°â,(1)AD 56% +(2) ý³Ý 24%+(3)¨ä¥L¾AÀ³¯g20%
¬ü°ê70%/¼Ú¬w°Ï AD,20%/¨ä¥L 10% ¡X¡X¥@¬É¾P°â¹w¦ô;
1.«D¬ü°Ï30% AD
AD 60»õ¬ü¤¸*56%*30%=10»õ¬ü¤¸
2.«D¬ü°Ï 30% ý³Ý
ý³Ý 60»õ¬ü¤¸x24%x30%=4.3»õ¬ü¤¸
3.¨ÌLebrikizumab 欧¬w区¾P°â±ÂÅv¦X约¡C¦ôp«D¬ü°Ï AD+ý³Ý±ÂÅv±ø¥ó
ASLAN004 (AD¡Ïý³Ý) /Lebri =(10¡Ï4.3=14.3)/5=2.86¿
(1)ñ¬ùª÷+ùµ{ª÷=1.1*2.86=3.14»õ¬ü¤¸(¤T´ÁÁ{§É¶}©l«e) +0.85*2.86=2.43»õ¬ü¤¸(¥¿¥«¤W¥«§¹¥I)=5.6»õ¬ü¤¸
(2)¾P°âùµ{ª÷¡A³Ì°ª销°â¹F30»õ¬ü¤¸¡A¤ä¥I³Ì¦h12.5»õ¬ü¤¸¡C
(¥H¾P°â14.5»õ¦ô¡A约5.5»õ¦h¬ü¤¸ªº¦¬¤J)¡C
(1)¡Ï¡]2)=¬ù 10~11»õ¬ü¤¸
(3)10%-20%销°â¤À¼í
¡X¡X¡X¡X¡X¡X¡X
-----AD¤T´Á¶}©l¥i¨ú±o2.2~2.5»õ¬ü¤¸²{ª÷.
¤G. ¥t¥~¦ô2.8»õ¬ü¤¸²{ª÷,¥²¶·¤½¶}¶Ò¸ê(2022¦~©³)
¦ô2023¦~Q2/Q3 ¶}©l3´ÁÁ{§É |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/31 ¤U¤È 11:01:31
²Ä 116 ½g¦^À³
|
www.sec.gov/edgar/search/?r=el#/q=Dermira
Dermira/Lebrikizumab ³Q¨ÖÁʳø§i
³Ì°ª¹w¦ôÀ禬2030¦~ ¬ù15»õ¬ü¤¸
**(Lebrikizumab ¹w¦ô2023¦~¤W¥«,²Ä¤@¦~3»õ¬ü¤¸/²Ä¤G¦~5»õ¬ü¤¸/²Ä¤T¦~7.5»õ¬ü¤¸, ¼Ú¬w°Ï¤w±ÂÅv,¶È¦¬ùµ{ª÷¤Î¾P°â¤À¼í))
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/3/31 ¤U¤È 04:05:04²Ä 4037 ½g¦^À³ ¬ü°ê¨ÖÁÊ°ª³z©ú«× ÅýªÑªF¦w¤ßÁÈ www.wealth.com.tw/home/articles/21569 2019-07-24 §@ªÌ: ÄǨq¬Ã
½÷·ç114»õ¬ü¤¸¦¬Áʦã·ç¡A¥æ©ö®É¶¡Áöº©ªø(2017¦~1¤ë~2019¦~6¤ë)¡A¦ý¹Lµ{¤½¶}³z©ú¡AÅý§ë¸ê¤H¸ûµLºÃ¼{¡C¡]¹Ï¡þ¨ú¦ÛArray Biopharma©xºô¡^
¥H¥þ²y³Ì¤jÃļt½÷·ç114»õ¬ü¤¸¦¬Áʦã·ç»sÃÄ¡]Array BioPharma¡^¬°¨Ò¡A¥i¥H±q³Q¦¬Áʤ½¥q¦ã·ç»sÃÄ´£¥æµ¹ÃÒºÞ·|ªº¤å¥ó¡A¤@¿sÂù¤è½Í§P¹Lµ{µ¾¹êªº¨ÓÀs¥h¯ß¥H¤Î¤½¥qµû»ùªº¤º²[¡C
2017¦~1¤ë¡A¦ã·ç§ä¨Ó¦b¨ÖÁʮ׫ܦ³¸gÅ窺Centerview Partners¨ÖÁÊ¿Ô¸ßÅU°Ý¤½¥q¡CCenterview´¿¸g¤âªº¥æ©ö°ª¹F3¥ü¬ü¤¸¡A¥B¤½¥q«È¤á¸s¥e¥þ²y«e50¤j¥ø·~ªº20%¡CCenterview«Ü§Ö´N¿z¥X¥|®a¦W³æ¡A¥]¬A½÷·ç¡C
±µµÛ¡A¦ã·ç»sÃĦb2018¦~6¤ë¤À§O¨ú±oBRAFTOVI©MMEKTOVI¦X¨ÖªvÀø¥Ö½§Àù¥H¤ÎGanovoªvÀøC¨x¯f¬rªºÃÄÃÒ¡A11¤ë±ÂÅv¥X¥hµ¹LOXOªºLarotrectinib¤]®³¨ìÃÄÃÒ¡A¤½¥qªº»ùȤ]¤ôº¦²î°ª¡C
2019¦~2¤ë¡A¦ã·ç»sÃĶi¤@¨B§ä¼ç¤O¶R®a¶i¦æ¤@¹ï¤@ªº°Q½×¡A¦P®É¤]¸Õ±´½÷·çªº·NÄ@¡C3¤ë¤¤¡A¦ã·ç»sÃÄ©M½÷·ç¨M©w¥ýñ«O±K¨ó©w¡A±µµÛ½÷·ç°ª¼h¿ËÁ{¦ã·ç¡A»PÀç¹BªøAndrew Robbins©M·~°ÈÀYÀYNicholas Saccomano¶i¦æ§ó²`¤J°Q½×¡C5¤ë17¤é¡A¦ã·çÀç¹Bªø³z¹L¹q¸Ü»P½÷·ç°ÆÁ`John DeYoung»P¬ãµoªøChristopher Boshoff¤À¨ÉªvÀø¸zÀùªºBEACONÁ{§É¥O¤H¿³¾Äªº¼Æ¾Ú¡]Âù¤è¦³Ã±«O±K¨ó©w¡^¡C¤£¹L½÷·çÁÙ¬O¨S¦³´£¥X¦¬ÁÊ»ù®æ¡A·í®É¦ã·çªÑ»ù¤w¸gº¦¨ì¤j¬ù21¬ü¤¸¡C
5¤ë21¤é¦ã·ç»sÃÄ¥¿¦¡¦V¥«³õ¤½¥¬BEACON¤T´Á¼Æ¾Ú¡A¤TÁpÃĦbªvÀø¤W¬Û¸û¤ÆÀøÃĪº¤ÏÀ³²v¡]26.1%¡B1.9%¡^©M¾ãÅé¦s¬¡´Á¡]9Ó¤ë¡B5.4Ó¤ë¡^¡A¦¹¥~¥i¥H´î¤Ö¦º¤`48%¡A¦P®É«Å¥¬¤U¥b¦~¥Ó½ÐÃÄÃÒ¡C³o¤TÁpÃĪº»ùȦb©ó¡A¦pªGÀòã±N¬O²Ä¤@Ó°w¹ï¸ÓÀù¯gªº«D¤ÆÀøÀøªk¡C§Q¦h¤½¥¬¤]±a°ÊªÑ»ù¤jº¦18%¡A¨ì25.77¬ü¤¸¡C
3¤jª¾¦WÃļt·m¿Ë ½÷·ç²v¥ý·mñ«O±K¨ó©w
¥Ñ©ó¦ã·ç»sÃĤ]¥¿»P¨ä¥L¨â®aÃļt°Q½×¦¬Áʪº¨Æ©y¡A¦P®ÉÀHµÛªÑ»ù¤@¸ô¤Wº¦¡A½÷·ç¤]¤ß«æ¤F¡C5¤ë29¤é¡A½÷·ç³Ì°ª¥DºÞ°õ¦æªøAlbert BourlaÁpµ¸¤F¦ã·ç»sÃÄ°õ¦æªøRon Squarer¡A§iª¾¥H¨CªÑ44¬ü¤¸¦¬Áʦã·ç»sÃÄ¥þ³¡ªÑ¥÷¡C
¤£¹L¡A¦ã·ç»sÃħƱ洣°ª»ù®æ¡A½÷·ç¤]©È¦³30ÓÁ{§É¶i¦æ¤¤ªº¦ã·ç»sÃĤS¦³·sªº¼Æ¾Ú¤½¥¬¡A´X¤Ñ«á°¨¤W¦^À³´£°ª¬°48¡A·¸»ù¦¬ÁÊ¡C2019¦~6¤ë14¤éÂù¤è©ó¦¬½L«áñ¤U¨ÖÁʨóij¡A¨Ã©ó6¤ë17¤é¦±á¤½¥¬¨ÖÁÊ°T®§¡C
|
|
¡@ |
¦^°Q½×°Ï1¶ |
³Ì·s100«h¦^ÂÐ >> |
|
|